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Development of stapled peptide targeted covalent inhibitors 
and synthesis of novel ADC payloads for applications in 
cancer therapy 
Jiraborrirak Charoenpattarapreeda 
Cancer is one of the leading causes of deaths worldwide with 1 in 2 people estimated to 
develop the disease during their lifetimes. While great progress has been made in curing 
cancers, new therapeutics are still necessary to tackle this collection of diseases and minimise 
side-effects. This thesis presents two approaches towards the development of novel bioactive 
molecules with application in cancer therapeutics. 
1) Development of stapled peptide–targeted covalent inhibitors (SPTCIs) of p53–MDM2 
protein–protein interaction (PPI). 
Herein, the development and synthesis of three novel electrophilic staples and four stapled 
peptides are described. The stapled peptides bear moieties to covalently target a surface-
exposed lysine residue on MDM2, an important anti-apoptotic protein overexpressed in many 
cancer cells. Led by computational modelling and kinetic studies on stability and reactivity 
of the electrophiles, an SPTCI with an apparent Kd of 7.1 nM was discovered. The stapled 
peptide was built using two-component Cu-catalysed azide-alkyne cycloaddition (CuAAC) 
and an activated ester electrophile for targeted covalent inhibition. The peptide showed 
selective and complete covalent binding to MDM2. Crucially, this proof-of-concept study sets 
the basis for the development of SPTCIs for a wider range of PPIs. 
2) Novel total synthesis of hemiasterlin and its use as a payload in antibody–drug conjugates 
(ADCs). 
This thesis details the novel synthesis of hemiasterlin, an anti-mitotic marine natural product 
with low- to sub-nM potencies against several cancer cell lines. Rapid construction of 
hemiasterlin was achieved, through a four-component Ugi reaction, in total 14 steps (longest 
linear sequence of 10 steps) in 11% overall yield. The convergent synthetic route also enabled 
the synthesis of taltobulin (HTI-286), a similarly potent synthetic analogue. Through the 
synthesis of complex linker-drug molecules, two ADCs were made to investigate the potential 
of the two molecules as payloads. Remarkably, the conjugates were found to have mid-pM 
cytotoxicity against antigen-expressing breast cancer cell lines and no appreciable activity 
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Chapter 1 — Introduction to Cancer 
The term cancer is used to describe a large collection of diseases whose primary characteristic 
is an abnormal cell growth which can spread to other parts of the body. In 2018, it was 
estimated that 18.1 million people around the globe were diagnosed with cancer, and 9.6 
million people died because of the disease.1 With the expectation that the case number would 
rise even further in the future, cancer poses an ever-increasing threat to the health of 
humanity.  
A prominent feature of cancer is rapidly and uncontrollably dividing cells, which are caused 
by mutations in their proto-oncogenes and tumour-suppressor genes.2,3 The mutations can 
originate from several sources including amongst others: physical (e.g. ultraviolet radiation), 
chemical (e.g. polycyclic aromatic hydrocarbons and aromatic amines in tobacco), biological 
(e.g. human papillomavirus, also known as HPV), inherited mutation in certain genes, and 
random errors in DNA replication.4,5 More than 600 types of cancer have been categorised by 
the International Classification of Diseases (revision 11, ICD-11).1,6 While most of these 
cancers require different diagnosis and treatment approaches, many can now be completely 
cured.7 
The earliest form of cancer treatment was the use of surgery, which was documented by the 
Greek physician Hippocrates of Kos (460 – ca. 360 BC).8–10 Radiotherapy became an option 
after the discovery of X-ray by Wilhelm Conrad Röntgen in 1895.11,12 Up until the 1960s, 
surgery and radiation therapy dominated the field of treatment of solid tumours. However, it 
was found that the cure rates plateaued at 33% due to unnoticed micrometastases.13 It was 
then observed that combination chemotherapy was able to cure various advanced cancers. 
Chemotherapy was first coined by Paul Ehrlich in the early 1900s. Traditional 
chemotherapeutic agents target vital mechanisms for cellular division or survival and have 
been widely used for eliminating cancerous cells since the 1940s.13,14 Early examples include 
the DNA alkylating agent chlormethine for Hodgkin lymphoma patients,15,16 anti-folate 
methotrexate (amethopterin) for childhood leukaemia,17 anti-metabolites 5-fluorouracil (5-
FU) for solid tumours18 and 6-mercaptopurine for acute leukaemia,19,20 and anti-mitotic Vinca 
alkaloids21 such as vincristine and vinblastine (Figure 1). The Vinca alkaloids act as a 
suppressor of microtubule dynamics, blocking mitosis and causing cell apoptosis.22,23 Later,  
Pt-based drugs like cisplatin, carboplatin, and oxaliplatin,24 the microtubule stabiliser 
paclitaxel (Taxol®),25 nitrogen mustard cyclophosphamide,26 topoisomerase I inhibitor 
irinotecan27 entered clinical use (Figure 1). While these compounds affect rapidly 
proliferating cells (i.e. cancerous cells) more than healthy cells, their low selectivity means 
they have a narrow therapeutic window, and the collateral death of healthy tissues and 




Figure 1 Examples of chemotherapeutic agents: DNA-alkylating agent chlormethine and cyclophosphamide, 
anti-metabolites 5-fluorouracil and 6-mercaptopurine, anti-folate methotrexate, anti-microtubule agents 
vinblastine and vincristine, Pt-based DNA cross-linking agents, cisplatin, carboplatin and oxaliplatin, 
microtubule stabiliser paclitaxel, and topoisomerase I inhibitor irinotecan. 
To mitigate the side-effects arising from the low selectivity against tumour cells, more 
targeted approaches were taken. One major area in this field is the development of kinase 
inhibitors as dysregulation of kinases are implicated in many cancers.29–31 The first small 
molecule to use this targeted approach was imatinib (Figure 2), for treating chronic myeloid 
leukaemia (CML).32 Imatinib targets the kinase activity of the oncogenic fusion protein Bcr-
Abl, the formation of which is involved in the pathogenesis of CML.14,33,34 Other drugs 
targeting other kinases soon followed, such as gefitinib for the treatment of EGFR mutation–
positive metastatic NSCLC,35 dasatinib for the treatment of imatinib-resistant CML,36,37 
lapatinib for HER2-positive advanced breast cancer patients,38 and trametinib for BRAFV600E-
positive advanced melanoma (Figure 2).39 Despite these advances, adverse effects arising 




Figure 2 Examples of kinase inhibitors for cancer treatments: imatinib, gefitinib, dasatinib, trametinib, 
lapatinib, and osimertinib. 
One common problem encountered in cancer treatment is the decrease in treatment efficacy 
due to the emergence of drug resistance.40,41 Consequently, several strategies have been 
developed to overcome the resistance, e.g. combination therapy employing a cocktail of 
chemotherapeutic agents with distinct mechanisms of action,42 targeted degradation using 
proteolysis targeting chimaeras (PROTACs),43–46 designing compounds with multiple binding 
modes,47 and irreversible covalent inhibitors.48 Irreversible covalent inhibitors, in particular, 
were exemplified by osimertinib (Figure 2), a drug used for treating patients with EGFRT790M-
mutated NSCLC by binding covalently to Cys797 of the mutated EGFR.49,50 
Apart from the use of small molecules for treating cancer, the use of biologics has gained 
more interests in the past few decades. Among the fastest-growing and most developable 
biologics are monoclonal antibodies (mAbs), which were first approved by the United States 
Food and Drug Administration (US FDA) in 1986. Currently, more than 80 mAbs have been 
approved by the US FDA for a multitude of diseases, and approximately half of them are used 
in oncological indications.51,52 A subset of antibody-based therapeutics, called antibody–drug 
conjugates (ADCs), has also gained rapid traction in cancer treatment. Nine ADCs have 
already been approved for various cancers, and over 80 ADCs are being evaluated in clinical 
trials.53 
Another approach to oncotherapy, which is currently being researched, is the inhibition of 
protein–protein interactions (PPIs). Numerous aberrant PPIs have been identified to have a 
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link with oncogenesis or poor disease prognosis.54,55 As PPIs have large contact surfaces, it is 
challenging for small molecule inhibitors to be successfully developed. Conformationally 
constrained peptides, also known as stapled peptides, are one of the most promising ways to 
inhibit PPIs, as these peptides possess a native binding motif, with enhanced 
pharmacokinetics compared to native peptides.56,57 Stapled peptides have been used 
successfully for probing several PPIs implicated in cancer, such as p53–MDM2/MDMX, Bcl-2 
family, and Aurora-A/TPX2, with one such stapled peptide advancing through late-stage 
clinical trials.58,59 
The rest of the introduction section will outline in detail three modalities, namely, stapled 
peptides and covalent inhibitors in Chapter 2, and ADCs in Chapter 3 as other types of 




Chapter 2 — Targeting the p53–MDM2 Protein–Protein 
Interaction with Stapled Peptides and Covalent 
Inhibitors 
2.1. Protein–protein interactions  
Proteins are essential not only for cell structure and functions, being involved in enzymatic 
catalysis, and cell signalling, but also they can act as antibodies and transporters. To exert 
their functions, most proteins must interact with each other. Therefore, anomalous 
interactions and protein dysregulation can disrupt cellular processes, resulting in several 
human diseases.60 In recent years, attaining the ability to selectively modulate protein–
protein interactions (PPIs) has unlocked new opportunities for potentially powerful 
therapeutics.61,62 Historically, PPIs were deemed ‘undruggable’63, and less than 0.01% of the 
estimated 650,000 PPIs have been targeted by inhibitors.64 This was due to challenges in 
identifying small molecules via a classic drug discovery paradigm. PPI surfaces are large 
(1,000–6,000 Å2)62, generally flat, and lack pockets and grooves to accommodate small 
molecules (Figure 3a).65 Therefore, it is not surprising that there are no known small-molecule 
ligands as a starting point for drug design, making it challenging for high binding affinity to 
be achieved. Despite these hurdles, there has been a rapid progression towards PPI inhibition 
within the last two decades with small molecules, biologics, and peptidomimetics.65–70 These 
PPI inhibitors that are approved by the FDA are exemplified by the followings (Figure 1b):  
∑ tirofiban, a small molecule antiplatelet drug inhibiting the interaction between 
fibrinogen and platelet integrin receptor GP IIb/IIIa;71,72  
∑ trastuzumab (Herceptin®), monoclonal antibody biologic for treatment of breast 
cancer by binding to human epidermal growth factor receptor 2 (HER2);73,74  
∑ eptifibatide, a cyclic peptide peptidomimetic antiplatelet drug acting similarly to 
tirofiban.75  
For the scope of this dissertation, only the p53–MDM2 PPI and two approaches for its 




Figure 3 Protein-protein interactions and examples of FDA-approved inhibitors. a) PPI of Bcl-XL (grey) and BAD 
(red). Dotted blue box highlights the large PPI interface. (PDB ID: 2BZW)76 b) Examples of FDA-approved PPI 
inhibitors: the small molecule tirofiban, the peptidomimetic eptifibatide and the biologic trastuzumab. In the 
case of trastuzumab, the crystal structure of its Fab region (cyan) is shown interacting with human soluble HER2 
(orange). (PDB ID: 1N8Z)73 
 
2.1.1. p53–MDM2 protein–protein interaction 
The tumour suppressor protein p53, sometimes dubbed “the guardian of the genome”, is a 
pro-apoptotic protein present at a low concentration in normal cells.77 Various stress signals 
such as oncogene activation or DNA damage can raise the level of p53 and cause its 
translocation and aggregation in the nucleus to trigger repairing pathways, cell cycle arrest, 
or ultimately apoptosis.78 It has been estimated that approximately 50% of human cancers 
contain mutated p53.79 
MDM2, an E3 ubiquitin ligase, is a negative regulator of p53, where MDM2 ubiquitinates p53, 
thus limiting its transcriptional activity.80,81 The structure of MDM2 consists of four main 
regions: an N-terminal p53-binding domain,82 a central acidic domain,83–85 a Zn-finger 
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domain,86 and a C-terminal RING finger domain (Figure 4).87 The RING finger domain is 
mainly responsible for ubiquitination of p53, which eventually leads to its proteasomal 
degradation. The central acidic domain also contributes to this process.83–85,87 In the interest 
of this report, only the N-terminal domain will be described in detail. 
 
Figure 4 Schematic representation of the structure of full-length MDM2. Known motifs are shown. NLS = 
nuclear localisation signal; NES = nuclear export signal; NoLS = nucleolar localisation signal. The numbers 
above the drawing indicate the amino acid positions.88 
The N-terminal domain contains four α-helices and two β-sheets arranged in a 
pseudosymmetrical fashion.82 The trans-activation domain of p53 binds to the hydrophobic 
cleft, which consists of the α2 helix on one side and both β-sheets on the other side. The 
primary contacts from p53 are made by its amphipathic α-helix. The hydrophobic face of this 
α-helix buries into the MDM2 hydrophobic cleft. Phe19, Trp23, and Leu26, often referred to 
as ‘hot spots’, are the three key residues that most strongly interact with MDM2 and sit deep 
into the cleft (Figure 5). 
As the trans-activation domain of p53 binds to MDM2, its transcriptional machinery is 
shielded from functioning.82 In abnormal cells where MDM2 is overexpressed, the p53 
becomes deactivated, causing uncontrolled cell proliferation and tumour development.89,90 
Inhibition of p53–MDM2 interaction is, therefore, vital to the restoration of p53 cellular 






Figure 5 Structure of complex of the trans-activation domain of p53 (red) and the N-terminal domain of MDM2 
(PDB ID: 1YCR).82 The α-helices of MDM2 are shown in green, and the β-sheets are shown in blue. a) The 
overview of the p53–MDM2. b) Details of the hydrophobic cleft showing the three key residues of p53 that drive 
the hydrophobic contact: Phe19, Trp23, and Leu26. 
At least 14 inhibitors of the p53–MDM2 (or closely related MDMX) PPI have progressed to 
clinical trials.94–96 Among these, RG7388 (Figure 6),97 a small molecule inhibitor developed by 
Hoffmann-La Roche, advanced to phase III clinical trial for the treatment of acute myeloid 
leukaemia, and ALRN-6924,98 a hydrocarbon stapled peptide (see section 2.2) with an 
undisclosed structure developed by Aileron Therapeutics, reached phase II clinical trial for 
the treatment of peripheral T-cell lymphoma.57,99–105 Both molecules bind to the N-terminal 
hot-spot region of MDM2, which the trans-activation domain of p53 typically occupies, and 
hence prevent the binding of native p53. Currently, no drugs targeting the p53–MDM2 PPI 





development and progression for a variety of cancer types, there is an unmet need for the 
swift development of new inhibitors to maximise the chances of clinical success.77 
 
Figure 6 Structure of RG7388, a small molecule inhibitor of MDM2. 
 
2.2. Stapled peptides 
Because PPIs generally have relatively large surfaces and lack obvious binding pockets,62,65 
peptides are a suitable strategy for their inhibition due to the high similarity to native 
proteins and greater coverage of contact surface area compared to small molecules.106 
However, peptides may suffer from poor proteolytic stability and bioavailability.56,57,102,107 
Aiming to overcome these intrinsic limitations, stapled peptides—i.e. peptides constrained 
into their binding conformation by chemically cross-linking two amino acid side chains—has 
emerged as a very promising approach.56,57,107 While generally the term ‘stapling’ is applied to 
α-helical peptides, it can also be used more widely to refer to other types of secondary 
structures.57 In this section, only the α-helix definition will be discussed. 
A single turn of an α-helix contains 3.6 residues, and therefore, stapling involves cross-
linking between residues at the i and i + 4, i + 7, or i + 11 positions corresponding to the same 
face of an α-helix after 1, 2, and 3 turns, respectively (Figure 7). These residues can either be 
mutated to non-native amino acids prior to cross-linking or directly joined together (i.e. 
‘stapled’) using appropriate techniques. By optimising the length of the side chain and 
position of the staple, a more rigid structure with a greater degree of helicity can be achieved. 




i i + 4 i + 7 i + 11
 
Figure 7 Shown in blue are amino acid residues at positions i, i + 4, i + 7, and i + 11, which are on the same face 
and suitable for stapling.  
Several techniques exist for peptide stapling where a variety of macrocyclisation chemistries 
were employed, resulting in different bioactivities.56,57,108 These are covered in detail in the 
following section. 
  
2.2.1. Techniques in peptide stapling 
Stapling techniques are broadly categorised into three classes: one-component, two-
component, and multi-component stapling. One-component stapling refers to covalent bond 
formation between two usually non-native amino acid side chains of the same linear 
sequence. In contrast, two-component and multi-component staplings involve another 
molecule(s) bridging the two amino acid side-chains of the same sequence together (Scheme 
1). For this dissertation, only two-component techniques will be covered. For one- and multi-
component techniques, more information can be found in these excellent reviews.56,108,109 
 
Scheme 1 Schematic representation of a) one-component, b) two-component, and c) multi-component peptide 




2.2.1.1. Two-component peptide stapling techniques 
Two-component peptide stapling (2C-PS) involves a bifunctional linker that reacts with two 
complementary, usually non-native amino acids in the peptide of interest. Compared to the 
one-component stapling, two-component methodologies offer a simpler way of diversifying 
both peptide sequences and staple linkages, which can be both elaborated independently. 
Thus, chemically or biologically different stapled peptides can be accessed more efficiently.102 
Moreover, the use of external linkers allows for further functionalisation on the staples.57,102 
The functionalisation can be used to modulate the pharmacological properties of the stapled 
peptides, such as an addition of cell-permeable motif or PEGylation to improve their 
solubility, binding to plasma proteins, and protease stability.102,110,111 In addition, 
fluorophores or affinity tags can be added to the staples to aid biological assays.57,102,112,113 
Attachment of these moieties on the staple position, rather than at the traditional N-, C-
terminus or side chains, has advantages such as combinatorial diversification of the peptides, 
lower risk of decreased binding affinity by altering the peptide conformation, and avoidance 
of steric clashes between the target protein and the added functionality.57 
Nevertheless, this highly attractive methodology involves certain complications to be 
considered. Most of the two-component reactions are performed in solution phase due to 
potential issues of site-isolation on resin, which necessitates an extra purification step.56 
Another issue is the potential of side reactions, such as a formation of double coupled linear 
peptides and an oligomerisation due to a more complicated reaction pathway. Regardless of 
these disadvantages, several effective two-component stapling techniques have been 
developed and optimised with success in biological contexts. For this report, the focus will be 
on the technique using functionalised double-click linkers. 
One of the most prominent strategies of functionalisable 2C-PS is the use of bioorthogonal 
copper-catalysed azide–alkyne cycloaddition (CuAAC) or “copper-click” reaction. By 
incorporating two unnatural azido amino acids into a peptide sequence, functionalisable bis-
alkyne linkers can be used for stapling. The first example of the CuAAC reaction in a 2C-PS 
was reported by Bong and co-workers.114 Azidoalanine was used to replace the i and i + 4 
residues in a peptide derived from the GCN4 leucine zipper. Unfunctionalised 1,5-hexadiyne 
was employed as the optimal bis-alkyne linker. Based on this work, the Spring group 
developed a protocol for i, i + 7 stapling to generate functionalised stapled peptides targeting 
the p53–MDM2 interaction (Scheme 2a).102,115 Using p53-based diazidopeptide stapled with 
1,3-diethynylbenzene, a nanomolar inhibitor was obtained, but cell permeability could not 
be observed. By introducing three Arg residues onto the linker, enhanced cell permeability 
and p53 reactivation in cells were observed, showcasing the importance of peptide 
functionalisation. Further development of this methodology by Pedersen and co-workers saw 
the use of 1,3,5-triethylnylbenzene (TEB) as a linker that allows extra functionalisation 
through a second CuAAC reaction post-stapling (Scheme 2b).111 
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Another bioorthogonal click reaction that has recently gained popularity is the strain-
promoted azide–alkyne cycloaddition (SPAAC) reaction.116–118 The use of a strained alkyne 
avoids the need for a copper catalyst, which is cytotoxic. The Spring Group devised a protocol 
based on the SPAAC reaction using Sondheimer-Wong diyne (SWD, R = H)119 and a phage 
display PDI-based peptide to generate i, i + 7 stapled peptides targeting the p53–MDM2 
interaction (Scheme 2c).103 The generated stapled peptide was shown to bind MDM2 strongly, 
with a Kd of 7.5 nM. In situ stapling could also be performed but with moderate loss in cellular 
activity compared to the use of pure stapled peptides. Further investigation by the Spring 
group added fluorine or methoxy substituents to the SWD linker (Scheme 2c).120 While the m-
fluoro derivative resulted in a slightly diminished binding affinity (Kd = 17.3 nM), an in situ 
stapling of this analogue provided an improved cellular activity compared to the use of 
unsubstituted SWD linker. 
 
Scheme 2 Azide-alkyne cycloadditions in two-component peptide stapling a) CuAAC reaction for i, i + 7 peptide 
stapling.102,115 THPTA = tris(3-hydroxypropyltriazolymethyl)amine; TAMRA = 5-(and-6)-
carboxytetramethylrhodamine. b) CuAAC reaction using TEB as the staple allows functionalisation with another 




Scheme 2 (continued) c) SPAAC reaction for i, i + 7 peptide stapling to generate MDM2 inhibitors.103,120  
Whilst azido amino acids are the most used unnatural amino acids for functionalisable 2C-
PS, cysteines are the most exploited proteinogenic amino acids for these applications owing 
to their unique nucleophilicity and low abundance in the proteome, as evidenced by the 
plethora of methodologies developed.57 The use of natural amino acids entails an advantage 
of high availability, which simplifies and reduces the cost of peptide synthesis. However, 
issues of chemoselectivity and orthogonality may arise. SN2 reaction and conjugate addition 
are the most frequently reported reactions for Cys-based 2C-PS, with SNAr and nucleophilic 
vinylic substitution (SNV) also being employed (Figure 8).  
 
Figure 8 Various functionalised 2C-PS through cysteine residues. The linkages are categorised according to their 
chemistries: SN2 in cyan background, SNAr in pink background, SNV in lavender background, and conjugate 
addition in green background. Each linker is annotated with its inventor. Stars indicate functionalisation with 
various moieties such as fluorophores, cell-permeable motifs, or affinity tags. Yellow circles represent cysteine 
residues, but distances between any two cysteines do not indicate actual numbers of residues across the 
stapling. 
Hartman et al. first introduced the use of derivatives of 1,3-bis(bromomethyl)benzene for 
peptide macrocyclisation and functionalisation through an SN2 reaction with cysteine side-
chains (Figure 8).121 Timmerman et al. then disclosed the incorporation of quaternary 
ammonium to aryl halide linkers for functionalisation and improved water solubility.122 They 
termed the linkage between cysteine thiols and aryl halides “CLIPS (chemical ligation of 
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peptide onto scaffolds)”, which is being used to generate bi-, tri-, and tetracyclic peptides by 
pharmaceutical companies.123,124 Another example of the use of SN2 reaction for peptide 
stapling was demonstrated by Dawson et al., who employed 1,3-dichloroacetone, with 
functionalisation achieved through post-stapling oxime formation.125 
Pentelute et al. pioneered the adoption of perfluoroaromatic compounds for SNAr cross-
linking of cysteines or lysines, but functionalisation on the staple was not possible.126,127 
Subsequently, Brown and Smith utilised 3,6-dichloro-1,2,4,5-tetrazine as the linker, which 
allows post-stapling modification through inverse-electron-demand Diels–Alder reaction 
with bicyclo[6.1.0]non-4-yne for incorporation of fluorescent dyes (Figure 8).128 
Dibromomaleimides were employed by Wilson et al. for reversible cysteine or homo-cysteine 
peptide stapling via nucleophilic vinylic substitution (SNV; Figure 8).110 Peptides can be 
unstapled through a reaction with glutathione, and functionalisation can be done on the 
imide nitrogen. 
Several examples of thiol–ene conjugate addition for peptide stapling and macrocyclisation 
have been reported (Figure 8). First, Keillor et al. reported the use of functionalised 
dimaleimide compounds to incorporate a fluorescent tag.129 Further example by Jiang et al. 
showed the use of functionalised divinylsulfonamides as linkers.130 Recently, the Spring 
Group reported similar reactions using divinylheteroarenes (pyrimidine or 1,3,5-triazine) 
staples with the possibility of dual functionalisation through the pyrimidine version.113,131 
With wide-ranging stapling methodologies, each one displaying unique features, the choice 
of a stapling technique to be used depends on the nature of the targeted PPI and the biological 
aspects being explored.108 Thanks to the functionalities that can be easily introduced with 
two-component stapling, stapled peptides have become not only potential therapeutics but 
also chemical tools for probing and understanding biological processes.57–59,132 
 
2.2.2. Stapled peptide inhibitors of p53–MDM2 PPI 
Several stapled peptides have been developed using various methodologies to target p53–
MDM2 PPI (Table 1). While a majority of the stapled peptides utilised a classic one-
component hydrocarbon stapling effected by an olefin metathesis,99–101,133,134 CuAAC and 
SPAAC 2C-PS developed by the Spring group also generated a number of potent MDM2 
binders.102,103,120,135,136 
In general, an appropriate peptide stapling leads not only to increased binding affinity against 
MDM2, but also to improvement in their α-helicity, protease stability, and cell permeability. 
In the case of peptide “11B”, the inclusion of triarginine (RRR) tag on the staple imparted cell 
permeability onto the stapled peptide—otherwise, cell permeability was not observed.135 Sub-
nanomolar binding affinity was also attainable in three stapled peptides shown in Table 1. 
























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































2.3. Covalent inhibitors 
In addition to peptides, covalent inhibitors can be used in targeting shallow, ‘undruggable’ 
pockets such as those at PPI surfaces. Covalent inhibitors are molecules that contain reactive 
functionalities leading to a covalent bond formation with the targeted protein. Despite the 
historical success of aspirin and amoxicillin, covalent inhibitors have been generally excluded 
from high-throughput screenings, citing concerns in potential toxicity.138 Recent 
developments in the field, namely ‘targeted covalent inhibitors’ (TCI), have sparked renewed 
interest in this class of compounds.139–146 Using this approach, a compound is rationally 
designed to form a specific and controlled covalent binding to a site on the target of interest.  
 
2.3.1. General mechanisms 
A general mechanism for TCIs involves two steps (Scheme 3).147 First, the inhibitor binds to 
the target protein reversibly to form a non-covalent complex [PI], governed by the 
equilibrium constant Ki = kon/koff. Then, a covalent bond is formed to give the protein–
inhibitor covalent complex P–I, the rate of which is governed by the first-order rate constant 
kinact.  
 
Scheme 3 General mechanism of action for targeted covalent inhibitor I against a generic protein target P. 
Created with BioRender.com 
For a TCI to achieve selective binding, two criteria must be satisfied. Firstly, the non-covalent 
binding affinity (Ki)* must be sufficiently high to attain a good non-covalent binding to the 
desired target. Secondly, the electrophile should be stable enough to avoid off-target 
reactivity, while reactive enough so that the covalent bond formation occurs within the 
lifetime of the [PI] complex. This reactivity will arise from the careful placement of the 
electrophile spatially close to the nucleophilic site on the target.139 
 








2.3.2. Advantages of covalent inhibitors 
 
Some of the advantages of covalent inhibitors over non-covalent inhibitors are listed below: 
 
1) Overcoming competing endogenous substrate binding more easily 
It has been estimated that approximately 80% of approved drugs compete with 
endogenous ligands in binding with the same protein binding site.148 A non-equilibrium 
binding mode can potentially mitigate any competing endogenous substrates, e.g. ATP 
substrate in the case of kinase inhibition.149 
2) Extended duration of action due to “permanent” binding of the inhibitor 
With covalent binding, an irreversible inhibitor can exert an effect on its target protein 
for a prolonged period, even if the drug has been cleared from the system—i.e. its 
pharmacodynamics and pharmacokinetics can be decoupled. A good example is 
omeprazole (Scheme 4), a proton pump inhibitor targeting H+/K+-ATPase, which has a 
half-life of 1-2 hours. Due to its covalent binding, omeprazole can be administered daily 
and be efficacious up to 28 hours.150 This increased duration of action could result in less 
frequent drug administration and propel the development of efficient drugs that can be 
cleared from the system quickly to reduce a patient’s drug burden.147 
 
Scheme 4 Structure of omeprazole, a small-molecule proton pump inhibitor, and its mechanism of action. 
Omeprazole is activated in an acidic environment to a sulfenic acid intermediate before an attack by Cys913 of 
H+/K+-ATPase, its target, forms a covalent disulfide bond.150,151 
3) Ability to combat drug resistance caused by a mutation 
It has been reported that irreversible covalent inhibitors could overcome some drug-
resistant mutations acquired after treatment in cancer and infectious diseases.139 For 
example, 50% of patients with NSCLC developed resistance against non-covalent EGFR 
inhibitors due to mutations in the ATP binding site (T790M or L858R).152–154 The use of 
irreversible inhibitors such as osimertinib (Tagrisso) and WZ4002 was shown to be 
effective against these mutated cells and may reduce side-effects associated with the 
inhibition of wild-type EGFR in healthy cells (Scheme 5).152,155–157 Osimertinib is now 




Scheme 5 Structures of WZ4002 and osimertinib, EGFRT790M covalent inhibitors, and their bound structures with 
Cys797. 
4) Ability to target shallow, ‘undruggable’ targets 
Covalent inhibitors have been shown to be efficacious for tackling more challenging and 
‘undruggable’ targets. For example, while Cathepsin K (Cat K) had previously been 
identified as an ‘undruggable’ target due to its small and solvent-exposed binding site,158 
odanacatib could be used as its covalent inhibitor (Scheme 6).159 The nitrile group reacts 
reversibly with a cysteine residue in the Cat K active site generating a thioimidate 
linkage.138 Odanacatib could advance to phase III clinical trials for the treatment of 
osteoporosis,160 though its development was stopped due to an associated increase in the 
risk of stroke.161 Another example is AMG 510, an inhibitor of KRASG12C mutant, present 
in approximately 13% of lung adenocarcinoma (Scheme 6).162 AMG 510 features an 
acrylamide and specifically targets the Cys12 residue of KRASG12C. The inhibitor is now in 
clinical trial phase 1/2 for the treatment of advanced solid tumours and NSCLC with the 




Scheme 6 Structures and mechanisms of action of odanacatib, a covalent inhibitor of Cat K, and AMG 510, a 
KRASG12C covalent inhibitor. 
 
2.3.3. Lysine-targeting covalent inhibitors 
Most covalent inhibitors have been designed to target a cysteine residue near the substrate 
binding site.163,164 The advantages of targeting cysteines include high selectivity due to its low 
abundance in the proteome and its unique reactivity as a thiol, a soft and reactive nucleophile, 
which can react even with a modest electrophile.165,166 But its low abundance is also its 
limitation, as not all binding sites have a cysteine in their proximity. Therefore, other 
nucleophilic residues, such as lysine, serine, threonine, tyrosine, glutamate, and aspartate, 
have also been targeted.142,143,172,144,147,166–171 Whilst TCIs exist for all these nucleophilic amino 
acids, this section will focus only on lysine-targeting inhibitors, considering the scope of this 
dissertation.  
Although the ε-NH2 group of lysine could potentially be an excellent nucleophile, unless 
perturbed, its pKa value (10.3) renders it challenging to target at physiological pH.173 The 
perturbation depends on the microenvironment around the lysine, which is affected by the 
nearby residues and the binding ligand. Lysine residues in catalytic sites are more likely to 
have pKa values perturbed to act as a nucleophile, while those located outside are less likely 
to do so. Despite the challenges, examples of inhibitors that target different types of lysine 
residues have been published.172 Electrophiles that have been reported include aldehydes, aryl 
sulfonyl fluorides, fluorosulfates, vinyl sulfones, and acrylate esters, and notable examples 




2.3.4. Examples of covalent inhibitors targeting lysine residues 
2.3.4.1. Natural products 
One of the early sources of lysine-targeting covalent inhibitors is natural products.  An 
example is wortmannin, a steroidal antibiotic produced by Penicillium wortmanni. 
Wortmannin was found to irreversibly inhibit a family of phosphatidylinositol 3-kinases 
(PI3K), a promising target in oncology.147,174,175 Depending on the isoform, Lys802 or Lys833 
attacks the enoate in a furan ring of wortmannin resulting in the ring-opening and the bound 
enamine product (Scheme 7).176,177 PX-866, a wortmannin analogue, was developed to address 
the poor selectivity and biological instability of wortmannin by replacing the furan ring with 
an open-chain enamine (Scheme 7).178 PX-866 has advanced into phase II clinical trials for 
the treatment of glioblastoma, castration-resistant prostate cancer, and NSCLC.179–181 
 
Scheme 7 Wortmannin and its analogue PX-866. Both target Lys802 or Lys833 of PI3K to form an enamine 
covalent complex. 
 
2.3.4.2. Targeting catalytic lysine residues 
Catalytic lysine residues are the simplest to target as they tend to have sufficiently perturbed 
pKa such that the amino group becomes nucleophilic at physiological pH.172 Recently, Dalton 
et al. developed a selective, irreversible inhibitor 1 targeting PI3Kδ at its conserved catalytic 
Lys779 (Scheme 8).182 The design of 1 was based on the clinical candidate GSK2292767, a 
potent and selective PI3Kδ inhibitor.183 The Lys779 in PI3Kδ attacks the activated ester in 1 
to form the covalently bound amide complex. The inhibitor was found to be selective to the 
δ isoform over α, β, and γ isoforms of PI3K and had a duration of action for over 48 hours in 




Scheme 8 A selective irreversible PI3Kδ inhibitor 1 equipped with an activated ester. Its design was based on 
GSK2292767, a reversible inhibitor. 
Gushwa et al. developed the covalent inhibitor 2 targeting the Src-family tyrosine kinases, a 
potential drug target for cancer treatment.184 The design combined the affinity-labelling 
agent 5’-p-fluorosulfonylbenzoyladenosine (FSBA) and the Src-family inhibitor PP1 whose 
p-tolyl group can interact with a hydrophobic pocket found in all Src-family kinases (Scheme 
9).185 The catalytic Lys295 covalently binds 2 through the attack on the sulfonyl fluoride group.  
The alkynyl group was appended to the solvent-exposed 2’ position for monitoring the 
covalent cross-linking via CuAAC.186 
 
Scheme 9 Irreversible Src-family kinase inhibitor 2, designed by combining affinity-labelling agent FSBA and 
the reversible inhibitor PP1. The catalytic Lys295 binds to 2 by attacking the sulfonyl fluoride. 
 
2.3.4.3. Targeting non-catalytic lysine residues 
Targeting non-catalytic lysine residues, while more challenging because the pKa may not be 
perturbed adequately,187 can be achieved, and a few examples have been reported in the 
literature. NU6300, an irreversible inhibitor for cyclin-dependent kinase 2 (CDK2), is one such 
example (Scheme 10).188 CDK2 is involved in cell cycles and is an important target in 
oncology.189 Anscombe et al. developed NU6300 based on the structure of NU6102,190 a potent 
reversible inhibitor of CDK2 lacking in cellular activity.188 It was noticed that the sulfonamide 
in NU6102 is close to Lys89, so the electrophilic vinyl sulfone analogue NU6300 was made. 
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NU6300 binds CDK2 via Michael addition (Scheme 10). The covalent analogue was shown to 
have a better cellular activity compared to its reversible version. 
 
Scheme 10 The vinyl sulfone NU6300, an irreversible CDK2 inhibitor based on NU6102, was developed by 
Anscombe et al.188 Lys89 forms a covalent bond with NU6300 via Michael addition. 
The 70 kilodalton heat shock proteins (HSP70s) are a family of molecular chaperones, which 
regulate protein folding and refolding and are essential to protein homeostasis.191 The 
inducible isoform HSP72 has been established as an oncological target and linked to drug 
resistance.192 Pettinger et al. disclosed the development of the adenosine-derived HSP72 
inhibitor 4 in a series of publications (Scheme 11).193,194 The design was based on the previous 
high-affinity reversible inhibitor 3, with the inclusion of an aryl sulfonyl fluoride moiety at 
position 5’ and a change in the purine substituent. The inhibitor was confirmed to react with 
the non-catalytic Lys56 and showed efficient covalent binding. 
 
Scheme 11 Developed by Pettinger et al., 4 is an irreversible inhibitor targeting HSP72 derived from reversible 
analogue 3.194 The sulfonyl fluoride at the 5’ position reacts with non-catalytic Lys56. 
Overexpression of eukaryotic translation initiation factor 4E (eIF4E), a part of the eIF4F 
protein complex, results in the stimulation of protein translation implicated in several types 
of cancer.195,196 Taunton et al. generated a small library of aryl sulfonyl fluorides targeting the 
non-catalytic Lys162 proximal to the m7GTP binding pocket.197 Guided by their virtual library, 
molecular docking, and co-crystal structures, compound 5 was synthesised as part of the 
study (Scheme 12). Compared to previously known inhibitors, which were inactive in cells 
because of a lack of cell permeability,198–200 5 was found to label eIF4E efficiently both as a 




Scheme 12 Aryl sulfonyl fluoride 5 was developed by Wan et al. as an eIF4E covalent inhibitor targeting non-
catalytic Lys162 near the binding site.197 
 
2.3.4.4. Targeting solvent-exposed lysine residues 
The most challenging Lys residues to target are those that are solvent-exposed as their pKa 
values would be largely unperturbed, thus possessing little nucleophilicity.172 Mcl-1 is an 
anti-apoptotic protein that binds to BH3-only proteins, preventing the activation of pro-
apoptotic proteins, and is overexpressed in several refractory cancers, making it a validated 
target for cancer treatment.201–203 Akçay et al.204 developed the pseudo-irreversible covalent 
inhibitor 7 by appending a boronic acid–aldehyde warhead to the indole–acid in the non-
covalent inhibitor 6 (Scheme 13).205 The pyrazole and phenol rings were used as spacers to 
place the electrophilic warhead within 3 Å of the solvent-exposed Lys234. A boronic acid 
group was incorporated to stabilise the bound imine product 8 against hydrolysis. Compound 
7 was shown to gain a 5-fold increase in cellular activity compared to its non-covalent version. 
 
Scheme 13 Based on the indole-acid 6, the boronic acid–aldehyde 7 is a pseudo-irreversible covalent inhibitor 
targeting Mcl-1. Lys234 covalently binds 7 through the formation of boronic acid–stabilised imine 8. 
The inhibitors of apoptosis proteins (IAPs) are a protein family that plays a crucial role in 
regulating cell survival and death processes.206–208 XIAP, cIAP1, and cIAP2, three of the eight 
members, are overexpressed in many human tumour tissues, leading to poor prognosis.209–213 
Pellecchia research group disclosed successive reports of Lys-targeted pan-IAP and XIAP-
selective covalent inhibitors.214–216 Based on the tetrapeptide AVPF, which was known to 
interact with several IAPs, they conducted a series of screening campaigns and molecular 
docking studies that led to sulfonyl fluoride 9 and fluorosulfates 10–11 (Figure 9). 
Compounds 9 and 10 were designed to target surface-exposed Lys311 of XIAP.214,216 
Subsequently developed as a pan-IAP inhibitor, the fluorosulfate 11 can react with Lys297 of 
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XIAP and Lys291 of both cIAP1 and cIAP2.215 The fluorosulfate 11 displayed 9–14 nM IC50 
values for the three IAPs after six hours of incubation.  
 
Figure 9 Developed by Pellechia and co-workers, the aryl sulfonyl fluoride 9 and the fluorosulfates 10-11 were 
used as IAP inhibitors targeting surfaced-exposed lysines.214–216 
Overall, covalent inhibitors have re-emerged as an extremely powerful tool in therapeutics. 
Using rational design and a broad range of electrophiles available, they have gained ground 
in oncology and are likely to develop into other fields.140 While initially, cysteinyl thiols were 
the primary target for TCIs, targeting the ε-NH2 in lysines has been shown to also be a viable 
strategy. With the ever-increasing interest in TCIs,145,147 we have gained more insight into this 
field, and the future for covalent inhibitors is promising. 
 
2.3.5. Combining stapled peptides and covalent inhibition 
Given the outlined advantages of covalent inhibition (section 2.3.2), its combination with 
stapled peptide can be considered as a progression towards a more effective drugging of PPIs. 
The merging of the two modalities was exemplified by the work of Hoppmann and Wang, 
which inspired the work described in Chapter 4 of this thesis. They described the 
incorporation of an aryl sulfonyl fluoride–bearing amino acid into a stapled peptide sequence, 
mSF-SAH, for irreversible inhibition of p53–MDM2/4 PPI.134 The sulfonyl fluoride group was 
placed close to histidines and surfaced-exposed lysines of both MDM2 and MDM4. While no 
significant improvement to binding against MDM2 was achieved, mSF-SAH gained a 10-fold 
improvement in MDM4 binding relative to SAHp53-8, the unmodified stapled peptide (Figure 
10).99,134  The formation of a covalent complex of MDM4–mSF-SAH was confirmed by ESI-MS 





Figure 10 SAHp53-8 (by Bernal et al.)99 was used as a basis for MDM4 inhibitor mSF-SAH developed by 
Hoppmann and Wang.134 
Currently, research into combining stapled peptides and covalent inhibitors is still in its 
infancy, with scarce examples in the literature.134,217 All instances feature one-component 
hydrocarbon stapling, which lacks a functionalisable handle; hence an electrophilic moiety 
must be placed on a side-chain or the N-terminus, making its incorporation and optimisation 
more laborious than via stapling. Thus, there is an opportunity to improve the process by 
switching the stapling procedure to 2C-PS. The utilisation of external linkers would 





Chapter 3 — Antibody–Drug Conjugates 
3.1. Description and mechanism of action of antibody–drug 
conjugates 
The concept of targeted cancer therapeutics is not new. In fact, Paul Ehrlich (1854–1915), a 
German physician, developed the concept of “Zauberkugel” or “magic bullet” which can 
specifically target microbes or tumour cells.218 Ehrlich’s ground-breaking work opened up the 
field of chemotherapy and eventually led to the conception of antibody–drug conjugates 
(ADCs). 
ADCs consist of three parts: a monoclonal antibody acting as a delivery motif, a cytotoxic 
drug (also called “payload” or “warhead”) for killing target cells, and a chemical linker 
covalently connecting the two parts (Figure 11). While each component has its own role in 
the ADC, they can exert influences on one another. Thus, designing an ADC requires careful 
consideration of all components. 
 
Figure 11 General structure of ADCs. The “spacer” can be used for physicochemical property modulation. The 
release mechanism is not present in some ADCs. Created with BioRender.com. 
ADCs utilise the exquisite targeting ability of the antibody to specifically bind to the chosen 
antigen.219,220 After recognising and binding to the cell-surface receptor, the ADC-antigen 
complexes are internalised via receptor-mediated endocytosis.219,220 Subsequent trafficking 
inside the cell liberates the payload either in the endosome or the lysosome, dependent upon 
the release mechanism. The payload is then able to execute its mechanism of action and cause 




Figure 12 Mechanism of action of ADCs. Payloads may be liberated in the endosome or the lysosome depending 
on the release mechanism. Created with BioRender.com. 
The use of targeting motif like an antibody to guide cytotoxic drugs results in a larger 
percentage of drugs reaching the target cells, decreasing a minimum effective dose (MED).  
Also, as fewer drug molecules enter healthy cells, the toxicity decreases, hence increasing a 
maximum tolerated dose (MTD). Overall, the therapeutic window is expanded (Figure 13).225 
 




3.2. Marketed ADCs 
The first ADC, reported in 1958 by Mathé et al., was constructed from a hamster-derived IgG 
antibody conjugated with the anti-cancer drug methotrexate.226,227 The ADC was found to be 
superior in killing leukaemia cells in mice compared to methotrexate alone or co-
administration of the immunoglobulin and methotrexate. While Mathé’s ADC did not reach 
clinical application, it provided a proof of principle for this now rapidly growing area of 
immunoconjugates. 
The field had to wait over 40 years for the first ADC to arrive on the market. In 2000, 
Gemtuzumab ozogamicin (Mylotarg®) was approved by the FDA for the treatment of acute 
myeloid leukaemia (AML).228 However, Mylotarg® was voluntarily withdrawn by Pfizer in 
2010 after results from the confirmatory trial showed no clear benefit over standard of care 
and associated toxicity.229,230 Mylotarg® was re-introduced in 2017 after an adjustment in its 
dosing regimen and employed for a restricted subset of CD33-positive AML patients.53,231,232 
The setback from the withdrawal of Mylotarg® did not remain for long and was quickly turned 
around by the approval of brentuximab vedotin (Adcetris®) in 2011 for treatment of relapsed 
or refractory Hodgkin lymphoma and anaplastic large cell lymphoma.233 Since then, the 
number of ADCs in the market has increased to nine—five of these were approved by the FDA 





















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































3.3. Monoclonal antibodies 
Antibodies or immunoglobulins (Ig) are large, Y-shaped glycoproteins, which are secreted by 
B-cells upon activation of the immune system (Figure 14).252 They consist of four polypeptide 
chains, namely, two identical heavy chains (HCs) and two identical light chains (LCs). For 
IgG1, which is the most commonly used antibody subtype in ADCs, the chains are connected 
via four disulfide bonds in the hinge region.253 Each HC contains three constant domains (CH1, 
CH2, and CH3) and one variable domain (VH), while each LC contains one constant domain (CL) 
and one variable domain (VL). All constant domains constitute the constant region, which is 
highly conserved across each antibody subtype. In contrast, the variable region, containing 
VH and VL domains, are much more diverse in structure and sequence. The two Fab (fragment, 
antigen-binding) arms, which are the antigen-binding region, comprise the entire LCs and 
the VH and CH1 domains of HCs. The rest of the HCs form the Fc (fragment, crystallisable) 
stems, which are responsible for binding to other receptors or immune molecules, ensuring 
appropriate immune responses for each antigen.254 IgG, the most abundant antibody in 
human, also contains a conserved glycosylation pattern at Asp297 in the CH2 domains.252,255 
 
Figure 14 General structure of an immunoglobulin G1 (IgG1) antibody. Created with BioRender.com. 
Antibodies have two main functions. First, they recognise foreign pathogens by the binding 
of complementary binding regions (CDRs) at their paratopes (the amino acids at the tip of the 
Fab region) to specific cell-surface antigens.256 Upon recognition, antibodies then perform 
their second function by recruiting effector cells like phagocytes or natural killer (NK) cells 
to destroy the bound cells, the specifics of which depend on a particular Fc region. This 
process can also invoke antibody-dependent cell-mediated cytotoxicity (ADCC) for 
eliminating pathogens through the interaction of the Fc region with Fc-gamma receptors 
(FcγRs) on immune cells such as NK cells.256,257 
The selection of antibodies for constructing ADCs requires them to pass the following 
criteria.258,259 Firstly, ADCs should specifically target a receptor that is highly expressed on 
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cancer cells and has significantly lower expression on healthy cells, thereby ensuring the 
delivery of the cytotoxin to the malignant cells. Secondly, they should possess an excellent 
target-binding affinity to allow for efficient internalisation. Thirdly, the antibodies should 
have long circulating half-life as it may take days or weeks before they can bind to the target. 
In addition, they should have low immunogenicity, i.e. the immune system should not 
recognise the antibodies as foreign and hence does not prematurely remove them from the 
body.   
 
3.4. Linkers 
Linkers are heterobifunctional molecules, having two orthogonal functionalities for 
connecting a mAb to a drug molecule. The properties of these chemical linkages can directly 
influence the performance of ADCs, including their stability, pharmacodynamics (PD), 
pharmacokinetics (PK), and therapeutic window.258,260–262 Absolute requirements for ADC 
linkers are stability in circulation to avoid premature cleavage of the payload, which can 
contribute to systemic toxicity, and an ability to release the payload upon internalisation in 
a traceless fashion (i.e. unmodified drug) or such that there is no detrimental effect on the 
performance of the drug if a remnant of the linker remains. Apart from these criteria, low 
hydrophobicity is also desired to reduce aggregation of the resulting ADCs; high aggregation 
can cause faster clearance, hepatotoxicity, and an undesired immune response.262 
 
3.4.1. Antibody attachment site 
The sites of linker-antibody conjugation can have a large effect on the pharmacology of an 
ADC. The potency and PK are primarily controlled by the drug-to-antibody ratio (DAR). While 
a greater DAR can elicit a better efficacy (with limitation), too high DAR may cause 
aggregation and poor PK profile due to the hydrophobic nature of most warheads.262 The sites 
of attachment can also have a significant impact to the stability of the linkage and the binding 
affinity of the antibody—e.g. conjugation in the Fab region may negatively affect the antigen 
recognition ability of the antibody.263,264 
Most ADCs in the clinic use either native surface Lys side chains or reduced Cys in the hinge 
region for conjugation (Scheme 14). For Lys conjugation, amide coupling using NHS ester as 
the reagent is currently the main method which is used, such as in the synthesis of 
gemtuzumab ozogamicin, trastuzumab emtansine, and inotuzumab ozogamicin.53 However, 
as there are approximately 80 lysine residues, with approximately 40 of them chemically 
accessible,265 a heterogeneous mixture of ADC species with varying DARs are inevitably 
obtained.262 To address the problem of heterogeneity, cysteines can be modified instead. The 
four interchain disulfides can first be reduced to reveal free thiols, without affecting the 
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structural integrity of the antibody. These liberated thiols can then be modified through a 
variety of chemical means with maleimides being the most commonly used alkylating 
reagents; six of the nine approved ADCs utilise this reagent.53 
 
Scheme 14  Selected examples of antibody modification using native lysine or cysteines. Examples of stochastic 
modification include the use of NHS ester and maleimide reagents for lysine and cysteine conjugations, 
respectively. For site-selective re-bridging modification, dibromomaleimide, dibromopyridazinedione, and 
divinylpyrimidine (DVP) reagents are shown. Stars refer to payloads. 
To further improve the homogeneity of the resultant ADCs, site-selective modification 
strategies have been invented. An example is re-bridging reactions of native cysteines 
(Scheme 14). By re-bridging pairs of cysteines, precise installation of a controlled number of 
payloads (typically four per antibody) can be achieved. Examples of such reagents include 
dibromomaleimide,266,267 dibromopyridazinedione,268 and divinylpyrimidine (DVP).269 Other 
approaches to site-selective modification include antibodies engineered with unnatural 
amino acids for bioorthogonal conjugations, non-natural cysteines, and enzymatic 
modification of amino acids or the antibody glycan.261,262 
 
3.4.2. Release mechanism 
The second role of linkers is to release the drug when ADCs have arrived in the target cells. 
Depending on the release mechanisms, the linkers can be broadly categorised into either 
cleavable or non-cleavable.  
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3.4.2.1. Non-cleavable linkers 
Non-cleavable linkers contain stable bonds that do not suffer breakage in a cellular 
environment.262 Therefore, the warheads are released when the ADCs undergo lysosomal 
degradation and will have the conjugation amino acid attached to the active warhead.262 Thus, 
the success of this strategy requires that the drug molecule is not affected by the extra 
appendage. Non-cleavable linkers are currently used in two marketed ADCs, trastuzumab 
emtansine a0nd belantamab mafodotin. In the former ADC, conjugation was achieved using 
succinimidyl 4-(N-maleimidomethyl)cyclohexane-1-carboxylate (SMCC) resulting in final 
thioether linkage,235 while the latter contains a maleimidocaproyl (MC) amide linkage 
(Scheme 15).251 It has been demonstrated that the modified DM1 (from trastuzumab 
emtansine) and MMAF (from belantamab mafodotin) retain their cytotoxicity with these 
appendages.235,270 
 
Scheme 15 Non-cleavable linkers of trastuzumab emtansine and belantamab mafodotin. Lysosomal degradation 
of both ADCs results in amino acid–linker modification to the payloads. Bold blue bond indicates payload-linker 
bond; red refers to payload; pink atoms are part of an antibody. 
 
3.4.2.2. Cleavable linkers 
An alternative strategy is to utilise the unique environment in the malignant cells to release 
an unmodified payload from the antibody, e.g. low pH in the endosomes and lysosomes, 
reducing environment, or intracellular enzymes. The first two examples are termed 
“chemically cleavable”, while the last is called “enzyme cleavable”. 
As the ADCs are internalised via receptor-mediated endocytosis, they are trafficked through 
endosomes and lysosomes. These cellular compartments are significantly more acidic (pH 
5.0-6.0 for endosomes, pH 4.8 for lysosomes) than in plasma (pH 7.4).262 Chemists exploit this 
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difference by using acid-labile functional groups like acyl hydrazones and carbonates for 
intracellular drug release (Scheme 16). Gemtuzumab ozogamicin and inotuzumab 
ozogamicin contain the acyl hydrazone linkage,228,237 whereas sacituzumab govitecan bears 
the acid-sensitive carbonate moiety.249 Alternatively, a high concentration of free thiols such 
as GSH in cells can be exploited to release payloads from disulfide linkages.271,272 This strategy 
is used mainly in maytansinoid-containing ADCs but is also a part of the double release 
mechanism in calicheamicin-based ADCs, Mylotarg® and Besponsa® (Scheme 16).228,237,273 
 
Scheme 16 Chemically cleavable linkers. Two main types are reducible disulfides and acid-labile linkage. 
Internalised ADCs are often trafficked to lysosomes, which contain several unique hydrolytic 
enzymes that can be exploited for intracellular release of unmodified cytotoxins.274 One 
heavily targeted enzyme is cathepsin B, a lysosomal protease overexpressed in many cancer 
types.275 Cathepsin B can recognise certain short dipeptide sequences such as valine-citrulline 
(Val-Cit), valine-alanine (Val-Ala), or phenylalanine-lysine (Phe-Lys), cleaving the C-
terminal amide bond (Scheme 17).276–278 The installation of a self-immolative spacer such as 
p-aminobenzyloxycarbonyl (PABC) allows the enzyme room to access the peptide bond and 
a traceless release of the payload (Scheme 17).277 Val-Cit-PABC linkers are successfully used 
in three marketed ADCs, all of which use MMAE as the payload: brentuximab vedotin, 
polatuzumab vedotin-piiq, and enfortumab vedotin.53 The tetrapeptide sequence glycine-
glycine-phenylalanine-glycine (GGFG) has also recently been exploited for constructing 
cathepsin B–cleavable ADC, trastuzumab deruxtecan.242 Other moiety like cyclobutane-1,1-
dicarboxamide-citrulline (cBu-Cit) was developed for greater specificity towards cathepsin 
B.279 
Because cytotoxic warheads tend to be lipophilic, the use of abovementioned peptidic linkers 
contributes to the formation of undesired aggregates.280,281 Thus, several hydrophilic, 
cleavable linkers have been invented to reduce this issue (Scheme 17). Examples include the 
use of sugars such as glucuronic acid or galactose, cleavable by their corresponding 
glycosidases,282,283 and anionic linkages like aryl sulfates and pyrophosphates, cleavable by 




Scheme 17 Enzyme-cleavable linkers used in ADC constructions. The endogenous enzymes include cathepsin B, 
β-glucuronidase, β-galactosidase, arylsulfatase, and phosphatase. Cleavage sites are shown with red bold wavy 
lines. Stars indicate payloads. The self-immolative motif p-aminobenzyloxycarbonyl (PABC) or p-
hydroxybenzyloxycarbonyl is frequently used as a spacer. 
With a wide variety of linker technologies, each with its advantages and disadvantages, 




Cytotoxic drugs, usually called payloads or warheads, are an integral part of ADCs and 
responsible for killing the target cells. Early ADCs utilise traditional chemotherapeutic agents 
such as methotrexate and doxorubicin (Figure 15).226,227,286 The Lewis-Y specific chimaeric 
mAb–doxorubicin immunoconjugate (BMS-182248) reached phase II clinical trials but was 
discontinued due to the lack of efficacy.287 The failure to reach full clinical applications of 
these first-generation ADCs can be attributed to several factors, key amongst them being the 




Figure 15 Early ADCs used traditional chemotherapeutic agents as payloads (red). R in BMS-182248 indicates 
the same modification on cysteine. Antibodies and linkers are shown in pink and black, respectively.  
As it has been shown that only a tiny fraction of the administered ADC binds to the tumour 
cells (approximately 0.001–0.01%), extreme cytotoxicity of the payloads is of great 
importance.289 Currently, it is recognised that payloads with a sub-nM in vitro IC50 values are 
generally required to produce effective ADCs.225,290 While high cytotoxicity is critical to the 
ADC construction, there are also other important criteria to be fulfilled: a known mechanism 
of action, stability in plasma, amenability to linker attachment, moderate aqueous solubility, 
and acceptable lipophilicity.291 
Due to the stringent prerequisites, only a limited number of compounds are being employed 
as ADC payloads. There are two main classes of drugs currently employed in ADC fields: 
microtubule disruptors and DNA-damaging agents (including topoisomerase I inhibitors).291 
Alternative payload classes such as RNA polymerase II inhibitors, Bcl-XL inhibitors, and 
spliceosome inhibitors are also being investigated to a lesser extent.291 In the following 
sections, focus will be placed on payloads used in marketed ADCs or those that are in late-
stage clinical trials. 
 
3.5.1. DNA-damaging agents 
DNA integrity is critical to proper cellular functions and cell survival.292 Thus, damaging DNA 
in tumour cells constitutes an attractive strategy to afford cell death. DNA-damaging agents 
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can be categorised into four broad types: DNA alkylators, DNA cross-linkers, DNA 
intercalators, and DNA double-strand breakers.291 
3.5.1.1. Calicheamicins 
Calicheamicins are a family of enediyne anti-tumour antibiotics first isolated from a 
bacterium Micromonospora echinospora subsp. calichensis in caliche clay soil.293–296 The 
enediyne natural products kill tumour cells by binding to DNA minor groove and cause a 
scission in DNA double-strands through a reaction with reactive 1,4-dehydrobenzene 
diradical (Scheme 18).297 Calicheamicin γ1I, the most abundant calicheamicin family member, 
is known to be the most potent cytotoxin of the family and was found to be highly active 
against leukaemia in a P388 murine model.298 Although it was later found that the 
calicheamicins were too toxic to be used as chemotherapy,298 its potential in targeted therapy 
was recognised. Currently, two marketed ADCs, Mylotarg® and Besponsa®, are equipped with 
N-acetyl calicheamicin γ1I, a semi-synthetic derivative.228,237 
 
Scheme 18 Mechanism of action of calicheamicin γ1I. After trisulfide exchange with free thiols, intramolecular 
cyclisation follows. Consequent conformational shift triggers Bergman cyclisation to produce the diradical 1,4-
dehydrobenzene which cleaves the bound DNA strand. 
Its intriguing structure and elegant mode of action prompted organic chemists to synthesise 
calicheamicin γ1I, first accomplished by Nicolaou and co-workers in 1992,299 followed by 
Danishefsky and co-workers in 1994.300 Owing to the complexity of this natural product, both 
total syntheses were long and arduous, with over 50 total steps, resulting in minimal yield of 
the final product. Thus, the industrial manufacture of calicheamicin γ1I is by fermentation.298 
Modification of this fermentation product was performed by installing an N-acetyl group to 
improve stability, followed by disulfide exchange with 3-mercapto-3-methylbutyryl 
hydrazide (DMH), hydrazone formation with 4-(4’-acetylphenoxy)butanoic acid (AcBut), and 
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final NHS ester formation to give the desired linker–drug, ready for bioconjugation with an 
antibody (Scheme 19).227,298 
 




The first member of the pyrrolobenzodiazepine (PBD) monomer natural product family, 
anthramycin, was first isolated from the Streptomyces refunius bacterium in 1965 (Figure 
16).301 PBD monomers were found to be potent anti-tumour antibiotics, and several other 
members of the family such as tomaymycin were soon discovered afterwards (Figure 16). 
 
Figure 16 Anthramycin and tomaymycin, two members of the PBD monomer family. 
PBDs are sequence-selective DNA minor-groove binders. After a PBD binds to a DNA 
sequence, the C2-amino group of guanine can attack the C11 imine in the PBD core (Scheme 
20).302 The resulting covalent PBD–DNA adduct can cause various biological effects, including 
the inhibition of transcription or DNA repair, leading to cell death.303,304 
 
Scheme 20 Mechanism of action of PBDs. After its insertion into DNA minor groove, C2-amino group of 
guanine attacks the electrophilic imine in PBD to form aminal linkage. 
A study by Bose et al. in the 1990s found that linking two PBD monomers can dramatically 
increase its in vitro potency, as demonstrated by connecting two DC-81 molecules via a 
propane diether linker at C8-alkoxy group to form the PBD dimer DSB-120 (Figure 17a).305 
Subsequently, many PBD dimers have been developed, including SJG-136 (Figure 17b), which 
displayed an in vitro IC50 of 0.27 pM against the A2780 human ovarian carcinoma cell line.306 
SJG-136 advanced to phase II clinical trials for the treatment of advanced chronic lymphocytic 




Figure 17 a) Dimerisation of PBD monomer DC-81 improved IC50 in murine AJD/PC6 plasmacytoma cell line by 
more than 600 folds. Data were taken from Bose et al.305 b) Structure of PBD dimers SJG-136. 
PBD dimers are attractive as ADC payloads because of their distinct mechanism of action and 
extreme potency. Two prominent examples are SGD1882 (payload of linker–drug talirine) and 
SG3199 (payload of linker–drug tesirine; Figure 18). Both payloads are highly potent anti-
cancer agents with low-pM in vitro IC50 values, but SG3199 is significantly less hydrophobic 
due to the removal of the pyrroline-linked phenyl rings.307 They are used in vadastuximab 
talirine (phase III for treatment of AML, terminated due to higher rate of deaths)53 and 
loncastuximab tesirine (phase III for treatment of relapsed or refractory diffuse large B-cell 
lymphoma clinical trials).308 
 
Figure 18 Two PBD dimers, SGD1882 and SG3199, and their respective linker–drugs, talirine and tesirine. Both 
compounds are used in ADCs which are being investigated in clinical trials. Linker portions are indicated in blue. 
The synthesis of tesirine was disclosed by researchers at Spirogen in 2016 (Scheme 21).309 
Starting from benzylvanillin (12), one PBD monomer was synthesised with Val-Ala-PABC 
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attached (19) and another without the linker (21); the key step was the formation of the 
central seven-membered ring via a spontaneous cyclisation between the carbamate nitrogen 
and the aldehyde formed after Swern oxidation. The heterodimerisation was then achieved 
using diiodopentane, giving PBD dimer 22. Removal of all protecting groups and 
incorporation of maleimide-PEG unit produced tesirine in 0.54% overall yield over 30 steps.  
 
Scheme 21 Total synthesis of tesirine (SG3249) starting from benzylvanillin (12) by Tiberghien et al.309 DCC = 
N,N’-dicyclohexylcarbodiimide, HOBt = 1-hydroxybenzotriazole, TEMPO = (2,2,6,6-tetramethylpiperidin-1-
yl)oxyl, TCCA = trichloroisocyanuric acid, DBU = 1,8-diazabicyclo[5.4.0]undec-7-ene, TBAF = 




Duocarmycins are a family of natural product anti-cancer antibiotics featuring a reactive 
spirocyclopropane motif. Its first member, CC-1065, was isolated from a Streptomyces 
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bacterium in the 1970s (Scheme 22a).310,311 Duocarmycins are known to bind the DNA minor 
groove in A-T-rich regions and selectively alkylate N3 of adenine, providing mid-pM in vitro 
cytotoxicity (Scheme 22b).312 CC-1065 was extremely potent in vitro, but its lacklustre activity 
and irreversible hepatotoxicity in vivo hampered its therapeutic development.310,313 Thus, 
other synthetic analogues have been investigated to improve the biological properties of 
duocarmycins. In particular, halogen-containing seco analogues were developed as prodrugs, 
which require cyclisation for cytotoxicity. Seco-duocarmycin-hydroxybenzamide-azaindole 
(seco-DUBA, Scheme 22b), developed by Synthon Biopharmaceuticals, is being used as an 
ADC payload in trastuzumab duocarmazine, currently in phase III clinical trial for the 
treatment of metastatic breast cancer.53,314–316 
 
Scheme 22 a) Structure of CC-1065, first isolated duocarmycin. b) Activation of seco-duocarmycin-
hydroxybenzamide-azaindole (seco-DUBA) via Winstein-Baird spirocyclisation and its mechanism of action. 
The synthesis of seco-DUBA was disclosed by Elgersma et al. in 2015 (Scheme 23). The DNA-
binding moiety 25 (indicated by green in Scheme 22b) was synthesised in four steps from 5-
nitropyridin-2-amine (23) via a Chichibabin cyclisation. Separately, the synthesis of the 
DNA-alkylating unit 30 (indicated by red in Scheme 22b) was achieved in ten steps via the 
key incorporation of an epoxide to form intermediate 29, which allowed subsequent 
intramolecular cyclisation, via lithium-halogen exchange, to form the five-membered ring 
portion. The two units were then coupled using EDC, and then the removal of benzyl and 




Scheme 23 Synthesis of seco-DUBA by Elgersma et al.315 TFAA = trifluoroacetic anhydride, DPPA = 
diphenylphosphoryl azide, Ns = nosyl 
 
3.5.1.4. Camptothecins 
Camptothecin is an alkaloid natural product first isolated from the Chinese plant 
Camptotheca acuminata in the 1960s (Figure 19).317 It acts as a potent anti-cancer agent by 
binding to a topoisomerase I–DNA cleavage complex, preventing DNA religation, 
subsequently causing DNA double-strand breaks and apoptosis.318 Whereas camptothecin 
showed good in vitro anti-cancer activity, it suffered from poor solubility and severe side 
effects in vivo.318 Analogues with better pharmacological profiles have been developed, and 
two (irinotecan and topotecan) are approved by the US FDA for cancer treatment (Figure 
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19).319 Furthermore, two other camptothecin derivatives are successfully used as payloads in 
marketed ADCs: SN-38 and exatecan.319 
 
Figure 19 Structure of camptothecin and its four analogues: irinotecan and topotecan (used in chemotherapy), 
SN-38 (the active metabolite of irinotecan), and exatecan. The last two are used in marketed ADCs. Blue capital 
letters denote ring names. 
SN-38 is the active metabolite of the prodrug irinotecan.320 While SN-38 is 2-3 orders of 
magnitude more potent than irinotecan, it has low aqueous solubility and so cannot be 
administered on its own.319,321 On the contrary, as SN-38 has in vitro IC50 in the low nanomolar 
range,322 it has generated widespread interest in targeted therapeutics and is used as the 
payload in sacituzumab govitecan (Trodelvy®).247 Reported by Sawada et al., SN-38 can be 
accessed semi-synthetically from camptothecin in three steps (Scheme 24).323 Ethylation at 
the 7-position of camptothecin was effected by Minisci-type reaction using propionaldehyde 
and ferrous sulfate to give intermediate 32. Compound 32 was then oxidised to N-oxide 33 
with hydrogen peroxide and following irradiation with mercury lamp in the presence of 
sulfuric acid gave SN-38 in 30-35% overall yield.  It is also possible to obtain SN-38 via a total 
synthesis, accomplished in 17 steps in 2011 by Yao et al.324 
 
Scheme 24 Semi-synthesis of SN-38 from camptothecin by Sawada et al.323 
Exatecan (DS-8201) is a more potent camptothecin derivative compared to SN-38, exhibiting 
sub-nM cytotoxicity towards several cancer cell lines.325–328 Exatecan contains the amine-
substituted six-membered F ring bridging the A and B rings which increases its stability and 
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aqueous solubility.319 The latest total synthesis of exatecan mesylate was disclosed in a patent 
filed by Daiichi Sankyo’s scientists in 2019 (Scheme 25a).329 Starting from commercially 
available 2-fluoro-4-nitrotoluene (34) as the template for the A-ring, the F-ring was installed 
through appending the carbon chain to compound 35 using a Heck reaction and cyclised via 
a Friedel-Crafts-type acylation. Annulation to form the B-ring was achieved with the 
Friedländer reaction between aminoaryl ketone 37 and compound 38, which already contains 
C-, D-, and E-rings, to give protected exatecan 39. Removal of the remaining acetyl group 
with methanesulfonic acid then gave exatecan as a mesylate salt in a total of 10 steps, not 
counting those required for the synthesis of the building block 38. Amongst other procedures, 
a multi-decagram-scale asymmetric synthesis of the tricyclic compound 38 was reported by 
Henegar et al., which comprised of a total of 18 steps and is summarised in Scheme 25b.330 
 
Scheme 25 Total synthesis of exatecan mesylate and its building block 38 a) Total synthesis of exatecan 




Scheme 25 (continued) b) Asymmetric synthesis of compound 38, an important building block for the synthesis 
of camptothecin and its analogues, was published by Henegar et al.330 DPPP = 1,3-
bis(diphenylphosphino)propane. 
 
3.5.2. Tubulin inhibitors 
Microtubules are dynamic protein polymers with a cylindrical shape consisting of 
heterodimers of α- and β-tubulins.23 These filaments are a major component of the 
cytoskeleton, essential to all eukaryotic cells. The highly dynamic polymerisation-
depolymerisation of microtubules is vital to a myriad of cellular processes, including 
intracellular transport, structural integrity maintenance, cell division, and mitosis.331 Thus, 
inhibition of tubulin biology has been a very effective strategy to target rapidly proliferating 
cancer cells. Many traditional chemotherapeutic agents, such as vincristine, vinblastine, and 
paclitaxel are anti-tubulin compounds.27  
Tubulin inhibitors can be divided into two broad classes according to their effects on the 
microtubule polymer; microtubule stabilisers enhance polymerisation, while microtubule 
destabilisers impede polymerisation.332 The former class includes the vinca alkaloids, 
colchicines, and dolastatins, while the latter class contain compounds such as the taxanes 
and discodermolide.332 Of the tubulin inhibitors, the auristatins and maytansines are amongst 




Auristatins are a class of synthetic peptides originated from anti-mitotic marine natural 
product dolastatin 10 isolated from Dolabella sea hares.276,333,334 Dolastatins and auristatins 
are highly cytotoxic with sub-nM in vitro IC50 values.270,276,335 They exert their cell-killing 
effects through the inhibition of tubulin polymerisation by binding near the Vinca alkaloid 
site, resulting in cell cycle arrest. However, auristatins are more water-soluble than their 
parent dolastatins.291,332,336,337 Combined, monomethyl auristatin E (MMAE) and monomethyl 
auristatin F (MMAF) are the most widely used cytotoxins in ADC development (Figure 
20).291,337 
 
Figure 20 Structures of dolastatin 10, monomethyl auristatin E (MMAE), and monomethyl auristatin F (MMAF). 
MMAE contains a norephedrine moiety at the “C-terminus” of the molecule, and its neutral 
charge gives it good membrane permeability.338 This auristatin analogue is currently used in 
three marketed ADCs, Adcetris®, Polivy®, and Padcev®.53 The total synthesis of MMAE was 
developed and licenced by Seattle Genetics,339 while Pettit et al. had earlier developed the 
synthesis of the constituent non-canonical β-methoxy-γ-amino acids, dolaproine (Dap) and 
dolaisoleuine (Dil) (Scheme 26).340,341 The total synthesis of MMAE centred on a 
stereoselective aldol reaction utilising boron enolate and Evans’ oxazolidinone to produce 
Dap and Dil. The two γ-amino acids were then elaborated to give fragment 50 and the 
tripeptide Fmoc-MeVal-Val-Dil-OtBu, which were then united using diethyl 





Scheme 26 Total synthesis of monomethyl auristatin E (MMAE) in a patent filed by Seattle Genetics.339 
Synthesis of Boc-Dap-OH and H-Dil-OtBu·HCl was according to Pettit et al.340,341 Proton sponge = 1,8-
bis(dimethylamino)naphthalene, Dap = dolaproine, MS = molecular sieves, DEPC = diethyl phosphorocyanidate, 
DIPEA = N,N-diisopropylethylamine, Dil = dolaisoleuine, MeVal = N-methylvaline, AIBN = 
azobisisobutyronitrile. 
MMAF differs from MMAE by replacing the norephedrine unit with phenylalanine. This 
change causes the generation of a charged terminal carboxylate at physiological pH, 
impairing its membrane permeability and lowering its potency in its free form.270 The 
decreased permeability can be seen as beneficial when used with targeted therapy against 
haematological cancers as seen in one marketed MMAF-containing ADC, Blenrep® for 
treatment of multiple myeloma.250,251 Doronina et al. reported the synthesis of MMAF using 
an Fmoc solid-phase peptide synthesis strategy on 2-chlorotrityl resin (Scheme 27).270 Resin-
bound phenylalanine was elongated with Dap, and then with tripeptide MeVal-Val-Dil. Final 




Scheme 27 Total synthesis of monomethyl auristatin F (MMAF) by Doronina et al.270 See Scheme 26 for 
structures of Dap and MeVal-Val-Dil. 
 
3.5.2.2. Maytansinoids 
Maytansine is a benzoansamacrolide first isolated from the bark of the Ethiopian shrub 
Maytenus ovatus in 1972 (Figure 21).342 Maytansine is a microtubule destabiliser that binds 
tubulin near the Vinca alkaloid binding site and has sub-nM potency against several cancer 
cell lines.343,344 Because of its high cytotoxicity, maytansine was evaluated as single-agent 
chemotherapy, but clinical benefits were not observed.345 Later, attention was focussed on 
using maytansine or its derivatives, maytansinoids, in targeted therapeutics.346 SAR study of 
maytansine by Widdison et al. found that while the ester side chain at C3 is required for 
bioactivity, its exact nature is variable without negatively affecting its cytotoxicity, except for 
the essential (S)-configuration at C2’.344 Thus, thiol-bearing maytansinoids DM1 and DM4 
were developed to facilitate their conjugation to an antibody.344 Currently, DM1 is used in 
Kadcyla® for treatment of HER2-positive metastatic breast cancer,234–236 and DM4 is a payload 
of mirvetuximab soravtansine, an ADC being examined in phase III clinical trial for folate 
receptor α–positive epithelial, primary peritoneal, or fallopian tube cancers.53,347,348 
 
Figure 21 Structures of maytansine and maytansinoids DM1 and DM4. 
The total synthesis of maytansine was accomplished by Corey et al. in 1980 over 30 steps.349 
Due to the complexity of the total synthesis, on industrial scale, maytansinoids are instead 
accessed semi-synthetically from a mixture of ansamitocins, obtained from fermentation of 
Actinosynnema pretiosum bacterium (Scheme 28).235 The acyl group at C3-hydroxyl was 
removed by reduction with LiAlH(OMe)3 to afford maytansinol. The obtained alcohol was 
then coupled with disulfide-containing acids 54 using EDC and ZnCl2 to give intermediates 




Scheme 28 Semi-synthesis of DM1 and DM4 from ansamitocin mixture by Lambert and Chari.235 DTT = 
dithiothreitol. 
 
3.5.3. Other payloads 
Apart from the abovementioned payloads, there are also other classes of compounds 
currently under investigation for use in ADCs (Figure 22): the anti-tubulin tubulysins,350,351 
DNA-alkylating agent indolinobenzodiazepine dimers (IGNs),352 RNA polymerase II–
inhibitor amatoxins,353 and spliceosome inhibitors.354 All these compounds are extremely 
potent cytotoxins in vitro, except for the amatoxins which suffer from poor membrane 
permeability due to its hydrophilicity. The syntheses of these payloads are not presented here 




Figure 22 Other classes of cytotoxins under investigation for the use as ADC payloads. 
 
3.5.4. Summary 
The introduced payloads with their in vitro cytotoxicities are summarised in Figure 23. Most 
payloads require laborious total synthesis or are derived semi-synthetically from 
fermentation products. All current payloads have low- or sub-nM IC50 values (cf. earlier-






Figure 23 Summary of in vitro cytotoxicity of various payloads. Numbers in parentheses after the payload class 
indicate a representative number of total steps for the synthesis or semi-synthesis. Amatoxins are not included 
in this chart as their in vitro IC50 values do not reflect their actual cytotoxicity. *The number of steps includes the 
incorporation of a linker. †May also be accessed semi-synthetically in three steps. 
 
3.6. Hemiasterlin 
Hemiasterlin (56, Figure 24), first discovered in the marine sponge Hemiasterella minor, is a 
member of a family of marine cytotoxic tripeptides and is a microtubule destabiliser.355,356 The 
tripeptide binds in the vinca domain, disrupting microtubule dynamics, and causes apoptosis 
with low- to sub-nM  IC50  for several cancer cell lines.357,358 
 
Figure 24 Structures of hemiasterlin (56) and taltobulin (HTI-286, 57). 
Extensive SAR studies by Nieman et al. and Zask et al. revealed taltobulin (HTI-286, 57) to be 
a similarly potent hemiasterlin analogue, by replacing the indole ring with a phenyl ring 
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(Figure 24).359,360 It was reported that taltobulin, although slightly less cytotoxic than 
hemiasterlin, would be more synthetically tractable.358 Hence, taltobulin was investigated 
clinically as a treatment for NSCLC and advanced to phase II clinical trial.361 However, the 
development was terminated by Wyeth for business reasons.362 
There have been three published total syntheses of hemiasterlin to date. Each route is 
described in brief in the following paragraphs.* 
The first total synthesis of hemiasterlin was published by Andersen et al. in 1997 via the use 
of Evans’ oxazolidinone (Scheme 29).363  First, indole 58 was trimethylated with MeI using 
KHMDS as a base in two steps giving indole 60. Next, a five-step procedure, in a sequence of 
DIBAL-H reduction to alcohol, Ley-Griffith oxidation to aldehyde, Wittig reaction to install 
an enol ether, followed by acid hydrolysis and Pinnick oxidation, for homologation of the 
carboxylate was used to generate carboxylic acid 61. Subsequent installation of a chiral 
oxazolidinone via a reactive mixed anhydride was followed by azidation with 2,4,6-
triisopropylbenzenesulfonyl azide (TPS-N3) resulting in a chiral azide which was reduced to 
an amine with SnCl2 and then Boc-protected to give compound 63. The chiral auxiliary was 
then removed by treating compound 63 with LiOOH. Finally, double methylation followed by 
LiOH-mediated hydrolysis gave the Boc-protected amino acid 64. 
The synthesis of the dipeptide fragment began with the derivatisation of Boc-protected N-
methylvaline (Boc-MeVal-OH) to a Weinreb amide which was reduced to an aldehyde with 
LiAlH4, followed by a Wittig reaction and deprotection with TFA to give unsaturated γ-amino 
ester 65. The amine 65 was extended to dipeptide 66 by coupling with Boc-tert-leucine (Boc-
Tle-OH) and subsequent deprotection. The two fragments, 64 and 66, were joined using 
PyBroP and DMAP. Finally, ester hydrolysis and Boc-group removal gave hemiasterlin in a 
total of 23 steps with a longest linear sequence (LLS) of 17 steps and an overall yield of 13%. 
 




Scheme 29 Total synthesis of hemiasterlin by Andersen et al.363 KHMDS = potassium hexamethyldisilazide, 
DIBAL-H = diisobutylaluminium hydride, TPAP = tetrapropylammonium perruthenate, MS = molecular sieves, 
NMO = N-methylmorpholine, TPS-N3 = 2,4,6-triisopropylbenzenesulfonyl azide, DCC = 
dicyclohexylcarbodiimide, Tle = tert-leucine, PyBroP = bromotripyrrolidinophosphonium hexafluorophosphate, 
DMAP = N,N-dimethyl-4-aminopyridine. 
In 2001, Vedejs and Kongkittingam reported their total synthesis of hemiasterlin using a 
benzothiazol-2-sulfonyl (Bts) protecting group and asymmetric Strecker synthesis strategy 
(Scheme 30). The synthesis of dipeptide 66 started with the protection of the amino group of 
(S)-valinol with Bts chloride, followed by N-methylation, Swern oxidation and Wittig reaction 
to give Bts-protected amino ester 68. Ensuing removal of Bts group was effected using 
thiophenol and K2CO3 to reveal a free amine which was then coupled with the Bts-protected 
acyl chloride of tert-leucine—prepared from tert-leucine in two steps. Subsequent removal of 
the Bts group gave dipeptide 66. 
The synthesis of a chiral tetramethyltryptophan motif started with scandium(III)-catalysed 
asymmetric Strecker reaction via an imine generated from aldehyde 69 (prepared in four steps 
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according to Andersen et al.)363 and (R)-2-phenylglycinol (70) with Bu3SnCN as the cyanide 
source to give amino nitrile 71. The nitrile was hydrolysed with hydrogen peroxide and 
potassium carbonate, and the chiral auxiliary was removed via hydrogenolysis to give amino 
amide 72. The amino group in 72 was protected with BtsCl and methylated with MeI, and the 
amide was converted to a reactive bis-Boc derivative 73 by treatment with Boc2O and DMAP. 
Amine 66 and compound 73 were united by treatment with DMAP; final Bts-deprotection 
and ester hydrolysis gave hemiasterlin in a total of 20 steps (LLS 13 steps, overall yield 30%).* 
 
Scheme 30 Total synthesis of hemiasterlin by Vedejs and Kongkittingam.364 Bts = N-benzothiazol-2-sulfonyl. 
The most recent total synthesis of hemiasterlin was reported by Lang, Jones, and Lindel in 
2017 via an organocatalysed α-hydrazination (Scheme 31).365 First, 3-tert-prenylation on 1H-
indole was performed under modified Tamaru’s conditions366 and then followed by N-
methylation giving compound 74. Hydroboration-oxidation of the terminal alkene with .9-
BBN and oxidation of the resulting alcohol by IBX gave aldehyde 75. The α-hydrazine was 
installed enantiomerically through an enamine-catalysed process using D-proline-derived 
tetrazole analogue (prepared from Cbz-D-proline in four steps as summarised in Scheme 31) 
with dibenzyl azodicarboxylate, followed by NaBH4 reduction to give alcohol 77. Subsequent 
hydrogenolysis simultaneously removed the Cbz protecting group and reduced the N-N bond 
 
* The yield for the transformation of compound 58 to compound 69 was based on reference 359 as yields were 
not reported in reference 363 for the last two individual steps of this transformation. 
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to give an amine which was then protected with Boc2O to give amino alcohol 78. Conversion 
of compound 78 to amino ester 79 was carried out by Parikh-Doering oxidation of the alcohol 
and Pinnick oxidation of the resulting aldehyde to form a carboxylic acid which was 
methylated concurrently with the amine using methyl iodide and sodium hydride. To perform 
peptide coupling with dipeptide 66 (prepared according to Andersen et al. in six steps)363, the 
methyl ester 79 was first hydrolysed using barium hydroxide. The coupling was then effected 
using 2-bromo-N-ethylpyridinium tetrafluoroborate (BEP) as the activating agent to give 
protected hemiasterlin 67. Finally, removal of the Boc group and the ethyl ester gave 
hemiasterlin in a total of 21 steps (LLS 15 steps, overall yield 17%). 
 
Scheme 31 Total synthesis of hemiasterlin by Lang, Jones, and Lindel.365 9-BBN = 9-borabicyclo[3.3.1]nonane, 
IBX = 2-iodoxybenzoic acid, BEP = 2-bromo-N-ethylpyridinium tetrafluoroborate. 
With its high cytotoxicity and relatively short and accessible synthesis, hemiasterlin has the 
potential to become a widely used payload in ADCs. Indeed, STRO-002, an ADC developed by 
Sutro Biopharma, Inc. and currently in phase I clinical trial for the treatment of ovarian and 
endometrial cancers, uses 3-aminophenylhemiasterlin as its payload.367
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Chapter 4 — Development of Stapled Peptide–Targeted 
Covalent Inhibitors of p53–MDM2 PPI*368 
4.1. Project aims and overview 
The aim of this project was to develop a series of novel stapled peptides carrying dialkynyl 
linkers with an electrophilic functionality to covalently bind to MDM2 and hence inhibit the 
p53–MDM2 PPI. The stapled peptides, mimicking p53, would be synthesised using the two-
component CuAAC peptide stapling developed in the Spring Group and the electrophile will 
be added onto the staple. In such a way, the peptide and the staple could be optimised 
separately and merged in the click reaction. Upon binding of the peptide, we envisioned that 
the electrophile would be able to covalently bind to a nucleophilic residue (i.e. Lys) located 
in the proximity of the binding site of MDM2 and thus improving the overall binding 
efficiency (Scheme 32).134 
 
Scheme 32 Utilising two-component peptide stapling to generate electrophile-bearing stapled peptides and 
their proximity-enabled bioreactivity. E = electrophile, LG = leaving group. 
The ideal electrophile used on the linker should be stable in water, preferentially attacked by 
Lys over other nucleophilic amino acids, and compatible with our CuAAC stapling 
methodology. Initially, efforts were focussed on incorporating a sulfonyl fluoride—an 
electrophilic moiety that has already been reported in the literature to increase the inhibitory 
activities of peptides via covalent cross-linking—on the dialkynyl linker.134,369 This 
functionality displays desirable properties for biological applications, such as resistance to 
reduction and hydrolysis, and cleavage being exclusively heterolytic.370 Several examples that 
employed sulfonyl fluorides for targeting Lys are shown in Section 2.3.4. The linker would 
then be tested for its suitability for stapling by studying its stability under both CuAAC and 
physiological conditions, along with its reactivity towards Lys. 
Concurrent to the study of the electrophilic motif and dialkynyl linker, the design and 
synthesis of the peptides to be stapled were carried out. Based on previous work in the Spring 
Group, peptides PDI-E (Ac-LTFXEYWAQLXS-NH2, X = Orn(N3)) and PMI (H-
 
* The work described in this chapter has been published in Charoenpattarapreeda, et al., ChemComm, 2019.368 
Part of the text and figures were adapted from this publication. 
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TSFAEYWNLLSP-OH) were chosen as the starting point for our investigations, since both 
showed high affinity in binding MDM2.103 Stapling positions, sequence mutations and the 
type of linkers were investigated under the guidance of computational simulations 
(performed by our collaborator Dr Yaw Sing Tan at the Bioinformatics Institute, A*STAR, 
Singapore).  
Suitable electrophilic linkers were then used for stapling appropriate peptide sequences using 
the double-click stapling (Scheme 32).115 The binding of the obtained stapled peptides to 
MDM2 was examined using fluorescence polarisation (FP) and mass spectrometry (MS) 
experiments. 
 
4.2. Peptide and linker design 
Close to the p53 binding surface of MDM2, there are two potential lysine residues that can be 
targeted with a sulfonyl fluoride group: Lys51 and Lys94 (Figure 25).  
 
Figure 25 MDM2 shown with the two potential lysine residue targets (purple). p53 is shown in red and MDM2 in 
grey. (PDB ID: 1YCR)82 
Molecular modelling, conducted by Dr Yaw Sing Tan, suggested two different linkers that 
could be used to staple the p53 peptide while enabling access to the two lysine residues: 
• Strategy (1): the prediction to reach Lys51 showed peptide PDI-E stapled with 
compound 80, an aryl sulfonyl fluoride analogue of the strained diyne SWD (Scheme 
33a).  
• Strategy (2): 3,5-diethynylbenzene sulfonyl fluoride (81) was anticipated as the 




Scheme 33 Two proposed strategies for reaching lysines close to MDM2 binding site. a) Stapling PDI-E with the 
aryl sulfonyl fluoride 80 for targeting Lys51 (blue). b) Stapling P1 with 81 for targeting Lys94 (pink). 
Previous work in the Spring Group indicated that 80 is not readily available, due to long and 
challenging synthesis.120 Thus, it was decided to prioritise the second strategy. 
To pursue this strategy, several changes to the peptide sequence in PDI-E were needed. In 
order to obtain an optimal distance between the aryl sulfonyl fluoride group of 81 and Lys94 
(1.63 Å),371 it was necessary to move the position of the staple from what was previously 
published by the Spring group. In particular, the azido amino acids replaced Glu5 and Ser12 
of PDI-E, and the mutation Q9A was also introduced to minimise the steric clash between 
the side chains of the peptide and the linker 81. Orn(N3) was chosen as the azido amino acid 
for stapling as its side chain showed the optimum length to reach Lys94 and increased helicity 
according to computational modelling (Figure 26).102  
According to the design, the synthesis of linker 81 and peptide P1 was commenced to obtain 




Figure 26 Molecular modelling of stapled peptide P1-81 (shown in red and orange) bound with MDM2 (shown 
in grey) based on the crystal structure of the stapled peptide “E1” bound to MDM2 (PDB ID: 5AFG).103 Distance 
between the nitrogen atom of Lys94 and the sulphur atom of the sulfonyl fluoride (1.69 Å) is shown by the cyan 
line in the side view.  
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4.3. Synthesis of 3,5-diethynylbenzenesulfonyl fluoride 
The initial retrosynthetic route for the synthesis of sulfonyl fluoride 81 is outlined below 
(Scheme 34). 
 
Scheme 34 Initial retrosynthetic route for the synthesis of 81 
We envisioned the formation of the dialkynylbromobenzene 82 from 1,3,5-tribromobenzene 
via Sonogashira coupling372 in the presence of (trimethylsilyl)acetylene. Dialkyne 82 could 
then be converted into the desired product 81 via palladium-catalysed 
fluorosulfonylation373,374 followed by the removal of the trimethylsilyl group. 
The Sonogashira coupling of 1,3,5-tribromobenzene with 2.2 equivalents of 
(trimethylsilyl)acetylene gave 82 in moderate yield (Scheme 35). Flash column 
chromatography was not sufficient for purification of 82 as several unidentified by-products 
co-eluted with the desired product regardless of the solvent system used. Further purification 
by preparative TLC afforded pure 82. 
 
Scheme 35 Synthesis of 82 via Sonogashira coupling 
The fluorosulfonylation reaction utilises 1,4-diazabicyclo[2.2.2]octane–bis(sulfur dioxide) 
(DABSO) as a source of sulfur dioxide to first form a sulfinate salt via a Pd-catalysed process. 
The addition of an electrophilic fluorine source then provides the sulfonyl fluoride. The 
different conditions tried are shown in Table 3. The first attempt at this reaction used 
PdCl2(APhos)2 as the catalyst and N-fluorobenzenesulfonimide (NFSI) as the fluorine source 
(Table 3 Entry 1).373 The reaction gave a complex mixture, but the presence of F could not be 
observed in the NMR of the crude, while peaks corresponding to terminal alkyne were seen. 
It was speculated that the trimethylsilyl group might have interfered with the reaction. Thus, 
a reaction with five equiv. of NFSI was attempted, but the desired product was not obtained 
(Table 3 Entry 2). Consequently, a different condition reported in the literature, using 
Pd(OAc)2 as the Pd-source with CataCXium A as the ligand and Selectfluor™ as the fluorine 
source was tried (Table 3 Entry 3).374 Unfortunately, this condition gave little conversion. 
Considering the lack of alternative conditions in the literature for direct fluorosulfonylation, 
this synthetic route was abandoned. 
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Table 3 Conditions employed in attempts at fluorosulfonylation of 82 
 
Entry Pd source Ligand F+ source Yield (%) 
1 PdCl2(APhos)2 (APhos pre-complexed with Pd) NFSI (1.5 equiv.) 0a 
2 PdCl2(APhos)2 (APhos pre-complexed with Pd) NFSI (5 equiv.) 0b 
3 Pd(OAc)2 cataCXium® A (8 mol%) Selectfluor™ (3 equiv.) 0c 
 
Conditions: DABSO (0.6 equiv.), Pd source (5 mol%), Et3N (3 equiv.). aComplex mixture and alkyne deprotection; 
bcomplex mixture; cunreacted starting material recovered. NFSI = N-fluorobenzenesulfonimide, Selectfluor™ = 
1-chloromethyl-4-fluoro-1,4-diazoniabicyclo[2.2.2]octane bis(tetrafluoroborate). 
Since literature evidence suggested that fluorination via the sulfonyl chloride intermediate 
84 would be more convenient,370 we envisioned an alternative route to synthesise this key 
intermediate (Scheme 36). Sulfonyl fluoride 81 could be constructed by nucleophilic 
substitution at the sulfonyl centre from sulfonyl chloride 84. It was then envisaged that 
nitrobenzene 86 could be used as the precursor to compound 84 via a reduction to aniline 85 
and a Sandmeyer-type reaction with SO2 and a chloride source. Finally, nitrobenzene 86 could 
be obtained from commercially available 2,6-dibromo-4-nitroaniline (88) through 
Sonogashira coupling for installation of the dialkyne and a removal of the amino group. 
 
Scheme 36 Alternative retrosynthetic analysis for the synthesis of 81 
The forward synthesis of 81 began with the removal of the amino group in aniline 88 via 
formation of a diazonium salt followed by a reduction to form 87 in good yield. Subsequent 
Sonogashira coupling of 87 with (trimethylsilyl)acetylene followed by in situ TMS 
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deprotection afforded 86 in 68% yield. 86 was then reduced to the corresponding aniline 85 
using SnCl2 in 85% yield (Scheme 37). 
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    
Scheme 37 Synthesis of aniline intermediate 85. 
The conversion of aniline 85 to sulfonyl chloride 84 was performed via diazotisation followed 
by a Sandmeyer-type reaction. Initially, the procedure from Hogan et al.375 was employed 
because of its practicality—as it does not involve the use of SO2 gas—but the reaction was 
unsuccessful, yielding an unidentified product (found m/z = 447.4 (ES−); NMR showed a 
substitution at the amino group) (Scheme 38). 
 
Scheme 38 Attempted chlorosulfonylation via the use of aqueous sulfur dioxide. 
Alternative literature conditions, which used SO2 gas and a copper(II) salt as a catalyst to 
attenuate the reaction rate,376 were used to afford the key intermediate 84 in good yield 
(Scheme 39). The identity of sulfonyl chloride 84 was confirmed by elemental analysis and 
high-resolution mass spectrometry, as the compound suffered from hydrolysis during the 
LCMS. 
 
Scheme 39 Conversion of 85 to the aryl sulfonyl fluoride 81 
Sulfonyl chloride 84 was subsequently treated with excess KF and 18-crown-6 as the catalyst 




4.4. Stability and reactivity of aryl sulfonyl fluoride 81 
4.4.1. Stability in CuAAC reaction condition 
Since aryl sulfonyl fluorides have never been used in CuAAC stapling and considering the 
ease of hydrolysis of the related sulfonyl chloride, it was essential to test its compatibility to 
the reaction condition. 
To determine the stability of the sulfonyl fluoride moiety, p-toluenesulfonyl fluoride, 
compound 81 and 1,3-diethynylbenzene were subjected to the generic CuAAC reaction 
condition (condition a). Stability tests were also performed in the presence of the solvents 
tBuOH/H2O only (condition b). Results of the stability tests are shown in Table 4. 
Table 4 Stability test conditions: Condition a: tBuOH/H2O (1:1), 1.1 equiv. of the compound (0.73 mM 
concentration), CuSO4·5H2O (1 equiv.), THPTA (1 equiv.) and Na-L-ascorbate (3 equiv.) Condition b: tBuOH/ H2O 
(1:1), 1.1 equiv. of the compound (0.73 mM concentration). 
 
Entry Compound Condition Result 
1 p-toluenesulfonyl fluoride a No decomposition after two days 
2 p-toluenesulfonyl fluoride b No decomposition after two days 
3 81 a 
Approximately 85% decomposition 
after 24 hours. See Figure 27. 
4 81 b No decomposition after two days 




Figure 27 Decomposition of 81 under CuAAC condition showing approximately 85% decomposition after 24 
hours. Caffeine was used as an internal standard. Decomposition was monitored by analytical HPLC. The results 
are an average of two repeats and the errors shown as standard errors of mean. 
No decomposition was observed for p-toluenesulfonyl fluoride. In contrast, 81 decomposed 
under CuAAC reaction condition within approximately 24 h but was stable in tBuOH/H2O 
(Table 3 Entries 3 and 4). 1,3-diethynylbenzene was also stable under the click conditions 
employed in this study (Table 3 Entry 5). 
This observation suggested that the presence of both alkyne and sulfonyl fluoride is essential 
for the decomposition reaction to occur. The decomposition products could be tentatively 
identified via LCMS analysis (Figure 28). One decomposition product (peak 15, m/z = 205.2 
(ES−)) may correspond to the hydrolysed product of 81 to its corresponding sulfonic acid 
(calcd m/z for [M−H]− = 205.0) and the other product (peak 16, m/z = 189.3 (ES−)) may 
correspond to the sulfinic acid (calcd m/z for [M−H]−  = 189.0). 
 
Figure 28 a) UV trace of LCMS analysis of the reaction mixture of linker 81 in Cu-click condition after 23 hours. 
Peak 12 corresponds to caffeine. b) The two possible decomposition products. 
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These results suggested that, albeit the decomposition reaction is almost complete in 24 
hours, only 40% of the material is decomposed in the first 3 hours. Since the CuAAC reaction 
has an average reaction completion time of 1 hour,115 we hypothesised that this could 
outcompete the undesired decomposition pathway, leading to the formation of the stapled 
peptide product. Thus, we decided to continue our studies on 81 as candidate staple. 
 
4.4.2. Stability in aqueous media 
Next, linker 81 was subjected to stability tests in aqueous media at physiological pH and 
temperature, with MeCN as a co-solvent to aid dissolution (Figure 29). This experiment was 
performed to check whether the electrophile would be stable under physiological 
environment. It was found that the sulfonyl fluoride has a half-life of approximately 24 hours 
under these conditions. 
 
Figure 29 Stability test of linkers 81 in PBS (1x)/MeCN (1.94:1) at 37 °C. Caffeine was used as an internal 
standard. Decomposition was monitored by analytical HPLC. The results are an average of two repeats and the 
errors shown as standard errors of mean. For some data points, the error bars are smaller than the markers.  
 
4.4.3. Reactivity against lysine 
To assess the ability of the linker to react with Lys, 81 was incubated with Nα-Ac-Lys-OH in 
PBS (1x): MeCN at 37 °C (Figure 30). Fifty equivalents of Lys were employed to mimic the high 
local concentration of the Lys side chain when the electrophile is in close proximity. Under 
these conditions, the aryl sulfonyl fluoride was found to undergo conjugation and hydrolysis 






Figure 30 Reactivity of linker 81 against Nα-Ac-Lys-OH. Conditions: PBS (1x)/MeCN (1:1), 37 °C, linker at 1 mM 
concentration, Nα-Ac-Lys-OH (50 equiv.). Caffeine was used as an internal standard. Reactions were monitored 
by LCMS. The results are the average of two repeats. For all data points, the error bars are smaller than the 
markers.  
While the reactivity of the sulfonyl fluoride was not ideal, its good stability in aqueous media 
prompted us to further investigate this linker. To evaluate whether these results correlate to 
the ability to form a covalent complex with MDM2, we decided that a stapled peptide with 
compound 81 as a linker would be synthesised. 
 
4.5. Synthesis of linear and stapled peptides 
4.5.1. Synthesis of unnatural azido amino acid 
Synthesis of the proposed peptide P1 required the synthesis of the azido amino acid ornithine 
90, which was carried out as previously reported in the literature (Scheme 40).102 The first 
step was the Boc-deprotection of the commercially available Fmoc-Orn(Boc)-OH, followed 





Scheme 40 Synthesis of Fmoc-protected azido ornithine 90 
The diazo-transfer reagent 91 used in the above reaction was synthesised in large scale 
following a literature procedure giving 91 in moderate yield (Scheme 41).377 
 
Scheme 41 Synthesis of diazo-transfer reagent 91. 
 
4.5.2. Initial click reactions 
The peptide Ac-LTFEXYWAALTX-NH2 (P1) was synthesised by standard Fmoc solid-phase 
peptide synthesis (SPPS) protocol on LL Rink Amide resin (0.40 mmol/g) using DIPEA and 
HATU in DMF as the base and the coupling reagent respectively. The amount of P1 obtained 
was very low, possibly because of its high lipophilicity, causing a loss of material during the 
HPLC purification process. Evidencing this lipophilicity, P1 showed poor solubility in 
tBuOH/H2O (1:1), which we hypothesised that could be caused by the lack of positively 
charged residues in the sequence. The incorporation of nucleophilic amino acids was avoided 
due to the presence of the sulfonyl fluoride on the linker. MeOH, DMF, DMSO or further 
addition of tBuOH did not dissolve P1. Regardless of this issue, the click reaction between P1 
and linker 81 was attempted in DMSO/H2O/tBuOH (2:1:1), expecting that the small amount 
of P1 in solution would undergo stapling and push the solid–aqueous equilibrium of P1 
towards the aqueous phase. After four days, no stapled product was observed through LCMS, 
so stapling of P1 was abandoned. 
 
4.5.3. Attempts to improve the solubility of the linear peptide 
Peptide P1 was based on the PDI-E sequence103 with its staple position moved from the 4th 
and 11th to the 5th and 12th positions. Thus, 4th and 11th positions were reverted to Glu and Thr 
from the original PDI sequence. Sawyer and co-workers found that the H5E and H5A 
mutations on the PDI sequence lead to a four-fold increase and four-fold decrease in aqueous 
media solubility, respectively.100 Therefore, the H5X mutation may have had a deleterious 
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effect on the solubility. However, our target peptide requires those particular staple positions 
to efficiently target the Lys94 of MDM2. Thus, we decided to synthesise two variants: P2 with 
A8S mutation and P3 with L1E and A8S mutations based on the sequence PDI-Q published 
by Chen et al. (Table 5). 







However, the single mutation in P2 did not improve the solubility. Prior to purification, 
dissolution of crude P2 was done in DMSO as its solubility in MeCN/H2O (the solvent system 
used on the HPLC) was low. In DMSO, peptide P2 formed a jelly-like semi-solid. Further 
addition of DMSO and sonication turned it into a cloudy suspension. As a result, the 
purification of P2 was not attempted. 
While pure P3 had a noticeably better solubility in DMSO, it could not be dissolved 
completely in tBuOH/H2O (1:1) despite the use of a small amount of DMSO. Nonetheless, the 
CuAAC reaction in the presence of 81 and 92 (a non-electrophilic linker; to be used as a 
negative control peptide) was again attempted (Scheme 42). 
 
Scheme 42 CuAAC reaction between P3 and the linkers 81 and 92 
After three days, the reactions showed the presence of insoluble material, so it was decided 
to warm the reaction to 37 °C to aid the solubility. However, no visual change was observed 
after three hours. The reaction was therefore worked up, and the presence of traces of the 
desired product were found via LCMS analysis in both the reaction mixture and the crude 
product, with no purification possible. 
Altogether, further alternatives to improve solubility were explored. In the literature, several 
ways of improving the solubility of polypeptides included fusion with solubilising proteins 
such as maltose-binding protein (MBP),378 N-utilisation substance A (NusA),379 thioredoxin,380 
glycosylation,381,382 PEGylation,383 and N-terminal capping with trimethylglycine (betaine).384 
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Most of the aforementioned methods require the addition of large masses to the peptide, 
whereas the N-terminal capping with trimethylglycine only required the addition of one 
amino acid and looked the most feasible for our purpose. 
Additionally, the C-terminal amide was replaced with carboxylic acid, and an A8N mutation 
(P5) was included as asparagine should be more solubilising than serine. A variant with an 
uncapped N-terminus (P4) was also synthesised (Table 6). 
Table 6 Second generation of peptides with additional solubilising components. The sequence of P3 is also 






In order to obtain the C-terminal carboxylic acid, 2-chlorotrityl resin was used for the 
synthesis of P4 and P5. The 2-chlorotrityl resin was chosen over Wang resin because of its 
milder conditions for attaching the first amino acid, which lowers the possibility of 
racemisation. Although pre-loaded Wang resins are commercially available, the first amino 
acid needed in this study was the unnatural azido amino acids; none of the commercially 
available pre-loaded resins features that specific amino acid. The 2-chlorotrityl resin is a high 
loading resin (1.22 mmol/g); therefore, it was only partially loaded to reduce steric hindrance 
later on in the synthesis, and the rest of the sites capped with MeOH. The substitution rate 
was determined by UV absorbance at 301 nm (for the release of the Fmoc group in 
deprotection), and it was found to be at 0.22 mmol/g. Most of the amino acids required double 
coupling during the peptide synthesis. 
The N-terminal capping of P5 with trimethylglycine proved to be problematic. Owing to its 
zwitterionic character, trimethylglycine has poor solubility in DMF and could not be dissolved 
to 0.4 M concentration (the usual concentration for manual SPPS). However, a 0.2 M solution 
could be made. Even with the use of excess trimethylglycine, longer coupling times and 
repeated couplings, full conversion was not observed (both P4 and P5 were observed on LCMS 
from trial cleavage). Coupling with PyBOP, an alternative coupling reagent, was also 
attempted but did not give full conversion. Although the reaction did not proceed to full 
conversion, the peptide was cleaved from the solid support and purified. P5 was not obtained 
in a pure form due to the retention time on the HPLC being very similar to P4. In addition, 
another impurity with very close retention time, which may be a deletion sequence of P5 
where an Ala residue was missing (m/z = 1579.1 (ES−)), was observed. 
Despite the solubility-enhancing modifications, P4 and P5 still only showed partial solubility 
at 1 mg/mL concentration in tBuOH/H2O (1:1). The CuAAC reactions of P4 with 1,3-
diethynylbenzene (92) and the linker 81 were attempted. The stapled products were detected 
on the LCMS, but purification was not attempted due to the small amount of material. 
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Thereafter, we decided to explore the solvent system used in the click reaction. While DMF 
and MeCN, either neat or as a mixture with water, failed to dissolve P4 and P5, it was found 
that DMSO/H2O (11:4) could give a complete dissolution of both peptides. Therefore, the 
CuAAC reactions were performed using this solvent system (Table 7). 
Table 7 Isolated yields for stapled peptides from CuAAC reactions DMSO/H2O (11:4) 
 





aChromatogram turned complicated upon solvent removal, thus no product could be isolated. b64% purity. 
At first, P4 and P5 were reacted with 1.1 equivalents of 92 at a concentration of 1.0 mg/mL. 
The reaction proceeded to completion within 30 minutes, but a significant proportion of 1:2 
peptide-linker linear clicked peptide was formed (Figure 31 and 32). The 1:1 peptide linker 
complex was confirmed to be the stapled product by further addition of 1,3-diethynylbenzene 
(92) and the Cu-click reagent, at which no changes were observed. 
 




Figure 32 LCMS UV trace from reaction between P4 and 1,3-diethynylbenzene (92). Peak (14), (16), (19) 
correspond to 1:1 peptide linker complex (m/z = 841.0, [M+2H]+), 1:2 linear peptide linker complex (m/z = 1807.4, 
[M+H]+), and 1,3-diethynylbenzene, respectively. 
The purification of P4-92 was unsuccessful due to chromatogram turning complicated after 
solvent removal. On the other hand, P5-92 was purified by HPLC, but the obtained stapled 
peptide was impure and only available in a small amount due to the significant loss caused 
by the formation of the 1:2 peptide linker complex. 
To reduce the formation of the 1:2 linear peptide linker complex in the click reaction, the 
peptide concentration was reduced to 0.8 mg/mL (0.5 mM) and the number of equivalents of 
the linker reduced to 1 equivalent. Under these conditions, the reactions of P4 and P5 with 
linker 81 showed the desired product in their respective reaction mixtures via LCMS analysis 
(Figure 33). 
 
Figure 33 LCMS UV trace from reaction between P4 and linker 81. Peak (11) corresponds to 1:1 peptide-linker 
complex (m/z = 1763.2, [M+H]+). 
Unfortunately, similar to P4-92, the purification of P4-81 was not possible due to 
chromatogram turning complicated after solvent removal. On the other hand, P5-81 could 
be obtained, albeit with only 64% purity.  
 
4.5.4. Refinement of the peptide sequence 
The difficult synthesis of the linear peptide P5, its corresponding stapled peptides, and the 
low solubility of PDI-derived peptides led to a reconsideration of a different peptide sequence. 
PMI (H-TSFAEYWNLLSP-OH) was shown to be a potent MDM2-binding peptide from a phage 
display library and therefore represented an excellent alternative.385 PMI was reported to be 
more soluble in an aqueous environment and equipotent to PDI.385 
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A hydrocarbon-stapled PMI and double-click-stapled PMI have been made previously in the 
Lane101 and Spring groups respectively.103 In both cases, the 4th and 11th positions were used 
as the stapling positions, and Pro12 was removed from the sequence as it was not critical for 
the binding.101  
Similar to the initial design, the 5th and 12th positions of the peptide appeared to be the best 
residues for replacement by the azido amino acids to allow the staple to be in the correct 
position—close to the target Lys94. In addition, molecular dynamics simulation of covalent 
peptide–MDM2 complex that used 3,5-diethynylbenzenesulfonyl fluoride (81) as the staple 
showed that an L9G mutation was necessary to avoid Leu10 from pulling away from the 
binding pocket (Figure 34). Therefore, the sequence Ac-TSFAXYWNGLSX-NH2 (P6) was 
adopted as the new linear and more soluble sequence. 
 
Figure 34 Molecular dynamics simulation of PMI stapled peptide (red) covalently linked with MDM2 (grey) via a 
sulfonamide linkage. L9A mutation resulted in Leu10 pulling away from the pocket, whereas L9G did not. 
P6 was then synthesised by automatic SPPS and was found to be more soluble in tBuOH/H2O 




4.6. Synthesis and biological evaluation of sulfonyl fluoride–
bearing stapled peptide 
With the optimised peptide sequence and the staple for covalent targeting of Lys in hand, we 
decided to merge the two motifs and assess the binding of the stapled peptides. 
 
4.6.1. Computational binding energy for non-covalent binding of 
PMI stapled peptides 
To assess the non-covalent binding of the peptides to MDM2, molecular dynamics 
simulations were performed for the linear peptide P6 and the stapled peptide P6-81 (dialkyne 
81 as the linker). Data for the wild-type p53 peptide was also obtained for comparison (Table 
10). The simulations were performed by Dr Yaw Sing Tan. 
Table 8 Calculated binding energy data from molecular dynamics simulation for linear peptide P6, the stapled 
peptides P6-28 and P6-15, and p53 peptide. Computation was performed by Dr Yaw Sing Tan. 
Peptide ΔH / kcal mol-1 TΔS / kcal mol-1 ΔG / kcal mol-1 
P6 −53.67 ± 2.42 −37.47 ± 1.65 −16.20 ± 2.92 
P6-81 −47.66 ± 0.82 −35.34 ± 2.51 −12.32 ± 1.96 
p53 peptide† −56.8 ± 0.9 −44.1 ± 2.9 −12.7 ± 3.8 
†The sequence is Ac-ETFSDLWKLLPEN-NH2. The energies were obtained from Tan et al. for comparison 
purposes.386 
The simulation indicated that the linear peptide P6 would be a better binder than the p53 
peptide. However, the stapling appeared to weaken the binding by approximately 4 kcal  
mol-1. Whilst this was not favourable, the stapled peptide should still be able to compete with 
the p53 peptide, and the covalent linkage should permanently inhibit MDM2. 
 
4.6.2. Synthesis of stapled peptides 
The stapled peptide P6-81 and its negative control for covalent attachment, P6-92, were 
successfully synthesised by CuAAC reactions (Scheme 43). A small amount of DMSO was used 
to pre-dissolve P6 to ensure full solubility in tBuOH/H2O (1:1). The stapled peptides were 




Scheme 43 Two-component CuAAC stapling between peptide P6 and staples 81 and 92. 
 
4.6.3. Biological testing 
With the isolated stapled peptides in hand, we first verified their ability to covalently bind 
the target protein. The stapled peptides were incubated with MDM2 in PBS buffer 37 °C for 1 
hour. The mixture was then analysed for any covalent cross-linking using mass spectrometry. 
The assay was performed in collaboration with Dr Stephen Walsh from the Spring Group. 
The incubation of MDM2 with P6-81 resulted only in a small amount of the sulfonamide 
covalent complex formed (mass 15380 Da) (Figure 35b). For the incubation of MDM2 with P6-
92, the non-electrophilic control stapled peptide, detection of a peptide–MDM2 complex was 
not observed under the same assay condition (Figure 35c). 
 








Figure 35 (continued) b) P6-81 (2 µM) was incubated with MDM2 (1 µM) in PBS buffer (+ 0.01% Tween + 3% 
DMSO) at 37 °C for 1 hour.* The ESI-MS spectrum showed only a small amount of MDM2 was modified. [MDM2 + 
P6-81 − HF + H]+ = 15380 Da. c) Non-electrophilic P6-92 was incubated with MDM2 under the same condition as 
in b). Unmodified MDM2 was observed. 
Next, the apparent dissociation constant (Kd,app) of P6-81 to MDM2 was examined and 
compared to the non-covalent peptides using a competitive fluorescence polarisation (FP) 
assay (Table 9 and Figure 36).101,102 The assay was performed by Dr Rohan Eapen from the 
Itzhaki Group, Department of Pharmacology. The linear diazidopeptide P6 was found to have 
an attenuated affinity for MDM2 (Kd = 47.8 ± 1.5 nM) compared to the wild-type (WT) PMI (Kd 
= 16.6 ± 0.2 nM).385 Pleasingly, the stapled peptide P6-92 showed an affinity comparable to 
the WT (Kd = 19.3 ± 0.3 nM). Crucially, over the course of 120 minutes,† these dissociation 
constants did not change significantly (Figure 36a–c). P6-81, which contains the aryl sulfonyl 
fluoride moiety, displayed a diminished binding affinity (Kd = 112.9 ± 4.2 nM), in agreement 
with the predicted lower binding energy compared to P6. In addition, in line with the 
observation from the mass spectrometry experiment, no appreciable changes in its binding 
affinity were found throughout the assay (Figure 46d). Hence, this confirmed that the sulfonyl 
fluoride–bearing stapled peptide does not exhibit substantial covalent binding to MDM2. 
  
 
*  The conditions for the incubation between P6-81 and MDM2 were different from further experiments as a 
preliminary result. No further mass spectrometry experiments were conducted with P6-81. 






Table 9 Binding affinities of linear and stapled peptides from competitive FP assays, conducted by Dr Rohan 
Eapen. 
Peptide Kd (nM)† 
WT PMI 16.6 ± 0.2 
P6 47.8 ± 1.5 
P6-81‡ 112.9 ± 4.2 
P6-92 19.3 ± 0.3 
†The Kd values are the average of every time point, and the errors are standard errors of mean. ‡Quoted as Kd as 
no significant changes were observed over the course of the assay. 
 
Figure 36 Competitive FP assay binding curves over two hours of a) WT PMI b) P6 c) P6-92 d) P6-81. The four 
peptides show no change in the binding curves over the course of the assay; Each curve represents one time 
point: 9 min (red), 41 min (green), and 120 min (blue). Each data point is arithmetic mean of triplicate, and the 
errors shown are standard errors of mean. 
Considering the low reactivity and unsatisfactory MS and FP results of P6-81, we decided to 
explore alternative electrophilic moieties for the linker. 
 
4.7. Exploring alternative electrophiles for covalent bond 
formation 
A recent study by Cravatt and co-workers has shown that each lysine residue has its own 
unique reactivity and preference towards different electrophiles depending on its function 
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and location.387 This prompted us to expand the electrophiles pool to improve the chance of 
successfully achieving the covalent interaction on the MDM2. 
Two potential alternative electrophilic linkers, chosen based on the precedent of reactive 
functionalities used for lysine modification in the literature, comprised 
sulfotetrafluorophenyl ester (STP) ester 93 and 2,4-dinitrophenyl ester 94 (Figure 37). These 
activated esters were selected for their harder electrophilic character, which would make 
them more selective towards an amine attack as well as more stable towards GSH. Indeed, 
similar compounds with dinitrophenoxide and tetrafluorophenoxide as leaving groups have 
been used as a probe for proteomic profiling for lysine reactivity.387 
 
Figure 37 Two candidates as new electrophilic moieties. 
We envisioned that activated esters 93 and 94 could be made from a coupling between 3,5-
diethynylbenzoic acid and the corresponding phenols which are commercially available 
(Scheme 44).  
 
Scheme 44 Retrosynthetic analysis of the activated esters 93 and 94. 
The synthesis of 93 and 94 started from the synthesis of 3,5-diethynylbenzoic acid (95), 
which was carried out as previously reported by Lau et al.102 (Scheme 45). Commercially 
available methyl 3,5-dibromobenzoate underwent a double Sonogashira coupling with 
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trimethylsilylacetylene to form compound 96 in good yield. Ester 96 was hydrolysed, and its 
TMS group simultaneously deprotected with the treatment of aqueous 6 M KOH in THF to 
form the desired benzoic acid 95 in moderate yield. 
 
Scheme 45 Synthesis of 3,5-diethynylbenzoic acid (95). dba = dibenzylideneacetone. 
Benzoic acid 95 was then coupled with the corresponding phenols to form the activated esters 
93 and 94 (Scheme 46). Following literature procedures for similar compounds,388 93 was 
formed via the use of DCC, while 94 was generated through an acid chloride intermediate. 
 
Scheme 46 Synthesis of activated esters 93 and 94. 
 
4.8. Reactivity and stability of the activated ester linkers 
To enable a comparison of aqueous stability and reactivity to aryl sulfonyl fluoride 81, kinetic 
studies of the activated esters 93 and 94 were performed. 
 
4.8.1. Stability in CuAAC reaction condition for the activated esters 
Stability test of 93 in CuAAC reaction condition was conducted to determine its compatibility 
with our Cu-click stapling (Figure 38). Linker 93 decomposed to benzoic acid 95 by 
approximately 15% after 24 hours. In comparison, about 85% of aryl sulfonyl fluoride 81 





Figure 38 Decomposition of 93 and 81 under CuAAC condition. Stability test condition: tBuOH/H2O (1:1), 1.1 
equiv. of the compound (0.73 mM concentration), CuSO4·5H2O (1 equiv.), THPTA (1 equiv.) and Na-L-ascorbate 
(3 equiv.) at rt. Caffeine was used as an internal standard. Reactions were monitored by analytical HPLC. The 
results are average of two repeats and the errors shown as standard errors of mean. For some data points, the 
error bars are smaller than the markers. 
Linker 94 proved to be only partially soluble in tBuOH/H2O (1:1). Moreover, it was observed 
that linker 94 in tBuOH/H2O (1:1) underwent hydrolysis, confirmed by the appearance of 95 
on the LCMS ([M−H]− found m/z  = 169.1, calcd m/z = 169.0). Considering this evidence, linker 
94 was excluded from further investigation. 
 
4.8.2. Stability in aqueous media 
Linker 93 was also subjected to stability tests in aqueous media at physiological pH and 
temperature, the same as previously described in section 4.4.2. Results are shown, together 
with data of linker 81 for comparison, in Figure 39. The STP ester 93 was found to have 
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comparable stability to the sulfonyl fluoride 81 under the test condition. Both compounds 
underwent hydrolysis by approximately 50% after 24 hours. 
  
Figure 39 Stability test of linkers 81 and 93 in PBS (1x)/MeCN (1.94:1) at 37 °C. Caffeine was used as an internal 
standard. Reactions were monitored by analytical HPLC. The results are an average of two repeats and the errors 
shown as standard errors of mean. For some data points, the error bars are smaller than the markers. 
 
4.8.3. Reactivity against nucleophilic amino acids 
To compare the reactivities of the two linkers towards Lys, 81 and 93 were subjected to 
reactions against Nα-Ac-Lys-OH in PBS (1x)/MeCN at 37 °C. Similarly to section 4.4.3, 50 
equivalents of Lys were initially employed to mimic the high local concentration of the Lys 
side chain when the electrophile is in close proximity. In contrast to linker 81, the reaction 
with linker 93 was very fast (over 30% conversion under 5 minutes), making the reaction 
monitoring difficult. Thus, the amount was decreased to 2 equivalents (Figure 40). 
The STP ester 93 showed a faster reactivity against Lys compared to the sulfonyl fluoride 81 
(5% conjugation for 81 vs 95% conjugation for 93 after four hours). Remarkably, a negligible 





Figure 40 Reactivity comparison between linkers 81 and 93 against Nα-Ac-Lys-OH. Conditions: PBS (1x)/MeCN 
(1.94:1), 37 °C, linker at 1 mM concentration, Nα-Ac-Lys-OH (2 equiv.). Caffeine was used as an internal 
standard. Reactions were monitored by analytical HPLC. The results are average of two repeats and the errors 
shown as standard errors of mean. For some data points, the error bars are smaller than the markers. 
Given these data, we could establish that the activated ester 93 is a superior electrophile for 
our purpose. Whilst the STP ester is similarly stable to sulfonyl fluoride 81, its much higher 
reactivity towards Lys makes it a more suitable electrophile for targeting Lys residues. 
To shed light on the selectivity of linker 93 against other nucleophilic side chains, the STP 
ester was also reacted with Nα-Ac-Cys-OH. However, it was observed that the rate of reaction 






Figure 41 Comparison between the reactivity of linker 93 against Nα-Ac-Lys-OH and Nα-Ac-Cys-OH.  The 
amount of hydrolysed products were negligible and thus not shown. Conditions: PBS (1x)/MeCN (1.94:1), 37 °C, 
linker at 1 mM concentration, amino acid (2 equiv.). Caffeine was used as an internal standard. Reactions were 
monitored by analytical HPLC. For some data points, the error bars are smaller than the markers. The results are 
an average of two repeats and the errors shown as standard errors of mean. 
Even though these results imply that the activated ester may not be as selective towards an 
attack by amines in physiological conditions as initially hypothesised, the good reactivity 
towards Lys attack and the lack of Cys residues near the binding site could still be capitalised 
upon. Validation of this linker as a viable way to introduce and deliver an electrophile to bind 
a target lysine selectively and covalently would be a powerful proof of principle. In addition, 
such validation would establish a solid starting point for further optimisation of the 
electrophilic moiety to tackle the issues underlined by the tests described in this chapter. For 




4.9. Synthesis and biological evaluation of STP ester–
bearing stapled peptide 
4.9.1. Computational binding energy for non-covalent binding of STP 
ester–bearing stapled peptide 
Before proceeding to the synthesis, a computational assessment of stapled peptide P6-93 was 
performed. The simulations were performed by Dr Yaw Sing Tan. The calculation yielded a 
similar result to P6-81 (Table 10). As the change in the electrophilic moiety did not appear 
to negatively impact the non-covalent binding ability of the stapled peptide, we decided to 
proceed to synthesise P6-93. 
Table 10 Calculated binding energy data from molecular dynamics simulation for the stapled peptides P6-81 
and P6-93. Computation was performed by Dr Yaw Sing Tan. 
Peptide ΔH / kcal mol-1 TΔS / kcal mol-1 ΔG / kcal mol-1 
P6-81 −47.66 ± 0.82 −35.34 ± 2.51 −12.32 ± 1.96 
P6-93 −52.56 ± 2.32 −40.50 ± 1.33 −12.05 ± 1.23 
 
4.9.2. Synthesis of STP ester–bearing stapled peptide 
The stapled peptide P6-93 was successfully synthesised by the CuAAC reaction, using the 
same conditions described in section 4.6.2 (Scheme 47). P6-93 was purified by RP-HPLC and 
characterised by analytical HPLC and LCMS. 
 




4.9.3. Biological testing 
With P6-93 in hand, its covalent binding was first verified using an MS experiment. The assay 
was performed in collaboration with Dr Stephen Walsh from the Spring Group. After the 
incubation of P6-93 with MDM2, the mass corresponding to the covalent peptide–MDM2 
complex (15400 Da) was observed with a negligible amount of unmodified MDM2 (13783 Da) 
remained (Figure 42). This observation signified a complete modification of MDM2 by the 
stapled peptide P6-93. The covalent complex formation resulted in a loss of sodium 2,3,5,6-
tetrafluoro-4-hydroxybenzenesulfonate (STPOH). This result contrasted to the less reactive 
sulfonyl fluoride stapled peptide P6-81, which gave a meagre amount of the peptide–MDM2 
covalent complex (Figure 35). 
 
Figure 42 ESI-MS spectra for reactions with MDM2 a) the unmodified MDM2.* [MDM2 + H]+ = 13783 Da. b) P6-93 
(25 µM) was incubated with MDM2 (25 µM) in PBS buffer (+10% DMSO)† at 37 °C for 1 hour. ESI-MS spectrum of 
the reaction indicated the complete covalent binding of the stapled peptide. [MDM2 + P6-93 − STPOH + H]+ = 
15400 Da; STPOH = sodium 2,3,5,6-tetrafluoro-4-hydroxybenzenesulfonate. 
MDM2 was also incubated with P6-92, the non-electrophilic control stapled peptide. 
Pleasingly, no change in the mass of MDM2 was observed. (Figure 43) 
 
Figure 43 ESI-MS spectrum of MDM2 incubated with P6-92, the control peptide, which possessed no 
electrophilic moieties resulted in no change in the mass of MDM2. Condition: P6-92 (25 µM) was incubated with 
MDM2 (25 µM) in PBS buffer (+10% DMSO) at 37 °C for 1 hour. [MDM2 + H]+ = 13782 Da. 
 
* MDM2 for experiments in this section contains extra GGS amino acids attached at the N-terminus. 









Under the same conditions, mass spectrometry results of the STP ester 93 alone (i.e. without 
peptide) with MDM2 resulted in only a small amount of the protein being modified, therefore 
highlighting the importance of the specific non-covalent binding of P6-93 to MDM2 for the 
cross-linking event to occur (Figure 44). 
 
Figure 44 The same incubation as in Figure 43 but with P6-93 replaced with compound 93. ESI-MS spectrum 
showed low reactivity of the electrophile linker, with most MDM2 unreacted. [MDM2 + 93 − STPOH + H]+ = 13933 
Da. 
The selectivity of the stapled peptide was further investigated by the addition of human 
lysozyme (Lyz) to the incubation. Lyz contains five highly solvent-accessible lysine residues 
out of which, one is particularly active.389 Following the incubation, the formation of the 
peptide–lysozyme covalent complex was not detected, indicating that P6-93 selectively 
binds MDM2 (Figure 45). 
 
Figure 45 STP ester–functionalised stapled peptide was selective towards binding MDM2 covalently. a) ESI-MS 
spectrum of MDM2 and lysozyme (Lyz). [Lyz + H]+ = 14694 Da. b) P6-93 (25 µM) was incubated with MDM2 (25 
µM) and lysozyme (25 µM) in PBS buffer (+10% DMSO) at 37 °C for 1 hour. ESI-MS spectrum of the reaction 
showed the exclusive attack on MDM2 with no modified lysozyme observed. 
Next, the apparent dissociation constant (Kd,app) of P6-93 to MDM2 was examined using a 
competitive FP assay (Figure 46).101,102 The assay was performed by Dr Rohan Eapen from the 
Itzhaki Group, Department of Pharmacology. In contrast to the non-covalent peptides 
described in section 4.6.3, as expected for a TCI, the Kd,app of P6-93 improved over time as the 
covalent bond was formed, ultimately resulting in a potent MDM2 inhibition after two hours 












Figure 46 Competitive FP assays of P6-93. a) Binding curves for P6-93 over two hours. P6-93 showed a decrease 
of the apparent dissociation constant over time. Each curve represents one time point: 9 min (red), 41 min 
(green), and 120 min (blue). Each data point is arithmetic mean of triplicate, and the errors shown are standard 
errors of mean. b) Apparent dissociation constant (Kd,app) of P6-93 at each time point. The errors shown are 
standard errors of mean. 
Finally, circular dichroism (CD) analysis was used to measure the helicity of the stapled 
peptide (Figure 47). Pleasingly, CD measurements confirmed that the staple used was able to 
enhance the helicity of the peptide (12% for P6 vs 22% for P6-93, Figure 47b). The CD 
experiments were performed by Dr Jessica Iegre from the Spring Group. 
   
Figure 47 a) Circular dichroism (CD) spectra for peptides P6, P6-93, and wild-type (WT) PMI. The graph shows 
higher helicity for the stapled peptide P6-93 compared to the linear diazidopeptide P6 and WT PMI. The 
peptides were dissolved in MQ water/MeCN (1:1) at a concentration of 100 µM. The measurements were 
performed at 25 °C by Dr Jessica Iegre. b) % helicity for the three peptides. Stapling increased the helicity of the 
peptide compared to both wild-type and the linear diazidopeptide. 
 
4.10. Conclusion and future work 
In conclusion, we developed a strategy for covalent binding of a stapled p53-like peptide to 
MDM2, leading to increased apparent binding with respect to the unstapled peptide. 
Expanding on the two-component CuAAC peptide stapling developed previously in the 
Spring Group, the dialkynyl linker was functionalised with an electrophilic moiety for 
targeted covalent inhibition of a solvent-exposed lysine residue near the binding site. 
b) Time (min) Kd,app (nM)  
 9 30.0 ± 9.2  
 41 12.9 ± 4.1  
 120 7.1 ± 2.1  
b) Peptide %helicity 
 WT PMI 15 
 P6 12 





The investigation started from using aryl sulfonyl fluoride 81 as the electrophilic motif. 
However, through reactivity studies against lysine, the activated ester 93 (Figure 48) was 
found to be a more suitable option due to its superior kinetics. Linker 93 was then used to 
staple a peptide sequence adapted from PMI, a known MDM2 binder.385 The stapled peptide 
P6-93 exhibited complete and selective covalent binding to MDM2 with nanomolar inhibition 
demonstrated through a series of mass spectrometry and competitive FP assay experiments. 
 
Figure 48 Structures of linkers and stapled peptides. 
These results represent an initial proof-of-concept study towards the development of stapled 
peptide–targeted covalent inhibitors (SPTCIs) using two-component peptide stapling. 
Further optimisation of the electrophile-bearing staple is required for a more modulated 
electrophilic warhead since this study showed that the reactivity of 93 against Cys was 
comparable to that of Lys. Thus, future work will focus on screening alternative electrophiles, 
e.g. vinyl sulfones 97 and 98 (Figure 49). Vinyl sulfones have been used successfully in the 
development of a lysine-targeted covalent inhibitor for inhibiting CDK2.188 It was also 
reported that this functional group is more selective towards an attack by amine than thiol .390 
As vinyl sulfones were found to be very reactive, adding a methyl group would decrease its 
activity and should make it more stable. 
 
Figure 49 Structure of vinyl sulfones 97 and 98. 
It is envisioned that the concept herein developed, of careful design of an electrophilic moiety 
for selective covalent binding (Scheme 48), will be valuable for further development of this 
class of inhibitors for relevant PPI targets. Especially, target proteins with slow re-synthesis 




Scheme 48 Development cycle for SPTCIs. 
Future work will focus on applying the whole strategy to a different PPI for further validation. 
One interesting protein target is β-catenin (CTNNB1), a central hub in Wnt signalling 
pathway.391,392 Aberrant accumulation of β-catenin is implicated in several types of 
cancers.391–393 The accumulated β-catenin then shuttles into the nucleus where it associates 
with T-cell factor/lymphoid enhancer factor-1 (TCF/Lef1). This key downstream interaction 
results in subsequent cell proliferation.391 Thus, inhibition of this PPI serves as an attractive 
target for cancer therapeutics. As β-catenin has a longer half-life (t1/2 = 5-6 hours)394 compared 
to MDM2 (t1/2 < 30 minutes),395,396 the inhibition should also reap more benefits from the 
covalent cross-linking. 
Verdine and co-workers have developed, aStAx-35, a hydrocarbon-stapled peptide inhibitor 
of β-catenin.397 Crystal structure of the complex shows the presence of a solvent-exposed 
lysine in proximity to the binding site, which can potentially be targeted using a TCI (Figure 
50). Using the concept developed in this thesis (Scheme 48) and the available structural 
information,397 the development of SPTCIs for β-catenin will start from molecular modelling 
to find an appropriate point of stapling and linker with aStAx-35 as a starting peptide. The 
process will then progress to kinetics studies of the linkers, peptide stapling, and biological 
















Figure 50 Close-up of the crystal structure of aStAx-35 (red with the staple in orange) bound to β-catenin 
(green) showing nearby Lys292 (PDB ID: 4DJS).397 
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Chapter 5 — Novel Total Synthesis of Hemiasterlin and 
Its Application in Antibody–Drug Conjugate*398 
5.1. Project aims and overview 
Payloads used in the ADC field, as described in section 3.5, must be highly potent and thus, 
have complex structures, requiring lengthy synthesis or semi-synthesis relying on scarce 
natural products or fermentation. Despite its relatively simple structure, hemiasterlin 
(56),355–357,359,360,399–401 introduced in section 3.6, has a level of cytotoxicity that is similar to 
other ADC payloads; therefore, it is an ideal candidate for a widespread application in the 
ADC area. Nevertheless, only one ADC, STRO-002, has been described to employ a 
hemiasterlin analogue called 3-aminophenylhemiasterlin as its payload.367 
As mentioned in section 3.6, three previous total syntheses have been reported: Andersen et 
al. (17 LLS, 23 total steps),363 Vedejs and Kongkittingam (13 LLS, 20 steps),364 and Lang et al. 
(15 LLS, 21 total steps).365 In addition, Lesma et al. reported the use of four-component Ugi 
reaction (Ugi-4CR) to synthesise analogues of hemiasterlin with the L-tert-leucine central 
amino acid replaced by L-valine (Scheme 49).402 Hence, it was envisaged that a similar Ugi-
4CR could be used to simplify the route to hemiasterlin and thereby allow easy access to its 
analogues. This simpler synthesis would potentially enable widespread use of hemiasterlin 
or its analogues as an ADC payload. 
 
Scheme 49 Synthesis of hemiasterlin analogues using Ugi-4CR by Lesma et al.402 The central L-tert-leucine was 
replaced by L-valine. 
The project will be executed with the following aims. 
1) Synthesis of the key building blocks for Ugi-4CR for the synthesis of hemiasterlin. 
2) Optimisation of the Ugi-4CR step. 
3) Total synthesis of hemiasterlin using the optimised procedure in aim 2. 
4) Generation of an exemplary analogue, taltobulin (HTI-286, 57), according to aims 1 
and 2. 
5) Synthesis of linker–drug compounds with hemiasterlin and taltobulin. 
6) Synthesis of ADCs containing the linker–drugs in aim 5. 
 
* The work described in this chapter has been published in Charoenpattarapreeda, et al., Angew. Chem. Intl. Ed., 
2020.398 Part of the text and figures were adapted from this publication. 
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7) Investigation of cytotoxicity of the ADCs, comparing them to the parent small 
molecules. 
 
5.2. Synthesis of hemiasterlin and taltobulin 
5.2.1. Initial route design 
To commence the investigation, a retrosynthetic analysis of hemiasterlin was performed 
(Scheme 49). It was hypothesised that Ugi-4CR could be used to generate the dipeptide 99 
from four simple starting materials. Coupling of this dipeptide with unsaturated γ-amino 
ester 100, which would be accessible from Boc-N-methylvaline through a literature route,359 
followed by a global deprotection of the resulting amide, would then reveal hemiasterlin. 
 
Scheme 50 Retrosynthetic analysis of hemiasterlin (56). 
 
5.2.2. First-generation route 
With a proposed synthetic route to hemiasterlin in place, the synthesis of isonitrile 101 was 
undertaken. Commercially available L-tert-leucine methyl ester was heated under reflux in 
ethyl formate and triethylamine to give formamide 102 in excellent yield (Scheme 51).403 
While numerous reagents (phosgene,404–407 diphosgene,408 triphosgene,409,410 and POCl3411) in 
combination with tertiary amines (Et3N and N-methylmorpholine (NMM)) have been 
employed for the dehydration of formamides to generate isonitriles, many of these conditions 
can cause substrate racemisation. Zhu et al. reported the use of triphosgene with NMM as a 
base at low temperature to accomplish the dehydration without racemisation.410 Thus, these 





Scheme 51 Synthesis of isonitrile 101. 
Synthesis of the aldehyde building block 69 was initially attempted via a two-step procedure 
from N-methylindole (Scheme 52).402 Accordingly, treatment of N-methylindole (103) with 
elemental bromine in DMF generated 3-bromo-N-methylindole (104) in 65% yield.412 
However, the brominating agent was later switched to 1,3-dibromo-5,5-dimethylhydantoin 
(DBDMH), a safer and easier-to-handle alternative, which resulted in a similar yield (Scheme 
52).413 Unfortunately, Pd-catalysed C(sp3)-H α-arylation of isobutyraldehyde with 
bromoindole 104 using Q-Phos as the ligand gave the desired aldehyde 69 in poor yield,414 
with debrominated starting material obtained as the major product. No significant 
improvement was achieved after a screening of reaction conditions (Table 11). Literature 
reports also suggested that alteration of the Pd catalyst would not improve conversion to the 
desired product.415–417 Owing to the low yield of this step and the instability of bromoindole 
104, this route was abandoned. 
 
Scheme 52 Synthesis of aldehyde 69 via bromination and Pd-catalysed α-arylation of isobutyraldehyde. 
















1 1.17 0.5 1 2 80 25 1:4 
2 2.33 1 2 4 80 23 1:2.2 
3 2.33 0.5 1 4 80 - 1:2.4 
4 1.17 0.5 2 2 80 28 1:1.5 
5 1.17 0.5 1 2 60 - 1:2.5 
6 2.33 0.5 1 4 60 - 1:2.9 
*All reactions were stirred for 18 h. †Isolated yield. ‡Ratios were calculated from 1H-NMR of the crude product. 
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Nieman et al. have previously reported a four-step synthesis of aldehyde 69.359 Although 
requiring more synthetic steps than the original route, it was hypothesised that this route 
would provide access to the required aldehyde in better yield. Accordingly, starting from 
indole 58, simultaneous N- and α-methylation was performed using KHMDS and MeI 
(Scheme 53). Next, the second α-methylation was performed under the same conditions to 
give indole 60 in excellent yield. The ester was then reduced using diisobutylalumimium 
hydride (DIBAL-H), giving alcohol 105, which was then oxidised under Ley-Griffith 
conditions418 to afford aldehyde 69 in 70% yield over four steps. 
 
Scheme 53 Synthesis of aldehyde 69 using the four-step procedure by Nieman et al.359 
With all the components in hand, the Ugi-4CR of isonitrile 101, aldehyde 69, methylamine, 
and trifluoroacetic acid was first attempted with conditions published by Lesma et al. using 
anhydrous MgSO4 as the drying agent (Table 12 Entry 1). Trifluoroacetic acid was used as the 
acid component because the resulting N-trifluoroacetamide is stable towards mild ester 
hydrolysis conditions at room temperature, but it can be hydrolysed under elevated 
temperature or chemoselectively reduced, leaving the ester group intact.419,420 Under these 
conditions, separable mixtures of 99a and 99b were obtained in 41% combined yield (dr = 
1:1.2), but a significant amount of free amine product 106 (23%) was isolated. It was 
hypothesised that inefficient drying was responsible for this lower than desired yield (Scheme 
54). Pleasingly, switching to 3 Å molecular sieves eliminated the side-product formation, and 
the products 99 were obtained in 70% total yield (dr 1:1.3, Table 12 Entry 2). Their absolute 
stereochemistries were confirmed by X-ray crystallography analysis (see Appendix B for 




Table 12 Ugi-4CR of aldehyde 69, isonitrile 101, methylamine, and trifluoroacetic acid. 
 
Entry Drying agent %99 (dr = 99a:99b)* %106*,† 
1 anhydrous MgSO4 41% (dr 1:1.2) 23% 
2 3 Å molecular sieves 70% (dr 1:1.3) 0% 
*Yields refer to isolated yield. †Isolated as a mixture of diastereomers with undetermined dr. 
 
Scheme 54 The mechanism of Ugi reaction leading to the undesired free amine 108 if H2O attacks the nitrilium 
ion intermediate 107 instead. 
Prior to amide coupling for assembling the full carbon skeleton of hemiasterlin, hydrolysis of 
the methyl ester in esters 99a and 99b was achieved using lithium hydroxide to produce acids 
109a and 109b (Scheme 55). 
 
Scheme 55 Ester hydrolysis of compounds 99. 
Next, the amino ester 100 was synthesised according to literature procedures (Scheme 56).359 
Amide coupling of Boc-protected N-methylvaline with N,O-dimethylhydroxylamine 
hydrochloride was achieved using benzotriazol-1-yl-oxytripyrrolidinophosphonium 
hexafluorophosphate (PyBOP) as the activating agent to afford Weinreb amide 110 in 88% 
yield. Reduction of Weinreb amide 110 to the corresponding aldehyde 111 was conducted 
using lithium aluminium hydride (LiAlH4) and was directly reacted with ylid 112 to give 
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amino ester 100 in 53% yield over two steps. The Boc group was then removed with HCl in 
dioxane to give amine 65 in 90% yield.  
 
Scheme 56 Synthesis of amino ester 65.359 
With the required amine and acid in hand, the fragment amide coupling was first attempted 
using 2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate (HBTU) as 
the activating agent (Table 13 Entry 1). Unfortunately, the formation of protected 
hemiasterlin 113 was not observed in this reaction. Instead, undesired oxazolone 114 was 
isolated in 59% yield. The formation of an oxazolone is a common problem in fragment amide 
couplings as the nucleophilic amide oxygen can attack the activated ester intermediate to 
form a 5-membered heterocycle, which may also easily epimerise.421–425 This was somewhat 
surprising as Lesma and co-workers reported good yields for the fragment amide coupling 
with HBTU to generate their tripeptide library.402 Several other conditions were then 
attempted, which featured different active intermediate species including O-acylurea (Table 
13 Entries 4–5) and acyl fluoride (Table 13 Entries 6–7). CuCl2 was reported to reduce 
epimerisation and so employed in hope to suppress oxazolone formation (Table 13 Entry 4–
5).426 Fluoro-N,N,N’,N’-bis(tetramethylene)formamidinium hexafluorophosphate (BTFFH) 
was used to form an acyl fluoride intermediate which was reported to be suitable for amide 
coupling of sterically hindered secondary amines (Table 13 Entry 6–7).427 Unfortunately, all 




Table 13 Screening of conditions for fragment amide coupling of acid 109 with amine 65. 
 
 
Unless otherwise stated, all reactions were conducted at room temperature. a109a was used; b109b was used; 
cOxazolone 114 (59% yield) was isolated. HOAt = 1-hydroxy-7-azabenzotriazole, DIC = diisopropylcarbodiimide. 
 
5.2.3. Second-generation route 
Given the success of the Ugi-4CR, it was hypothesised that an analogous Ugi reaction could 
be used to assemble the full hemiasterlin scaffold with more elaborated components, in place 
of the fragment amide coupling in the final step. Favourably, isonitrile 117 was identified as 
the key component required for the proposed Ugi reaction and was potentially accessible from 
valine-derived amino ester 100, synthesised in the previous route.  
As such, Boc-deprotection of 100 was effected via treatment with hydrochloric acid in 
dioxane and followed by a HATU-mediated amide coupling with Boc-Tle-OH to give dipeptide 
115 in excellent yield (Scheme 57). Subsequent Boc-removal, followed by formamide 
formation, and triphosgene-mediated dehydration afforded the required isonitrile 117 in 81% 
yield over three steps. The conditions for the dehydration step was adjusted according to Zhu 
et al. for a peptide substrate, whereby the base was switched to 2,6-lutidine and the 
temperature was lowered to −50 °C.410 No justification for this modification was given in the 
original paper. 
Entry Conditions %yield 
1 HBTU, DIPEA, CH2Cl2402,a 0c 
2 HATU, DIPEA, DMF428,a 0 
3 EDC, HOAt, NMM, DMF429,a 0 
4 DIC, HOAt, CuCl2, DIPEA, DMF426,b 0 
5 DIC, NMM, CuCl2, DMF426,b 0 
6 BTFFH, DIPEA, CH2Cl2, 80 °C (sealed tube)427,b 0 




Scheme 57 Synthesis of isonitrile 117. 
With the isonitrile component in hand, the Ugi reaction between aldehyde 69, isonitrile 117, 
methylamine and TFA, using the same conditions as previously, was then attempted. 
Unfortunately, this reaction resulted in only 20% overall yield of diastereomeric mixtures of 
113a and 113b (Table 14 Entry 1). A significant amount of oxazole by-product 118 was 
tentatively identified by LCMS analysis ([M+H]+ found m/z = 537.8, calcd m/z = 537.4, Scheme 
58). Isonitrileacetamides have previously been used in three-component Ugi-type reaction to 
generate oxazoles due to favourable conformation and higher basicity of the amide oxygen 
which promotes intramolecular cyclisation (Scheme 58).430 It was hypothesised that by 
increasing the concentration of the trifluoroacetate anion in the reaction, it might be possible 
to outcompete the intramolecular pathway. While the addition of extra TFA resulted in a 
complex mixture (Table 14 Entry 2), pleasingly, the addition of CF3COONa increased the 
overall yield to 73% (dr 1:1.4, Table 14 Entry 3).  







(dr = 113a:b)* 
Remarks 
1 1.2 - 20% (dr 1:1.3) Oxazole side-product observed 
2 2.5 - - Complex mixture 
3 1.2 CF3COONa (1.2 equiv.) 73% (dr 1:1.4) - 




Scheme 58 Proposed cyclisation of the nitrilium intermediate 119 to form a tentative undesired oxazole side-
product 118. 
X-ray crystallography analysis of 113a was used to determine its absolute stereochemistry 
which corresponded to that of hemiasterlin (Figure 51). 
 
Figure 51 X-ray crystal structure of 113a. 
A commonly observed issue with Ugi-4CR and isocyanide-based multi-component reactions 
(IMCRs) in natural product total syntheses is the low diastereoselectivity of the reactions.431–
435 A notable exception to this problem is when cyclic imines are used instead of aldehyde and 
amine components.436,437 Consequently, several enantioselective IMCRs have been developed 
which utilise chiral phosphoric acids (CPAs) catalysts to control the enantioselectivity.438–440 
Thus, an attempt was made to improve the diastereoselectivity by screening several CPAs 
(Table 15). CPA2-4 were synthesised by Guillermo Caballero-Garcia, the Goodman Group, 

















1‡ MeOH (0.5 M) CF3COONa - 73§ 1:1.4 
2 MeOH CF3COONa - 20 1:1.3 
3 MeOH CF3COONa CPA1 15 1:1.4 
4 CH2Cl2 CF3COONa - 7 1:1.5 
5 CH2Cl2 CF3COOH, Et3N - 58 1:1.4 
6 CH2Cl2 CF3COOH, Et3N CPA1 15 1:1.3 
7 CH2Cl2 CF3COOH, Et3N CPA2 31 1:1.3 
8 CH2Cl2 CF3COOH, Et3N CPA3 22 1:1.3 
9 CH2Cl2 CF3COOH, Et3N CPA4 6 1:1.4 
 
Unless noted otherwise, all reactions were performed at 0.05 mmol scale of 69 with 1.1 equiv. of 117, 1.1 equiv. 
of MeNH2, and 1.2 equiv. of CF3COOH. *Analysed by 19F-NMR using 4,4’-difluorobenzophenone as the internal 
standard. †Determined with 19F-NMR of the crude product. ‡1.2 equiv. of 117 and at 0.1 mmol scale. §Isolated 
yield. 
The original, optimised Ugi conditions (Table 15 Entry 1) involved performing the reaction at 
0.5 M of aldehyde. However, reported diastereoselective Ugi reactions are performed at 
significantly lower reaction concentrations (about 0.05–0.1 M).438,439 As such, it was decided 
to perform the initial attempts to increase the diastereoselectivity of the reaction at this lower 
concentration (0.05 M). While this resulted in lower yield (Table 15 Entry 2), it was thought 
that initially, dr improvement was a priority. No change in the diastereoselectivity was 
observed when CPA1 was added (Table 15 Entry 3), which was an expected outcome. While 
polar protic solvents, e.g. MeOH or TFE, are preferred for Ugi-4CR as they can stabilise the 
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polar intermediates through H-bonding,441 the stereoinduction step requires H-bonding 
between the CPA and imine intermediate; these protic solvents would prevent this 
interaction from forming.439 Therefore, the solvent was switched to aprotic CH2Cl2, which was 
also used in an enantioselective Ugi-4CR.439 As seen previously (Table 14), to effectively form 
the products 113, extra trifluoroacetate anion was required in the reaction mixture. However, 
the insolubility of CF3COONa in CH2Cl2 was detrimental to reaction progression (Table 15 
Entry 4). Thus, an equimolar mixture of CF3COOH and Et3N was used to generate the anion 
instead, (Table 15 Entry 5) affording the desired products 113 in 58% yield by NMR. With 
CPA-compatible conditions in hand, four BINOL-based CPAs were screened using these 
conditions (Table 15 Entries 6–9).440 In all cases, the dr changes were negligible. Further 
screenings of other CPAs, e.g. SPINOL-based CPAs,439 are required to verify whether the 
stereoselectivity can be improved. However, it was decided that further investigation of the 
diastereoselective Ugi-4CR would be suspended as it was deemed a priority to finish the total 
synthesis of hemiasterlin and investigate its capabilities as an ADC payload. In addition, the 
non-diastereoselective Ugi-4CR was able to generate sufficient material to continue the 
synthesis.  
To complete the synthesis, the Ugi products 113 were subjected to lithium hydroxide 
monohydrate at 60 °C to simultaneously hydrolyse the methyl ester and the 
trifluoroacetamide group, producing hemiasterlin 56 and epi-hemiasterlin 56b in 86% and 
78% yield, respectively (Scheme 59).  
 
Scheme 59 Hydrolysis of 113 to give hemiasterlin (56) and its epimer (56b). 
To demonstrate the amenability of the developed synthetic route for the synthesis of 
hemiasterlin analogues, taltobulin was also synthesised from 2-methyl-2-phenylpropanal 
(120). This aldehyde was made from its corresponding acid by reduction to an alcohol using 
LiAlH4 and subsequent re-oxidation using Ley-Griffith conditions (Scheme 60). The Ugi-4CR 
of aldehyde 120 with isocyanide 117, methylamine, and TFA produced a partially separable 
diastereomeric mixture of 121 by flash column chromatography. The diastereomeric mixture 
was obtained in good yield and carried forward onto the final step. Treatment with lithium 
hydroxide monohydrate generated the desired compounds 57 and 57b, each in 20% yield after 




Scheme 60 Synthesis of taltobulin (57) and its epimer (57b). 
In summary, hemiasterlin (56) and taltobulin (57) were synthesised via a convergent strategy 
involving a multi-component Ugi-4CR in 14 and 12 total steps (both with an LLS of 10 steps), 
in 11% and 6% overall yield, respectively. 
 
5.3. Synthesis of linker–drugs for bioconjugation 
After successfully developing a superior synthetic route to hemiasterlin and taltobulin, their 
utility as ADC payloads was investigated. First, it was necessary to modify the natural product 
with bioconjugation linkers to facilitate their attachment to an antibody. 
 
5.3.1. Design and selection of the linkers 
Divinylpyrimidine (DVP) reagents, previously developed in the Spring Group,113,269 were 
chosen as the bioconjugation motif due to their efficient conjugation and excellent stability 
under physiological conditions (Scheme 61). IgG antibodies contain four interchain disulfide 
bonds, which can be reduced to reveal eight reactive cysteine thiols (other buried disulfide 
bonds are not reduced). DVP linkers react with these eight selectively reduced cysteines, 
“rebridging” (or cross-linking) the reduced disulfides. In doing so, each antibody can be 
modified with four payloads to give a consistent DAR of four. The cathepsin-cleavable Val-
Ala-PABC was incorporated into the linker design on the payload attachment side as it was 
deemed essential to release an unmodified drug from the antibody.278 Finally, to enable a 
convergent synthesis, it was hypothesised that modification of the payload  with an azide and 
the DVP linker with an alkyne would allow the use of a CuAAC reaction to assemble the 




Scheme 61 Design of the linker–drug for bioconjugation. 
 
5.3.2. Carbamate formation optimisation 
It was anticipated that the carbamate formation step would be the most challenging in this 
strategy as hemiasterlin possesses a sterically hindered secondary amine. To assess the 
viability of this route, it was decided that test reactions to form simpler carbamates were to 
be carried out first. For this purpose, reactive mixed carbonate Alloc-Val-Ala-PABC-p-
nitrophenoxy (OPNP; 123) was synthesised by a reaction between Alloc-Val-Ala-PABA (122) 
and bis(p-nitrophenyl)carbonate in the presence of DIPEA in excellent yield (Scheme 62). 
 
Scheme 62 Synthesis of mixed carbonate 123. 
Initially, the widely used protocol for carbamate formation between the trifluoroacetate salt 
of hemiasterlin (56·TFA) and p-nitrophenyl carbonate 123 with 1-hydroxy-7-
azabenzotriazole (HOAt) and DIPEA was used; however, the desired product 124 could not 
be detected (Scheme 63).285 Additional carbonate, raising the temperature, or addition of 
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catalytic DMAP did not result in the formation of the desired product. In all cases, only 
unreacted hemiasterlin was observed by LCMS analysis. 
 
Scheme 63 Attempted carbamate formation using hemiasterlin trifluoroacetate salt (56·TFA), carbonate 123, 
HOAt, and DIPEA. 
It was hypothesised that a more reactive electrophile was required for the reaction to proceed. 
Therefore, the synthesis of chloroformate 125 was attempted by reacting alcohol 122 with 
triphosgene (Scheme 64). Unfortunately, the chloroformate could not be isolated; instead, 
benzyl chloride 126 was tentatively detected ([M+H]+ found m/z = 396.5, calcd m/z = 396.2) in 
the crude product via LCMS analysis.  
 
Scheme 64 Attempt at synthesising chloroformate 125. None could be isolated with chloride 126 tentatively 
found instead. 
To preserve the precious hemiasterlin, a model substrate was sought to replace the natural 
product. It was thought that available N-protected dipeptides 109 from the first-generation 
route (see Scheme 55) were ideally suited to this purpose. By hydrolysing compounds 109, 
the obtained products can be used as the model substrate. Thus, dipeptide 127a was 
synthesised from hydrolysis of trifluoroacetamide 109a at 60 °C in good yield (Scheme 65). 
As chloroformate 125 may be too unstable for isolation, in situ generation of intermediate 





Scheme 65 Synthesis of 127a and attempt at making 128a. 
As the activation on the alcohol side proved ineffective, it was thought that the polarity of 
the carbamate formation reaction could be reversed by activation of the secondary amine 
followed by treatment with the benzyl alcohol Alloc-Val-Ala-PABA. To prevent interference 
from the acid moiety, dipeptide 127a was esterified using thionyl chloride in MeOH to give 
methyl ester 129a in moderate yield (Scheme 66).  First, conversion of amine 127a to the 
corresponding carbamoyl chloride 130 was attempted via a reaction with triphosgene 
(Scheme 66).442 While some carbamoyl chlorides are stable, attempts to isolate intermediate 
130 were unsuccessful. To detect whether compound 130 was being formed, an aliquot was 
removed from the reaction mixture and quenched with MeOH. No methyl carbamate was 
detected via LCMS analysis and an m/z corresponding to hydantoin 131 was observed ([M+H]+ 
found m/z = 414.5, calcd m/z = 414.2). The second proposed strategy involved the use of 1,1’-
carbonyldiimidazole (CDI) to first form a carbamoylimidazole which would then be further 
activated by methylation to a carbamoylimidazolium before conversion to a carbamate.443 
Unfortunately, amine 129a was unreactive towards CDI, and no carbamoylimidazole 132 





Scheme 66 Synthesis of amino ester 129a and attempts at making carbamate 128a through activation on the 
amine side. CDI = 1,1’-carbonyldiimidazole. 
It was thought that the zwitterionic nature of hemiasterlin (or its model substrate) might 
have hindered its reaction with Alloc-Val-Ala-PABC-OPNP (123), and that protection of the 
acid as an alkyl ester would potentially aid reactivity. A method for the synthesis of 
carbamates employing p-nitrophenyl carbonate was thus revisited with the use of an ester 
substrate. A patent by Kim et al. reported the reaction between taltobulin ethyl ester and a p-
nitrophenyl mixed carbonate with DIPEA and a catalytic amount of HOAt to form its 
corresponding carbamate in 43% yield.444 Under these literature conditions, a reaction 
between amine 129a and reactive carbonate 123 was performed (Scheme 67). Excitedly, a 
product which had an m/z corresponded to 128a was observed via LCMS analysis ([M+Na]+ 




Scheme 67 Carbamate formation between 129a and 123. Conditions: 123 (1 equiv.), HOAt (0.2 equiv.), py:DMF 
(1:6), rt. 
Encouraged by this result, it was decided to conduct an optimisation based on these 
conditions. Given the low availability of 129a at the time, it was thought that using its epimer 
129b, which could be obtained from amply available precursor 99b, as the model substrate 
instead would not cause a significant change to the reactivity of the amine. Thus, the epimer 
129b was synthesised via a NaBH4 reduction of trifluoroacetamide 99b in quantitative yield 
(Scheme 68).  
 
Scheme 68 Synthesis of amine 129b. 
With the model substrate in hand, an optimisation for the carbamate reaction was carried out 
(Table 16). It was found that the increase in HOAt and carbonate was critical for greater 
conversion (Table 16 Entries 2–3) while doubling the amount of pyridine stopped the reaction 
entirely (Table 16 Entry 4). Leaving the reactions for seven days, instead of 17 hours, 
approximately doubled the conversion (Table 16 Entries 5–7). However, changing the base to 















1c 1.1 0.2 2 1:6 8 
2 2 1 2 1:6 35 
3 2 0.2 4 1:6 10 
4 2 0.2 2 1:3 0 
5 2 1 4 1:6 54d 
6 2 1 4e 1:6 53d 
7f 2 1 4 1:6 55d 
All reactions were conducted at room temperature. aVolumetric ratio. bEstimated by LCMS analysis after 17 h of 
reaction time. c 129a was used to form 128a, and no changes were observed after heating to 50 °C. dAfter seven 
days of reaction time. eEt3N was used. fCarbonate 123 was pre-activated with HOAt before amine 129b was 
added. 
With feasible conditions in hand and to validate the reaction, carbamate 128b was 
synthesised and isolated in 25% yield (47% brsm, Scheme 69). Its identity was confirmed by 
high-temperature 1H-NMR; as at room temperature, a complex rotameric mixture was 
observed (see Appendix B for the spectra). 
 
Scheme 69 Synthesis of carbamate 128b. 
 
5.3.3. Preparation of the linker–drugs 
With confirmed reaction conditions for modifying hemiasterlin with a cleavable dipeptide, 
synthesis of an azide-functionalised Val-Ala-PABC-hemiasterlin (and Val-Ala-PABC-
taltobulin), to facilitate bioconjugation to an antibody was commenced (Scheme 70). First, 
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removal of the Alloc group from dipeptide 122 using Pd(PPh3)4 proceeded in excellent yield. 
The revealed free amine 134 was then amide coupled with N3-PEG4-COOH, giving azide 135. 
Subsequent treatment with bis(p-nitrophenyl)carbonate afforded mixed carbonate 136 in 
76% yield (Scheme 70a). Chemoselective removal of the trifluoroacetamide group from 
protected hemiasterlin 113a and taltobulin 121a was achieved using NaBH4 (59% yield for 
137 and 99% yield for 138). Finally, the free amines were reacted with activated carbonate 
136 to give azides 139 and 140 in moderate yields (Scheme 70b). 
 
Scheme 70 a) Synthesis of p-nitrophenyl mixed carbonate 136. b) Synthesis of azides 139 and 140.  
It was hypothesised that an alkynyl DVP could be prepared via a strategy resembling solid-
phase peptide synthesis.113 Introduction of a reactive alkyne could be achieved through the 
incorporation of propargylglycine (propargylGly) into the peptide-like chain. Furthermore, 
simultaneous incorporation of polyethylene glycol (PEG) chains and glutamic acid residues 
would improve the aqueous solubility of the linker–drug and decrease the hydrophobicity and 
aggregation propensity of the resultant ADCs. Thus, peptidomimetic H-PEG2-Glu3-PEG2-
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propargylGly-NH2 TFA (141) was synthesised using a standard Fmoc-protecting group 
protocol on LL Rink Amide resin (Scheme 71). Following cleavage from the resin and RP-
HPLC purification, amide coupling of amine 141 with DVP–carboxylic acid 142 (synthesised 
by Hikaru Seki, Spring Group, Department of Chemistry, University of Cambridge) produced 
the desired linker 143. CuAAC reaction of DVP–alkyne 143 with azides 139 and 140 was 
followed by ester hydrolysis to give the final linker–drug compounds 144 and 145 after 
reverse-phase flash chromatography purification, which were characterised by analytical 
HPLC and HRMS. 
 
Scheme 71 Synthesis of linker–drugs 144 and 145. 
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5.4. Synthesis of antibody–drug conjugates 
With the desired linker–drugs in hand, synthesis of ADCs was undertaken. Trastuzumab is an 
FDA-approved mAb targeting human epidermal growth factor receptor 2 (HER2), a 
transmembrane receptor that is overexpressed in 20–30% of breast cancers.445 The mAb also 
constitutes the antibody component of two marketed ADC drugs, Kadcyla® and 
Enhertu®.235,242 Trastuzumab was chosen for this study to enable a comparison of 
hemiasterlin-based ADCs against other reported ADCs loaded with alternative cytotoxins. 
To commence ADC synthesis, the four interchain disulfides in trastuzumab were reduced via 
treatment with tris(2-carboxyethyl)phosphine hydrochloride (TCEP) for 1 hour at 37 ∞C, 
revealing eight reactive thiols. The reduced antibody was then reacted with the DVP linker–
drug compounds 144 and 145 for 4 hours at 37 ∞C (Scheme 72a). Pleasingly, LCMS and sodium 
dodecylsulfate–polyacrylamide gel electrophoresis (SDS-PAGE) analysis revealed >95% 
conversion to the rebridged antibody species ADC 1 and ADC 2 with a loading of four drug 
molecules per antibody (Scheme 72b–f). The SDS-PAGE analysis also showed significant 
formation of the half-antibody species whereby the hinge disulfides did not undergo 
interchain rebridging, which would have resulted in forming the full-antibody species; 
instead, non-native intrachain cross-linking of the reduced heavy chain cysteines occurred 
(Scheme 72b). This observation is in line with the usage of DVP as a rebridging linker, noting 
that the structural integrity and the ability of half-antibodies to bind to their cell-surface 
receptor is not impacted.269 The LCMS and SDS-PAGE analysis was performed by Dr Stephen 




Scheme 72 a) Synthesis of ADC 1 and ADC 2. b) SDS-PAGE analysis of the two ADCs; lane 1 is non-reducing, 
lanes 2–4 are reducing; lanes: MW = molecular weight marker, (1) trastuzumab, (2) reduced trastuzumab, (3) 
ADC 1, (4) ADC 2. TCEP = tris(2-carboxyethyl)phosphine hydrochloride, TBS = Tris-buffered saline (Tris·HCl 25 





Scheme 72 (continued) c) Non-deconvoluted MS of ADC 1. d) Deconvoluted MS of ADC 1, expected for the half 
antibody 76806 Da, found 76809 Da e) Non-deconvoluted MS of ADC 2. f) Deconvoluted MS of ADC 2, expected 
for the half antibody 76700 Da, found 76704 Da. TCEP = tris(2-carboxyethyl)phosphine hydrochloride, TBS = 
Tris-buffered saline (Tris·HCl 25 mM, NaCl, 25 mM, EDTA 0.5 mM pH 8). 
To investigate the aggregation propensity of the ADCs, size-exclusion chromatography (SEC) 
analysis was carried out. This analysis demonstrated that both ADCs had ≥99.5% monomeric 
content, confirming minimal aggregation propensity with this linker–payload (Figure 52). 
The SEC analysis was performed by Teodors Pantelejevs, Hyvönen Group, Department of 
Biochemistry, University of Cambridge. 
           
 
Figure 52 Size-exclusion chromatography (SEC) of trastuzumab and the two synthesised ADCs. Chromatograms 
from SEC analysis of a) trastuzumab b) ADC 1 c) ADC 2. d) Monomeric content of trastuzumab, ADC 1, and ADC 
2. 
 
d) ADC % monomeric content 
 Trastuzumab 99.9 
 ADC 1 99.9 





5.5. Biological evaluation of the ADCs and the small 
molecules 
To investigate the biological activity of hemiasterlin, taltobulin, and their corresponding 
ADCs, their effect on the cell viability of both HER2-positive (SKBR3, BT474) and HER2-
negative (MCF7) cell lines was determined (Table 17 and Figure 53). The cellular assays were 
performed by Dr Stephen Walsh, Spring Group, Department of Chemistry, University of 
Cambridge. Hemiasterlin exhibited sub-nanomolar cytotoxicity against all cell lines, whilst 
the potency of taltobulin was approximately one order of magnitude lower.360 Pleasingly, both 
ADC 1 and ADC 2 displayed exquisite cytotoxicity against SKBR3 and BT474 cells, 
comparable to that reported for an analogous cathepsin-cleavable trastuzumab–MMAE 
ADC.113,285 Moreover, both ADCs had negligible activity against MCF7 cells at the 
concentrations tested. These combined data suggest that both hemiasterlin and taltobulin 
have the potential to serve as cytotoxic payloads in the development of ADCs and other 
targeted therapeutics, and that they can generate equivalent potency as clinically validated 
payloads.  
Table 17 In vitro cellular evaluation of 56, 57, ADC 1 and ADC 2 in comparison with MMAE and Tras–MMAE.  
IC50 (nM)† SKBR3 (HER2+) BT474 (HER2+) MCF7 (HER2-) 
Hemiasterlin (56) 0.18 0.15 0.37 
Taltobulin (57) 1.12 1.40 3.00 
MMAE* 0.08 0.12 0.2 
ADC 1 0.086 0.27 >50 
ADC 2 0.25 0.45 >50 
Tras–MMAE* 0.041 0.092 >30 




Figure 53 Cellular viability assays of 56, 57, ADC 1, and ADC 2 in a), b) HER2-positive SKBR3 cells, c), d) HER2-
positive BT474 cells, and e), f) HER2-negative MCF7 cells. 
 
5.6. Conclusion and future work 
In conclusion, the total synthesis of hemiasterlin (56) has been accomplished via a four-
component Ugi reaction with a longest linear sequence of 10 steps, in 11% overall yield. The 
improved synthetic approach allows for simple analogue exploration on the N-terminus of 
the molecule, which was demonstrated by the synthesis of taltobulin (57), a synthetic 
derivative of hemiasterlin. ADCs synthesised from the two compounds, ADC 1 and ADC 2, 
showed exceptionally potent and selective bioactivity, similar to that of an analogous MMAE 
ADC. With its relatively short synthesis and high cytotoxicity, this study paves the way for 
the future use of hemiasterlin and its analogues as payloads in ADC therapeutics. 
Furthermore, this represents the first documented use of hemiasterlin and its ADC in the 
treatment of breast cancer, showcasing its potential in the treatment of this disease. 
Future work will first focus on improving the Ugi-4CR step. While the overall yield of the 
reaction was satisfactory, the low diastereoselectivity can still be enhanced. Further catalyst 
exploration can be done with other available CPAs. Another two interesting CPAs are the 
octahydro-BINOL-based CPA5 and the SPINOL-based CPA6 which have been reported to 




Figure 54 Structures of CPA5 and CPA6. 
Another issue that was encountered during the synthesis of hemiasterlin was the poor 
scalability of the Ugi-4CR for generating protected hemiasterlin 113. It was noticed that the 
yield dropped significantly in larger-scale reactions (down to 24% at 100 mg scale with 
respect to aldehyde 69). In contrast, the Ugi-4CR in the first-generation route was not 
impacted (up to 400 mg scale with respect to aldehyde 69). Thus, it is hypothesised that using 
a convertible isonitrile, to avoid the formation of oxazole entirely may solve this problem 
(Scheme 73). Convertible isonitriles are isonitriles which can be easily replaced by various 
functional groups after IMCRs.446–449 One suitable candidate is compound 146, developed by 
Kobayashi and co-workers.450 Wessjohann et al. reported the application of this isonitrile for 
peptide ligation and macrocyclisation.451 Following their report, it is hypothesised that upon 
treatment of the Ugi products 147 with camphorsulfonic acid (CSA), the activated N-
acylindole is obtained which can then be converted to the desired peptide 113 via a reaction 
with free amine 66. 
 
Scheme 73 Proposed new route for the synthesis of analogues of hemiasterlin via the use of convertible 
isonitrile 146. 
Further work will also include synthesis of hemiasterlin analogues with the indole ring 
functionalised with an amino group. It was proposed that the steric bulk around the 
secondary amine of hemiasterlin was hindering the carbamate formation resulting in low 
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yield. To provide an alternative vector for a linker attachment, installation of an amino group 
on the indole ring will therefore be explored. The aldehydes 151 are thought to be accessible 
through commercially available aminoindoles 149 via a Ru-catalysed C3-alkylation of indole 
(Scheme 74).452 The amino group in 149 will first be protected and then alkylated at the C3 
position to give indoles 150. The alkylated indoles will then be N-methylated and 
transformed to aldehydes 151 using the same synthetic strategy as described in section 5.2.2. 
The generated aldehydes can then be used in the Ugi-4CR to produce other hemiasterlin 
analogues. The synthesised amino-substituted hemiasterlin analogues will then be tested in 
cytotoxicity assays to determine the most active regioisomer. Finally, this isomer will be 
investigated for the synthesis of corresponding linker–drug compound and ADC. 
 
Scheme 74 a) Proposed synthesis of amine-functionalised indoles 151 for the generation of hemiasterlin 








Chapter 6 — Experimental 
6.1. General experimental 
General methods: All reactions were carried out under nitrogen atmosphere using oven-
dried glassware at rt unless otherwise stated. Temperatures of −78 °C were maintained using 
a dry ice–acetone bath. Temperatures of 0 °C were maintained using an ice-water bath. Room 
temperature (rt) refers to ambient temperature.  
Solvents: Dichloromethane (CH2Cl2), methanol (MeOH) and toluene were distilled from 
calcium hydride. Tetrahydrofuran (THF) was dried using sodium wire and distilled from a 
mixture of calcium hydride and lithium aluminium hydride with triphenylmethane as an 
indicator. Diethyl ether (Et2O) was distilled from a mixture of calcium hydride and lithium 
aluminium hydride. Ethyl acetate (EtOAc) was distilled before use. 40–60 petroleum ether 
was distilled before use and refers to the fraction between 40–60 °C. Acetonitrile (MeCN), 
anhydrous dimethylformamide (DMF) and tert-butyl alcohol (tBuOH) were purchased from 
commercial sources and used without further purification. 
Reagents: Unless otherwise stated, all reagents were used as received from commercial 
sources or prepared as described in the literature. The chemicals were handled in accordance 
with COSHH regulations. 
Yield: Refer to chromatographically and spectroscopically pure compounds unless otherwise 
stated. 
Flash column chromatography: Carried out using slurry-packed Merck 9385 Kieselgel 60 
SiO2 (230–400 mesh) or Combiflash Rf200 automated chromatography system with Redisep® 
normal-phase silica flash columns (35–70 µm) or Redisep® reverse-phase C18-silica flash 
columns (20–40 µm). Yields refer to chromatographically and spectroscopically pure 
compounds unless otherwise stated. 
Analytical thin-layer chromatography (TLC): Carried out on glass plates coated with silica 
(0.2 mm, Merck Kieselgel 60 F254). Visualisation was done using UV irradiation (254 nm and 
365 nm) or staining with potassium permanganate, ninhydrin, or vanillin dips made using 
standard procedures. Retardation factors (Rf) are quoted to the nearest 0.01. 
Preparative thin-layer chromatography: Carried out on glass plates coated with silica (1 
mm, Merck Kieselgel 60 F254). Visualisation was done using UV fluorescence (254 nm and 
365 nm). 
Melting points (mp): Measured using a Büchi melting point B545 apparatus or Gallenkamp 
MPD350.BM2.5 melting point apparatus and are uncorrected.  
Optical rotations ([α]D): Recorded on an Anton-Paar MCP polarimeter and are reported in 
deg dm-1 cm3 g-1 at 589 nm. Concentrations (c) are given in g (100 mL)-1. 
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General nuclear magnetic resonance spectroscopy: Processed using TopSpin v. 3.5 or 4.0 
(Bruker). An aryl, quaternary, or two or more possible assignments were given when signals 
could not be distinguished by any means. Measured coupling constants are reported for 
mutually coupled signals; coupling constants are labelled apparent (app) in the absence of an 
observed mutual coupling, or multiplet (m) when none can be determined. 
Proton magnetic resonance (1H-NMR) spectroscopy: Recorded using an internal 
deuterium lock (at ambient temperature unless stated otherwise) on Bruker Avance III HD 
(400 MHz, Smart Probe), Bruker Avance III HD (400 MHz, BBO Probe), Bruker Neo Prodigy 
(400 MHz, Prodigy Cryoprobe), Bruker Avance III (400 MHz, QNP Cryoprobe), Bruker Avance 
III (500 MHz; DCH Cryoprobe), Bruker Avance (600 MHz, BBI probe), or Bruker Avance II+ 
(700 MHz, TBO Cryoprobe) spectrometers. Proton assignments are supported by 1H–1H COSY, 
1H–13C HSQC or 1H–13C HMBC spectra, or by analogy. Chemical shifts (δH) are quoted in ppm 
to the nearest 0.01 ppm and are referenced to the residual non-deuterated solvent peak.453 
Discernible coupling constants (J) are reported as measured values in Hz, rounded to the 
nearest 0.1 Hz. Data are reported as: chemical shift, multiplicity (br, broad; s, singlet; d, 
doublet; t, triplet; q, quartet; qn, quintet; m, multiplet; ABq, AB quartet; or a combination 
thereof), coupling constants, number of nuclei, and assignment.  
Carbon nuclear magnetic resonance (13C-NMR) spectroscopy: Recorded using an internal 
deuterium lock at ambient temperature on Bruker Avance III HD (101 MHz, Smart Probe), 
Bruker Avance III HD (101 MHz, BBO Probe), Bruker Neo Prodigy (101 MHz, Prodigy 
Cryoprobe), Bruker Avance III (101 MHz, QNP Cryoprobe), Bruker Avance III (126 MHz; DCH 
Cryoprobe), or Bruker Avance II+ (176 MHz, TBO Cryoprobe) spectrometers with broadband 
proton decoupling. Carbon spectra assignments are supported by DEPT editing, 1H–13C HSQC 
or 1H–13C HMBC spectra, or by analogy. Chemical shifts (δC) are quoted in ppm to the nearest 
0.1 ppm and are referenced to the deuterated solvent peak.453 Coupling constants between 
carbon and other nuclei (X) over n bonds (nJC-X) are reported as measured values in Hz, 
rounded to the nearest 0.1 Hz. Data are reported as: chemical shift, multiplicity (if not a 
singlet), coupling constants, number of nuclei (if not one), and assignment. 
Fluorine nuclear magnetic resonance (19F-NMR) spectroscopy: Recorded on Bruker 
Avance III (376 MHz; QNP Cryoprobe) or Bruker Avance III HD (376 MHz; Smart probe) 
spectrometers. Chemical shifts (δF) are quoted in ppm to the nearest 0.1 ppm, from CFCl3, and 
are uncorrected. Data are reported as: chemical shift, multiplicity (if not a singlet), and 
coupling constants. 
Infrared spectroscopy (IR): Recorded neat on a Perkin Elmer Spectrum One FT-IR 
spectrometer fitted with an attenuated total reflectance (ATR) sampling accessory. Selected 
absorption maxima ( max) are quoted in wavenumbers (cm-1) with the following abbreviations: 
w, weak; m, medium; s, strong; vs, very strong; br, broad. 
Ultraviolet–visible spectroscopy (UV-Vis): Recorded on a NanoDropTM One 
spectrophotometer. The absorption maxima (λmax) are reported in nanometres (nm). 
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Liquid chromatography–mass spectrometry (LCMS): Chromatographs were recorded 
using a Waters ACQUITY H-Class UPLC with an ESCi Multi-Mode Ionisation Waters SQ 
Detector 2 spectrometer using MassLynx 4.1 software; ESI refers to the electrospray 
ionisation technique; LC system: solvent A: 2 mM NH4OAc in H2O/MeCN (95:5); solvent B: 
MeCN; solvent C: 2% formic acid; column: ACQUITY UPLC® CSH C18 (2.1 mm × 50 mm, 1.7 
µm, 130 Å) at 40 °C; gradient: 5–95 % B with constant 5 % C over 1 min at flow rate of 0.6 
mL/min; detector: PDA eλ Detector 220–800 nm, interval 1.2 nm 
High-resolution mass spectrometry (HRMS): Recorded using Waters LCT Premier Time of 
Flight (ToF),  ThermoFinnigan Orbitrap Classic, Waters Vion IMS Qtof, or Micromass Q-TOF 
mass spectrometers using electrospray ionisation (ESI) or atmospheric solids analysis probe 
(ASAP) techniques. Reported mass values are within the error limits of ±5 ppm mass units. 
High-performance liquid chromatography (HPLC): Analytical chromatographs were 
obtained on an Agilent 1260 Infinity using a Supercosil ABZ+PLUS column (150 mm × 4.6 mm, 
3 µm) eluting with a linear gradient system (solvent A: 0.05% (v/v) TFA in H2O, solvent B: 
0.05% (v/v) TFA in MeCN) over 15 min at a flow rate of 1 mL/min. Retention times (tR) are 
quoted in minutes to 2 decimal places. Semi-preparative HPLC was carried out on an Agilent 
1260 Infinity using a Supercosil ABZ+PLUS column (250 mm × 21.2 mm, 5 µm) eluting with a 
linear gradient system (solvent A: 0.1% (v/v) TFA in H2O, solvent B: 0.05% (v/v) TFA in MeCN) 
over 20 min at a flow rate of 20 mL/min. HPLC was monitored by UV absorbance at 220 and 
254 nm. 
Elemental analysis: Performed by the University of Cambridge Microanalytical Laboratory 
in the Department of Chemistry and are quoted to the nearest 0.01% for all elements. 
Protein liquid chromatography–mass spectrometry (Protein LCMS): Performed on a 
Xevo G2-S TOF mass spectrometer coupled to an Acquity UPLC system using an Acquity UPLC 
BEH300 C4 column (1.7 µm, 2.1 × 50 mm). H2O with 0.1% formic acid (solvent A) and 95% 
MeCN and 5% H2O with 0.1% formic acid (solvent B), were used as the mobile phase at a flow 
rate of 0.2 mL/min. The gradient was programmed as follows: 95% A for 0.93 min, then a 
gradient to 100% B over 4.28 min, then 100% B for 1.04 min, then a gradient to 95% A over 
1.04 min. The electrospray source was operated with a capillary voltage of 2.0 kV and a cone 
voltage of 150 V. Nitrogen was used as the desolvation gas at a total flow of 850 L h-1. Total 
mass spectra were reconstructed from the ion series using the MaxEnt algorithm preinstalled 
on MassLynx software (v4.1 from Waters) according to the manufacturer’s instructions. 
Trastuzumab samples were deglycosylated with PNGase F (New England Biolabs) prior to 
LCMS analysis. The analyses were performed by Dr Stephen Walsh, Spring Group, 
Department of Chemistry, University of Cambridge. 
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6.2. Chapter 4 Experimental 
6.2.1. Molecular modelling 
Molecular modelling was performed by Dr Yaw Sing Tan, Verma Group, A*STAR Institute, 
Singapore. 
Initial molecular models of the covalent i, i+7 stapled peptide were created using the Builder 
module in PyMOL.454 
 
Preparation of structures 
The structure of MDM2 in complex with a stapled peptide (PDB code 5AFG)103 was used as the 
initial structure for molecular dynamics (MD) simulations. The stapled peptide 
(LTFXEYWAQLXS, in which X are the stapled residues) was mutated to the PMI peptide 
(TSFAEYWNLLSP) using the LEaP module of AMBER 14.455 The point mutations E69A and 
K70A in MDM2 were reversed. PMI was modified into stapled peptides P6-81 and P6-93 (Ac-
TSFAXYWNGLSX-NH2) by replacing residues 5 and 12 with a two-component triazole staple, 
formed by a double-click reaction between two azido-ornithine residues and 3,5-
diethynylbenzenesulfonyl fluoride (81), and between two azido-ornithine residues and 4-
((3,5-diethynylbenzoyl)oxy)-2,3,5,6-tetrafluorobenzenesulfonate (93), respectively. Leu9 
was mutated to Gly in these stapled peptides to avoid steric clashing of the side chain with 
the staple. The respective sulfonamide and ester covalent complexes of these stapled 
peptides with Lys94 of MDM2 were further generated. MDM2 was capped at its N- and C-
termini by acetyl and N-methyl groups respectively while the peptides were capped at their 
N- and C-termini by acetyl and amide groups, respectively. PDB2PQR456 was used to 
determine the protonation states of residues. Each MDM2 complex was solvated with TIP3P 
water molecules457 in a periodic truncated octahedron box, such that its walls were at least 9 
Å away from the complex, and neutralised with sodium ions. 
 
Molecular dynamics 
Energy minimisations and MD simulations were performed with the sander and PMEMD 
modules of AMBER 14,455 respectively. Three independent MD simulations were carried out 
on each of the complexes using the ff14SB458 and generalised AMBER force fields (GAFF).459 
Atomic charges for the stapled residues were derived using the R.E.D. Server,460 which fits 
restrained electrostatic potential (RESP) charges461 to a molecular electrostatic potential 
(MEP) computed by the Gaussian 09 program462 at the HF/6-31G* theory level. All bonds 
involving hydrogen atoms were constrained by the SHAKE algorithm,463 allowing for a time 
step of 2 fs. Nonbonded interactions were truncated at 9 Å, while the particle mesh Ewald 
method464 was used to account for long-range electrostatic interactions under periodic 
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boundary conditions. Weak harmonic positional restraints with a force constant of 2.0 kcal 
mol-1 Å-2 were placed on the protein and peptide non-hydrogen atoms during the 
minimisation and equilibration steps. Energy minimisation was carried out using the steepest 
descent algorithm for 500 steps, followed by the conjugate gradient algorithm for another 500 
steps. The systems were then heated gradually to 300 K over 50 ps at constant volume before 
equilibration at a constant pressure of 1 atm for another 50 ps. Subsequent unrestrained 
equilibration (2 ns) and production (100 ns) runs were carried out at 300 K using a Langevin 
thermostat465 with a collision frequency of 2 ps-1, and 1 atm using a Berendsen barostat466 with 
a pressure relaxation time of 2 ps. 
 
6.2.2. Synthetic procedures 
6.2.2.1. Synthesis of staple 81 
((5-Bromo-1,3-phenylene)bis(ethyne-2,1-diyl))bis(trimethylsilane) (82) 
 
PdCl2(PPh3)2 (362 mg, 0.516 mmol), PPh3 (271 mg, 1.03 mmol), iPr2NH (10 mL), 
(trimethylsilyl)acetylene (3.21 mL, 22.7 mmol), and CuI (98.3 mg, 0.516 mmol) were added to 
a solution of 1,3,5-tribromobenzene (3.25 g, 10.3 mmol) in THF (30 mL). After stirring at 50 °C 
for 20 h, the reaction mixture was allowed to cool to rt, filtered through Celite®, and 
concentrated in vacuo. H2O and CHCl3 were added, the phases separated, and the aqueous 
phase was extracted further with CHCl3 (3 × 25 mL). The combined organic phase was dried 
over Na2SO4, filtered, and the solvent removed in vacuo to give a brown liquid. The crude 
product was purified by column chromatography (100% hexane) and further purified by 
preparative thin-layer chromatography (100% hexane) to give compound 82 as a colourless 
liquid (1.75 g, 5.01 mmol, 48%). 
Rf = 0.34 (hexane) 
1H NMR (400 MHz, CDCl3): δH = 7.54 (d, J = 1.2 Hz, 2 H, H-2), 7.50 (t, J = 1.4 Hz, 1 H, H-4), 0.25 
(s, 18 H, H-7) 
13C NMR (101 MHz, CDCl3): δC = 134.6 (C-2), 134.1 (C-4), 125.2 (C-1), 121.8 (C-3), 102.6 (C-
5), 96.7 (C-6), −0.1 (C-7) 
IR (ATR): max / cm-1 = 2959 (m, -C-H), 2157 (m, C≡C), 1738 (m), 1550 (m, C=C) 
HRMS (ASAP+): m/z [M]+ calcd for C16H21BrSi2: 348.0365; found: 348.0352 (Δ = −3.7 ppm) 
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To an ice-cooled solution of 2,6-dibromo-4-nitroaniline (11.8 g, 40.0 mmol) in ethanol (250 
mL), was added drop-wise concentrated H2SO4 (21.3 mL, 0.383 mol) over 30 min. The reaction 
mixture was heated to 60 °C, and NaNO2 (8.83 g, 0.128 mol) was added portion-wise. The 
reaction was then heated to reflux at 90 °C for 3 h. The mixture was allowed to cool to rt 
before being poured into ice-water. The resulting brown solid was filtered and washed with 
H2O. The crude product was purified by column chromatography (eluting gradient 
hexane:CH2Cl2 from 40:1 to 6:1) to give 3,5-dibromonitrobenzene as a pale yellow solid (7.19 
g, 25.6 mmol, 64%). 
Rf = 0.25 (hexane:CH2Cl2 = 6:1) 
mp = 104–106 °C (lit.468 104 °C)  
1H NMR (400 MHz, CDCl3): δH = 8.33 (d, J = 1.7 Hz, 2 H, H-2), 8.01 (t, J = 1.7 Hz, 1 H, H-4) 
13C NMR (101 MHz, CDCl3): δC = 149.2 (C-1), 140.2 (C-4), 125.7 (C-2), 123.6 (C-3) 
IR (ATR): max / cm-1 = 3076 (s, =C-H), 1802 (w, =C-H), 1763 (w, =C-H), 1528 (s, N-O), 1334 (s, 
N-O) 
HRMS (ASAP+): m/z [M]+ calcd for C6H379Br2NO2: 278.8531; found: 278.8526 (Δ = −1.8 ppm) 




3,5-Dibromonitrobenzene 87 (1.18 g, 4.20 mmol), Pd(PPh3)Cl2 (884 mg, 1.26 mmol), CuI (40.0 
mg, 0.210 mmol) and PPh3 (110 mg, 0.419 mmol) were dissolved in iPr2NH (4 mL) and toluene 
(12 mL). The mixture was stirred at rt for 5 min before (trimethylsilyl)acetylene (2.37 mL, 16.8 
mmol) was added. The reaction mixture was stirred at 80 °C for 17 h. It was then allowed to 
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cool to rt, and a solution of KOH (943 mg, 16.8 mmol) in H2O (0.7 mL) and MeOH (2.8 mL) was 
added in one portion. The mixture was stirred for another 3 h, quenched with saturated 
aqueous NH4Cl solution (80 mL) and then extracted with CH2Cl2 (3 × 70 mL). The combined 
organic phases were filtered through Celite®, washed with aqueous HCl (2 M, 70 mL), H2O (70 
mL), and brine (70 mL), dried over MgSO4, and the solvent was removed in vacuo. The crude 
product was purified by column chromatography (eluting gradient hexane:CH2Cl2 from 40:1 
to 6:1) to give 1,3-diethynyl-5-nitrobenzene as a grey solid (488 mg, 2.85 mmol, 68%). 
Rf = 0.13 (hexane:CH2Cl2 = 6:1) 
mp = 115–117 °C (lit.470 113.5–115 °C) 
1H NMR (400 MHz, CDCl3): δH = 8.29 (d, J = 1.4 Hz, 2 H, H-2), 7.87 (t, J = 1.4 Hz, 1 H, H-4), 3.26 
(s, 2 H, H-6) 
13C NMR (101 MHz, CDCl3): δC = 148.1 (C-1), 140.9 (C-4), 127.0 (C-2), 124.4 (C-3), 80.8 (C-6), 
80.4 (C-5) 
IR (ATR): max / cm-1 = 3287 (m, ≡C-H), 3269 (s, ≡C-H), 3075 (w, =C-H), 2112 (m, C≡C), 1738 
(s), 1535 (vs, N-O), 1352 (vs, N-O) 
HRMS (ASAP+): m/z [M]+ calcd for C10H5NO2: 171.0320; found: 171.0319 (Δ = −0.6 ppm) 





A solution of 1,3-diethynyl-5-nitrobenzene 86 (771 mg, 4.50 mmol) and SnCl2·2H2O (5.08 g, 
22.5 mmol) in EtOH (45 mL) was heated to 70 °C for 1.5 h. The reaction mixture was allowed 
to cool to rt and quenched with addition of aqueous NaOH solution (2 M) to pH 9. The aqueous 
phase was extracted with Et2O (3 × 50 mL), and the combined organic phases were dried over 
Na2SO4 and solvent removed in vacuo to give 3,5-diethynylaniline as a brown solid (538 mg, 
3.81 mmol, 85%). This compound was used in the next step without further purification. 
Rf = 0.15 (hexane:EtOAc = 5:1) 
mp = 56–57 °C (lit.472 125–127 °C)  
1H NMR (400 MHz, CDCl3): δH = 7.03 (t, J = 1.3 Hz, 1 H, H-4), 6.78 (d, J = 1.3 Hz, 2 H, H-2), 3.72 
(br s, 2 H, NH2), 3.03 (s, 2 H, H-6) 
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13C NMR (101 MHz, CDCl3): δC = 146.4 (C-1), 126.2 (C-4), 123.2 (C-3), 119.0 (C), 83.0 (C-5), 
77.3 (C-6) 
IR (ATR): max / cm-1 = 3414 (m, N-H), 3331 (m, N-H), 3278 (s, ≡C-H), 2110 (w, C≡C), 1737 (s), 
1587 (vs) 
HRMS (ASAP+): m/z [M]+ calcd for C10H7N: 141.0578; found: 141.0576 (Δ = −1.4 ppm) 
Spectroscopic data are in accordance with the literature.473 
 
3,5-Diethynylbenzenesulfonyl chloride (84) 
 
Acetic acid (2.80 mL) and concentrated aqueous HCl (1.40 mL) were added to an ice-cooled 
solution of 3,5-diethynylaniline 85 (494 mg, 3.50 mmol) in MeCN (28 mL). A solution of 
NaNO2 (289 mg, 4.20 mmol) in H2O (525 µL) was added over 10 min at 0 °C. After stirring for 
further 20 min, SO2 was bubbled in over 40 min at 0 °C. A solution of CuCl2 (592 mg, 4.40 
mmol) in H2O (875 µL) was added, and the mixture was allowed to warm to rt and stirred for 
further 16 h. The solvent was removed in vacuo and the residue re-dissolved in H2O (20 mL) 
and CH2Cl2 (30 mL). The two phases were separated; the aqueous phase was extracted with 
CH2Cl2 (3 × 25 mL). The combined organic phases were dried over Na2SO4, filtered and the 
solvent removed in vacuo. The red-brown oily residue was purified by column 
chromatography (eluting gradient hexane:CH2Cl2 from 40:1 to 5:1) to give 3,5-
diethynylbenzenesulfonyl chloride as a beige solid (566 mg, 2.52 mmol, 72%). 
Rf = 0.27 (hexane:CH2Cl2 = 5:1) 
mp = 69–71 °C 
1H NMR (400 MHz, CDCl3): δH = 8.09 (d, J = 1.4 Hz, 2H, H-2), 7.89 (t, J = 1.4 Hz, 1H, H-4), 3.30 
(s, 2H, H-6) 
13C NMR (101 MHz, CDCl3): δC = 144.9 (C-1), 141.4 (C-4), 130.1 (C-2), 124.9 (C-3), 81.6 (C-6), 
80.1 (C-5) 
IR (ATR): max / cm-1 = 3292 (s, ≡C-H), 3268 (s, ≡C-H), 3072 (m, =C-H), 2111 (w, C≡C), 1590 (m, 
C=C), 1434 (s), 1375 (vs, S=O), 1172 (vs, S=O) 
HRMS (ASAP+): m/z [M]+ calcd for C10H535ClO2S: 223.9699; found: 223.9694 (Δ = −2.2 ppm) 
Elemental analysis: calcd for C10H5ClO2S: C 53.46%, H 2.24%, Cl 15.78%, O 14.24%, S 14.27%; 
found: C 53.38% H 2.04%, Cl 14.90%, S 12.14% 
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3,5-Diethynylbenzenesulfonyl fluoride (81) 
 
Potassium fluoride (87.2 mg, 1.50 mmol) and 18-crown-6 (3.96 mg, 0.0150 mmol) were added 
to a solution of 3,5-diethynylbenzenesulfonyl chloride 84 (67.4 mg, 0.300 mmol) in MeCN 
(1.5 mL), under a N2 atmosphere. The reaction mixture was stirred at rt for 3 days and the 
solvent removed in vacuo. EtOAc (10 mL) was added to the residue, and the organic phase 
washed with H2O (3 × 5 mL), and brine (5 mL), dried over Na2SO4, filtered, and the solvent 
removed in vacuo to give 3,5-diethynylbenzenesulfonyl fluoride as a white solid (37.3 mg, 
0.179 mmol, 60%). 
Rf = 0.20 (hexane:CH2Cl2 = 5:1) 
mp = 77–79 °C 
1H NMR (400 MHz, CDCl3): δH = 8.06 (d, J = 1.5 Hz, 2H, H-2), 7.92 (t, J = 1.4 Hz, 1H, H-4), 3.30 
(s, 2H, H-6) 
13C NMR (101 MHz, CDCl3): δC = 141.8 (C-4), 134.2 (d, 2JC-F = 26.2 Hz, C-1), 131.5 (C-2), 124.9 
(C-3), 81.6 (C-6), 80.0 (C-5) 
19F NMR (376 MHz, CDCl3): δF = 65.8  
IR (ATR): max / cm-1 = 3287 (s, ≡C-H), 2111 (w, C≡C), 1592 (w, C=C), 1434 (s), 1407 (s, S=O), 
1202 (vs, S=O) 
HRMS (ASAP+): m/z [M]+ calcd for C10H5FO2S: 207.9994; found: 207.9992 (Δ = −1.0 ppm) 
 
6.2.2.2. Synthesis of staples 93 and 94 
Methyl 3,5-bis((trimethylsilyl)ethynyl)benzoate (96) 
 
Methyl 3,5-dibromobenzoate (1.52 g, 5.17 mmol), Pd2(dba)3 (89.7 mg, 0.0980 mmol), CuI (19.1 
mg, 0.100 mmol) and PPh3 (129 mg, 0.492 mmol) were added to Et3N (25 mL), followed by 
trimethylsilylacetylene (9.94 mL, 70.3 mmol). The reaction mixture was stirred at 65 °C for 
20 h, then concentrated in vacuo. The residue was re-dissolved in CH2Cl2 (30 mL), filtered 
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through Celite®, then solvent removed in vacuo. The crude product was purified by flash 
column chromatography (hexane:EtOAc = 99:1) to give compound 96 as a yellow solid (1.41 
g, 4.29 mmol, 83%) 
Rf = 0.31 (hexane:EtOAc = 20:1) 
mp = 73–76 °C (lit.102 71–73 °C) 
1H NMR (400 MHz, CDCl3): δH = 8.05 (d, J = 1.6 Hz, 2H, H-2), 7.74 (t, J = 1.6 Hz, 1H, H-4), 3.92 
(s, 3H, H-9), 0.25 (s, 18H, H-7) 
13C NMR (101 MHz, CDCl3): δC = 165.8 (C-8), 139.2 (C-4), 132.8 (C-2), 130.7 (C-1), 124.0 (C-
3), 103.1 (C-5), 96.3 (C-6), 52.5 (C-9), −0.1 (C-7) 
IR (ATR): max / cm-1 = 2957 (m, -C-H), 2900 (w, -C-H), 2157 (m, C≡C), 1729 (s, C=O), 1588 (m) 
HRMS (ASAP+): m/z [M+H]+ calcd for C18H25O2Si2: 329.1393; found: 329.1383 (Δ = −3.0 ppm) 
Procedure adapted from Lau et al.102 Spectroscopic data are in accordance with the 
literature.102 
 
3,5-Diethynylbenzoic acid (95) 
 
Aqueous KOH (6.00 M, 2.50 mL, 15.0 mmol) was added to a solution of methyl 3,5-
bis((trimethylsilyl)ethynyl)benzoate 96 (850 mg, 2.59 mmol) in THF (15 mL). The reaction 
mixture was stirred at rt for 18 h, and the volatiles were removed in vacuo. The remaining 
aqueous mixture was acidified with aqueous HCl (2 M, 40 mL) and extracted with Et2O (3 × 40 
mL). The combined organic phases were dried over MgSO4 and the solvent removed in vacuo. 
The crude product was recrystallised from CHCl3 to give 3,5-diethynylbenzoic acid as a deep 
beige fine powder (255 mg, 1.50 mmol, 58%) 
mp = 173 °C (dec) (lit. 173 °C474; 250 °C (dec)102) 
1H NMR (400 MHz, CDCl3): δH = 8.19 (d, J = 1.6 Hz, 2 H, H-2), 7.82 (t, J = 1.6 Hz, 1 H, H-4), 3.17 
(s, 2 H, H-6) 
13C NMR (101 MHz, CDCl3): δC = 169.3 (C-7), 140.2 (C-4), 133.9 (C-2), 130.0 (C-1), 123.4 (C-
3), 81.5 (C-5), 79.3 (C-6) 
IR (ATR) : max / cm-1 = 3285 (m, ≡C-H), 2600 (br m, O-H), 1682 (vs, C=O), 1588 (s) 
HRMS (ASAP+): m/z [M+H]+ calcd for C11H7O2: 171.0446; found: 171.0448 (Δ = 1.2 ppm) 
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Procedure adapted from Lau et al.102 Spectroscopic data are in accordance with the 
literature.102 
 
Sodium 4-((3,5-diethynylbenzoyl)oxy)-2,3,5,6-tetrafluorobenzenesulfonate (93) 
 
To the solution of sodium 2,3,5,6-tetrafluoro-4-hydroxybenzenesulfonate (134 mg, 0.500 
mmol) and 3,5-diethynylbenzoic acid 95 (85.1 mg, 0.500 mmol) in DMF (1.25 mL) was added 
DCC (103 mg, 0.500 mmol), under a N2 atmosphere. The reaction mixture was stirred at rt for 
21 h, then stirred at 0 °C for 1 h, filtered and washed with DMF (80 µL). The product was 
triturated from the filtrate using Et2O then filtered to give sodium 4-((3,5-
diethynylbenzoyl)oxy)-2,3,5,6-tetrafluorobenzenesulfonate as a beige powder (181 mg, 0.431 
mmol, 86%). 
mp = 150 °C (dec) 
1H NMR (500 MHz, DMSO-d6): δH = 8.20 (d, J = 1.5 Hz, 2 H, H-3), 8.00 (t, J = 1.5 Hz, 1 H, H-1), 
4.50 (s, 2 H, H-6) 
13C NMR (126 MHz, DMSO-d6): δC = 160.8 (C-7), 143.0 (d, 1JC-F = 249.3 Hz, C-9 or 10), 140.4 
(C-1), 140.0 (dd, J = 249.5, 19.3 Hz, C-10 or 9), 133.3 (C-3), 127.9 (t, 2JC-F = 14.5 Hz, C-8 or 11), 
127.6 (C-4), 125.0 (t, 2JC-F = 18.7 Hz, C-11 or 8), 123.7 (C-2), 83.7 (C-6), 80.8 (C-5) 
19F NMR (376 MHz, DMSO-d6): δF = −140.0 (dd, J = 25.5, 9.7 Hz), −154.4 (dd, J = 25.5, 9.8 Hz) 
IR (ATR): max / cm-1 = 3282 (m, ≡C-H), 1756 (s, C=O), 1646 (m, C=C), 1480 (vs), 1184 (vs, S=O) 





2,4-Dinitrophenyl 3,5-diethynylbenzoate (94) 
 
DMF (20 µL) was added to a suspension of 3,5-diethynylbenzoic acid 95 (85.1 mg, 0.500 mmol) 
in CH2Cl2 (2.5 mL) and the mixture was then cooled to 0 °C. Oxalyl chloride (64.3 µL, 0.750 
mmol) was added and the reaction mixture stirred at rt for 5 h. The solvent was removed in 
vacuo to give the crude acid chloride. 
The crude acid chloride was re-dissolved in THF (1 mL) and added to a solution of 2,4-
dinitrophenol (138 mg, 0.750 mmol) and Et3N (69.7 µL, 0.500 mmol) in THF (1 mL) at 0 °C. 
The reaction mixture was stirred at rt for 21 h, then quenched by adding saturated NaHCO3 
(5 mL). The mixture was extracted with Et2O (3 × 10 mL). The combined organic phases were 
dried over MgSO4, filtered, and the solvent removed in vacuo. The crude product was purified 
by column chromatography (eluting gradient hexane:EtOAc from 40:1 to 5:1) to give 2,4-
dinitrophenyl 3,5-diethynylbenzoate as an off-white powder (59.2 mg, 0.176 mmol, 35%). 
Rf = 0.21 (hexane:EtOAc = 5:1) 
mp = 155 °C (dec) 
1H NMR (500 MHz, CDCl3): δH = 9.05 (s, 1 H, H-12), 8.60 (d, J = 8.9 Hz, 1 H, H-10), 8.26 (s, 2 H, 
H-3), 7.90 (s, 1 H, H-1), 7.65 (d, J = 8.9 Hz, 1 H, H-9), 3.22 (s, 2H, H-6) 
13C NMR (126 MHz, CDCl3): δC = 162.2 (C-7), 148.6 (C-8, 11 or 13), 145.5 (C-8, 11 or 13), 141.8 
(C-8, 11 or 13), 141.1 (C-1), 134.2 (C-3), 129.3 (C-10), 128.4 (C-4), 126.8 (C-9), 123.9 (C-2), 
122.1 (C-12), 81.1 (C-6), 80.0 (C-5) 
IR (ATR): max / cm-1 = 3285 (m, ≡C-H), 3082 (w, =C-H), 1750 (s, C=O), 1611 (m, C=C), 1532 (vs, 
N-O), 1348 (vs, N-O) 




6.2.2.3. Synthesis of azido amino acid 
Fmoc-Orn-OH·HCl (89) 
 
To a stirred solution of Fmoc-Orn(Boc)-OH (3.98 g, 8.76 mmol) in dioxane (14 mL) was added 
a solution of HCl in dioxane (4 M, 14 mL) in a single portion. The reaction mixture was stirred 
at rt for 16 h. The mixture was then diluted with Et2O (150 mL) and the white precipitate 
collected under filtration and washed with Et2O (4 × 25 mL) to give compound 89 as a white 
powder (3.42 g, 8.75 mmol, quant.) 
mp = 150 °C (dec) (lit. 179 °C (dec))475 
[α]D25 = −4.7° (c = 1.0, DMSO, lit.475 [α]D27 = −2.3°) 
1H NMR (400 MHz, DMSO-d6): δH = 12.71 (br s, 1 H, COOH), 7.99 (br s, 3H, H-Na), 7.90 (d, J = 
7.5 Hz, 2 H, H-13), 7.73 (d, J = 7.8 Hz, 1 H, H-10), 7.70 (d, J = 8.3 Hz, 1 H, H-Nb), 7.42 (t, J = 7.4 
Hz, 2 H, H-12), 7.34 (t, J = 7.4 Hz, 2 H, H-11), 4.32–4.21 (m, 3H, H-7 and 8), 3.98–3.93 (m, 1H, 
H-2), 2.77 (br s, 2H, H-5), 1.85-1.58 (m, 4H, H-3 and 4) 
13C NMR (101 MHz, DMSO-d6): δC = 173.5 (C-1), 156.2 (C-6), 143.8 (C-9), 140.7 (C-14), 127.7 
(C-12), 127.1 (C-11), 125.3 (C-10), 120.2 (C-13), 65.7 (C-7), 53.4 (C-2), 46.6 (C-8), 38.4 (C-5), 
27.7 (C-3), 24.0 (C-4) 
IR (ATR): max / cm-1 = 3333 (m, O-H), 3039 (br m, N-H), 1726 (s, C=O), 1690 (vs, C=O), 1531 
(s, C=C), 1477 (m, C=C), 1451 (m, C=C) 
HRMS (ESI+): m/z [M−Cl]+ calcd for C20H23N2O4: 355.1652; found: 355.1643 (Δ = −2.5 ppm) 






Fmoc-Orn-OH·HCl 89 (3.28 g, 8.39 mmol) was dissolved in a biphasic mixture of H2O (48 mL), 
methanol (96 mL) and CH2Cl2 (80 mL). CuSO4·5H2O (17.0 mg, 0.0681 mmol) and 1-
(azidosulfonyl)-1H-imidazol-3-ium chloride 91 (6.46 g, 30.8 mmol) were added to the 
mixture. The pH was adjusted to 9 with saturated aqueous K2CO3 solution followed by 
vigorous stirring at rt for 23 h. The reaction was diluted with CH2Cl2 (105 mL), then the two 
phases were separated. The organic phase was extracted with saturated NaHCO3 solution (2 
× 140 mL). The combined aqueous phases were washed with Et2O (2 × 140 mL), acidified to 
pH 2 with concentrated HCl and extracted with Et2O (3 × 160 mL). The combined organic 
extracts were dried with MgSO4, filtered and the solvent removed in vacuo to give an oily 
residue. The residue was re-dissolved in EtOAc and the volatile removed under a stream of N2 
to give compound 90 as a white solid (1.40 g, 3.68 mmol, 44%) 
mp = 131–133 °C (lit. 132–134 °C)102 
[α]D25 = −3.7° (c = 1.0, MeOH, lit.476 [α]D = −2.3°) 
1H NMR (400 MHz, CDCl3): δH = 7.78 (d, J = 7.8 Hz, 2 H, H-13), 7.63–7.52 (m, 2 H, H-10), 7.41 
(t, J = 7.5 Hz, 2 H, H-12c), 7.32 (app tt, J = 7.4, 0.7 Hz, 2 H, H-11), 5.34 (d, J = 8.0 Hz, 1 H, H-N), 
4.63–4.40 (m, 3 H, H-2 and 7), 4.23 (t, J = 6.7 Hz, 1 H, H-8), 3.39–3.10 (m, 2 H, H-5), 2.06–1.42 
(m, 4 H, H-3 and 4) 
13C NMR (101 MHz, CDCl3): δC = 175.8 (C-1), 156.2 (C-6), 143.9 (C-9), 143.7 (C-9’), 141.5 (C-
14), 127.9 (C-12), 127.2 (C-11), 125.2 (C-10), 120.2 (C-13), 67.3 (C-7), 53.3 (C-8), 50.9 (C-5), 
47.3 (C-2), 29.8 (C-3), 25.0 (C-4) 
IR (ATR): max / cm-1 = 3335 (m, O-H), 2960 (br w, N-H), 2087 (s, N=N=N), 1709 (s, C=O), 1678 
(s, C=O), 1530 (s, C=C), 1450 (m, C=C) 
HRMS (ESI+): m/z [M+Na]+ calcd for C20H20N4O423Na: 403.1377; found: 403.1369 (Δ = −2.0 ppm) 




1-(azidosulfonyl)-1H-imidazol-3-ium chloride (91) 
 
Sulfuryl chloride (16.1 mL, 200 mmol) was added dropwise to an ice-cooled suspension of 
NaN3 (13.0 g, 200 mmol) in MeCN (200 mL) and the mixture stirred overnight at rt. The 
mixture was then cooled to 0°C and imidazole (25.9 g, 380 mmol) was added portion-wise. 
The resulting slurry was allowed to warm to rt and stirred for 5 h. The mixture was diluted 
with EtOAc (400 mL) and then separated. The organic phase was washed with H2O (2 × 400 
mL), saturated NaHCO3 solution (2 × 400 mL), dried over MgSO4 and filtered. A solution of 
HCl in EtOH [obtained by the dropwise addition of AcCl (21.3 mL, 300 mmol) to ice-cooled 
dry ethanol (75 mL)] was added dropwise to the ice-cooled filtrate while stirring. The 
precipitate was collected under filtration, washed with EtOAc (3 × 100 mL) to give compound 
91 as white needles (19.3 g, 92.1 mmol, 46%). 
mp = 101–102°C (lit. 100–102°C)377 
1H NMR (400 MHz, D2O): δH = 9.31 (t, J = 1.3 Hz, 1 H, H-1), 8.01 (t, J = 1.8 Hz, 1 H, H-3), 7.60 
(t, J = 1.6 Hz, 1 H, H-2)  
13C NMR (101 MHz, D2O): δC = 137.7 (C-1), 124.1 (C-2), 119.9 (C-3) 
IR (ATR): max / cm-1 = 3102 (m, C-H), 3057 (m, C-H), 2169 (s, N=N=N), 1581 (s, C=C), 1298 (m, 
S=O), 1137 (vs, S=O) 
Procedure adapted from Goddard-Borger et al.377 Spectroscopic data are in accordance with 
the literature.377 
 
6.2.2.4. Linear peptide syntheses 
Peptide synthesis was carried out on solid-phase using Fmoc-protecting group strategy on a 
CEM LibertyBlue Automated Microwave Peptide Synthesizer using Rink Amide MBHA LL 
resin (0.33 mmol/g) (Merck Millipore). Fmoc-protected amino acids were made up as a 
solution of 0.2 M in DMF to give 5 equivalents relative to resin loading. Oxyma Pure was made 
up as a 1 M solution in DMF to give 5 equivalents relative to resin and N,N’-
diisopropylcarbodiimide as a 1 M solution in DMF to give 10 equivalents relative to the resin. 
All amino acid couplings were double coupled and heated to 90 °C for two mins, except for 
Fmoc-Orn(N3)-OH which was single coupled and heated to 90 °C for 270 s for each coupling. 
Fmoc deprotection was carried out using 20 % (v/v) piperidine in DMF and heated to 90 °C for 
60 s twice. The Ac capping of the N-terminus was carried out using 20 % (v/v) Ac2O in DMF 
and heated to 40 °C for 10 min. 
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6.2.2.5. Peptide stapling 
Under a N2 atmosphere, a solution of diazidopeptide in DMSO (1 equiv., 0.4 mg/µL) was added 
to a degassed tBuOH/H2O (1:1) making the concentration of the peptide to 1 mg/mL. A 
dialkynyl linker (1.1 equiv.) was then added to the peptide solution. Sodium L-ascorbate (3 
equiv.) was added to a degassed aqueous solution of CuSO4·5H2O (1 equiv.) and THPTA (1 
equiv.) under N2. The copper solution was added to the reaction mixture, stirred at rt, and 
monitored by HPLC until its completion. The mixture was lyophilised and then purified by 
semi-preparative HPLC. 
 











P1 Ac-LTFEXYWAALTX-NH2 1534.77 766.9 766.4 [M−2H]2− 10.57c 
P3 Ac-ETFEXYWSALTX-NH2 1566.72 783.2 782.4 [M−2H]2− 10.82d 
P4 H-ETFEXYWNALTX-OH 1552.71 1552.2 1551.7 [M−H]− 9.82e 
P5 Tmg-ETFEXYWNALTX-OH 1652.78 1653.4 1652.8 [M]+ 10.21e 
P6 Ac-TSFAXYWNGLSX-NH2 1465.69 734.5 733.9 [M+2H]2+ 8.97 
WT PMI Ac-TSFAEYWNNLSP-NH2 1467.70 735.0 734.9 [M+2H]2+ 9.16 
P5-81  1860.78 929.8 929.4 [M−2H]− 10.90e 
P6-81  1673.68 838.6 837.8 [M+2H]2+ 9.38 
P6-92  1591.73 797.6 796.9 [M+2H]2+ 8.76 
P6-93  1885.66 933.5 932.9 [M−Na+3H]2+ 8.71 
aShown for linear peptides only; X = Orn(N3); Tmg = trimethylglycyl which contains a permanent +1 charge. 
bObtained from analytical HPLC runs with 5-95%B over 15 min gradient (an x-y gradient signifies the amount of 
solvent B being x % at the start and y% at the end of the run, respectively.). c30-80%B over 15 min gradient used. 
d10-80%B over 15 min gradient used. e20-60%B over 15 min gradient used. 
 
6.2.2.7. Circular dichroism 
Circular dichroism measurements were performed by Dr Jessica Iegre, Spring Group, 
Department of Chemistry, University of Cambridge. 
CD spectra of selected peptides were recorded on an AVIV 410 circular dichroism 
spectropolarimeter using a 1 mm path length quartz cuvette. CD measurements were 
performed at 298 K over a range of 185–260 nm using a response time of 0.5 s, 1 nm pitch and 
0.5 nm bandwidth. Peptides were dissolved in 1:1 MQ water/acetonitrile to a final 
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concentration of 100 µM. The recorded spectra represent a smoothed average of three scans, 
zero-corrected at 260 nm. The %helicity was calculated from mean residue ellipticity ([ ] ) 
and compared to the theoretical maximum value (  = -39,500 deg cm2 dmol-1) according to 
the following equation:477  




where i is the number of helices in the sample, k is the wavelength specific constant (2.57 at 
222 nm), and n is the number of amino acid residues in the peptide. 
 
6.2.3. Stability and reactivity test protocols 
6.2.3.1. Stability tests in CuAAC peptide stapling condition 
Sodium L-ascorbate (3 equiv.) was added to a degassed aqueous solution of CuSO4·5H2O (1 
equiv.) and THPTA (1 equiv.) under nitrogen. The mixture was then added to a solution of a 
dialkynyl linker (1.1 equiv., 0.73 mM) and caffeine (0.3 equiv.) in degassed tBuOH/H2O (1:1) 
at rt under nitrogen. The reactions were monitored by analytical HPLC, and conversions were 
calculated by comparing the integrations of the area under the chromatogram peaks of the 
linker with the internal standard (caffeine) at 254 nm. 
 
6.2.3.2. Stability tests in aqueous media for linkers 
At 37 °C, PBS (1 mL) was added caffeine solution in MeCN (0.75 mM, 200 µL) and linker 
solution in 3:2 MeCN/PBS (2.5 mM, 800 µL). The mixture was incubated at 37 °C, and the 
reactions were monitored by analytical HPLC. Conversions were calculated by comparing the 
integrations of the area under the chromatogram peaks of the remaining linker and the 
internal standard (caffeine) determined by analytical HPLC at 254 nm. 
 
6.2.3.3. Reactivity tests with lysine for linkers 
At 37 °C, a stock solution of Nα-Ac-Lys-OH in PBS (4 mM, 1 mL) was added caffeine solution 
in MeCN (0.75 mM, 200 µL) and linker solution in 3:2 MeCN/PBS (2.5 mM, 800 µL). The 
reactions were monitored by analytical HPLC. Conversions were calculated by comparing the 
integrations of the area under the chromatogram peaks of the products and the internal 




6.2.4. Biological experiments 
6.2.4.1. Expression and purification of MDM2 (6–125) 
The protein expression and purification were performed by Dr Elaine Fowler from the Spring 
Group, Department of Chemistry, University of Cambridge and Dr Rohan Eapen from the 
Itzhaki Group, Department of Pharmacology, University of Cambridge. 
Coding region of MDM2, residues 6–125 were cloned into a pRSET vector with an N-terminal 
6His-tag and TEV protease cleavage site via BamHI & KpnI restriction sites. The plasmid was 
transformed into C41 cells and expressed in 2xYT medium supplemented with 100 µg/mL 
ampicillin. Cultures were grown in baffled 2 L flasks to an OD600 = 0.6, prior to induction 
with 0.3 mM IPTG at 18 °C for around 16 h. Cells were harvested by centrifugation at 7000 × 
g at 4 °C and were resuspended in 50 mM Tris-HCl, 300 mM NaCl, 15 mM imidazole, 1 mM 
DTT, SigmaFAST EDTA-free protease inhibitor cocktail tablet (Sigma) and DNaseI (Sigma), 
pH 8.0. Resuspended cells were lysed using a C5-emulsiflex (Avestin). The lysate was then 
clarified by centrifugation at 45,000 × g at 4 °C. His-tagged proteins were bound to a 5 mL 
HisTrap Excel column using an AKTA PURE chromatography system and washed with 20 CV 
of 50 mM Tris-HCl, 300 mM NaCl, 15 mM imidazole, 1 mM DTT, pH 8.0. Proteins were eluted 
with 5 CV of 50 mM Tris-HCl, 300 mM NaCl, 300 mM imidazole, 1 mM DTT, pH 8.0, directly 
into a pre-equilibrated 26/10 desalting column of 20 mM Tris-HCl, 180 mM NaCl, 1 mM DTT, 
pH 8.0. Eluent fractions containing 6His-tagged MDM2 were pooled and 6His-TEV protease 
(S219V) was added to cleave overnight at 4 °C. Cleaved proteins were then run over a 5 mL 
HisTrap Excel column, collecting the flow through. Proteins were diluted in 20 mM Bis-Tris, 
1 mM DTT, pH 6.5 to approximately 20 mM NaCl. MonoS 10/100 GL column was then 
equilibrated in 20 mM Bis-Tris, 30 mM NaCl, 1 mM DTT, pH 6.5 before loading protein samples 
onto the column. Proteins were then eluted in a linear gradient with 20 mM Bis-Tris, 1 M NaCl, 
1 mM DTT, pH 6.5 over 20 CV. Elution fractions were run on a 15% SDS PAGE gel to assess 
purity (>90%), before concentrating using a Vivaspin 20, 5K MWCO centrifugal concentrator 
(Sartorius Stedim). Proteins were snap-frozen in liquid nitrogen and stored at -80 °C for long- 
term storage.  
 
6.2.4.2. Covalent cross-linking determination 
The LCMS analyses were performed by Dr Stephen Walsh from the Spring Group, Department 
of Chemistry, University of Cambridge. 
MDM2 protein stock solution (195 µM) was diluted in PBS buffer to 55.6 µM. PBS (5 µL) was 
added to the diluted MDM2 solution (5 µL) in a 500 µL-centrifuge tube. DMSO (0.556 µL) and 
the peptide solution (0.556 µL, 500 µM in DMSO) were then added successively and the 
mixture incubated at 37 °C for 1 h. The negative control used DMSO in place of peptide 
solution. Lysozyme solution (55.6 µM) was used instead of PBS for selectivity assay. The mass 
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of the protein was detected by protein LCMS as described in the general experimental except 
that the electrospray source was operated with a cone voltage of 40 V. 
 
6.2.4.3. MDM2 competitive fluorescence polarisation assay 
The assay was conducted by Dr Rohan Eapen from the Itzhaki Group, Department of 
Pharmacology, University of Cambridge. 
Competitive fluorescence polarisation was carried out using MDM2 and a 5-TAMRA-labelled 
FP tracer peptide in a similar fashion as previously described.101,102 The dissociation constant 
was previously described by Lau et al.102 Stock solutions of peptide inhibitors in DMSO (10 
mM) were diluted in assay buffer (1 × PBS + 0.05% (v/v) Tween-20 + 3% (v/v) DMSO) to a top 
concentration of 80 µM (final assay concentration of 40 µM). 1.5-fold serial dilutions were 
performed by multichannel pipette, in the assay plate (OptiPlate™ -384 F, Perkin Elmer) to 
produce a 24-point titration with a volume of 20 µL. An equal volume of MDM2 and 
fluorescent tracer peptide were then added to each well, by multichannel pipette for a final 
concentration of 95 nM and 50 nM, respectively. All titrations were conducted in triplicate. 
Fluorescence polarisation was measured using a BMG ClarioStar plate reader using an 
excitation filter at 540 nm and an emission filter at 590 nm, with a 20 nm bandwidth. Plates 
were read at time points indicated. Graphs were plotted using GraphPad Prism 7.0 and 
analysed using the equations below.478 The equations described by Wang describe competitive 
binding, where neither protein nor ligand was depleted. However, in the case of a covalent 
ligand (P6-93), both the target protein and covalent ligand were depleted in a stoichiometric 
manner over the course of the incubation, resulting in a deviation from the model fit over 
time. Nonetheless, the system could still illustrate the time-dependent nature of a covalent 
ligand’s interaction with the target protein and thus an apparent dissociation constant, Kd,app, 
was quoted.  
Here, r = anisotropy measured, r0 = anisotropy of free peptide, rb = anisotropy of MDM2:5-
TAMRA peptide complex, Kd1 = dissociation constant of 5-TAMRA peptide to MDM2, Kd2 = 
(apparent) dissociation constant of non-labelled ligand to MDM2, [P]t = MDM2 concentration, 
[L]t = non-labelled ligand concentration and [L]st = 5-TAMRA peptide concentration. 
= + (  + ) ×
2 ( − 3 ) cos( 3)⁄ − 9
3 + 2 ( − 3 ) cos( 3)⁄ −
 
= + + [ ] + [ ] − [ ]  
= ([ ] − [ ] ) + ([ ] − [ ] ) +  
= cos
−2 + 9 − 27
2 ( − 3 )
 
= − [ ]  
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6.3. Chapter 5 Experimental 
6.3.1. Synthesis of hemiasterlin and taltobulin 
Methyl (S)-2-formamido-3,3-dimethylbutanoate (102) 
 
Triethylamine (1.53 mL, 11.0 mmol) was added to a suspension of methyl (S)-tert-leucinate 
hydrochloride (1.82 g, 10.0 mmol) in ethyl formate (15 mL). The reaction mixture was refluxed 
for 20 h, allowed to cool to rt, then filtered through a short silica plug. The solvent was 
removed in vacuo to give formamide 102 as a white solid (1.68 g, 9.70 mmol, 97%). The 
product was used in the next step without further purification.  
Rf = 0.52 (EtOAc) 
[α]D20 = +13.4° (c = 1.06, CHCl3, lit.403 +14.2°, c = 1.0) 
1H NMR (400 MHz, CDCl3): Major rotamer δH = 8.24 (d, J = 0.8 Hz, 1 H, H-1), 6.23 (br s, 1 H, 
H-N), 4.57 (dd, J = 9.6, 0.7 Hz, 1 H, H-2), 3.74 (s, 3 H, H-6), 0.99 (s, 9 H, H-4); Minor rotamer 
(observed peaks) δH = 7.99 (d, J = 11.7 Hz, 1 H, H-1), 3.79 (d, J = 10.6 Hz, 1 H, H-2), 3.76 (s, 3 
H, H-6) 
13C NMR (101 MHz, CDCl3): Major rotamer δC = 171.9 (C-5), 160.8 (C-1), 58.6 (C-2), 52.1 (C-
6), 34.9 (C-3), 26.6 (C-4); Minor rotamer δC = 170.7 (C-5), 163.6 (C-1), 63.7 (C-2), 52.2 (C-6), 
34.8 (C-3), 26.3 (C-4) 
HRMS (ESI): m/z [M+H]+ calcd for C8H16NO3: 174.1130; found: 174.1128 (Δ = −1.1 ppm) 
Prepared according to Ackermann et al.403  Spectroscopic data are in accordance with the 
literature.403 
 
Methyl (S)-2-isocyano-3,3-dimethylbutanoate (101) 
 
To a solution of methyl (S)-2-formamido-3,3-dimethylbutanoate 102 (866 mg, 5.00 mmol) in 
anhydrous CH2Cl2 (50 mL) was added N-methylmorpholine (1.10 mL, 10.0 mmol). The mixture 
was then cooled to −78 °C. Triphosgene (519 mg, 1.75 mmol) was then added in a single 
portion and the reaction mixture stirred at −78 °C for 5 min before being slowly warmed to -
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30 °C and then stirred at this temperature for 3 h. The reaction was then quenched with H2O 
(50 mL) and the phases separated. The aqueous phase was then extracted with Et2O (3 × 50 
mL). The combined organic phases were dried with Na2SO4, and the solvent was removed in 
vacuo (the bath temperature was kept below 15 °C). The crude product was purified by flash 
column chromatography (eluting gradient Et2O:30–40 petroleum ether from 0:1 to 1:4) to 
give isocyanide 101 as a clear colourless liquid (731 mg, 4.71 mmol, 94%). 
Rf = 0.64 (EtOAc:hexane = 1:1) 
[α]D20 = +33.3° (c = 0.990, CHCl3, lit.403 +39.7°, c = 1.0) 
1H NMR (400 MHz, CDCl3): δH = 4.00 (s, 1 H, H-2), 3.81 (s, 3 H, H-6), 1.10 (s, 9 H, H-4) 
13C NMR (101 MHz, CDCl3): δC = 166.3 (C-5), 160.0 (C-1), 66.4 (t, J = 7.0 Hz, C-2), 52.8 (C-6), 
35.2 (C-3), 26.2 (C-4) 
HRMS (ESI): m/z [M+H]+ calcd for C8H14NO2: 156.1025; found: 156.1022 (Δ = −1.9 ppm) 





DBDMH (157 mg, 0.550 mmol) was added in five portions to a solution of N-methylindole 
(125 µL, 1.00 mmol) in dioxane (10 mL) at 10 °C over 2 min. The reaction mixture was stirred 
at this temperature for 10 min before being poured into saturated aqueous NaHCO3 (10 mL). 
The mixture was extracted with EtOAc (2 × 15 mL), the combined organic phases were dried 
over anhydrous Na2SO4, and the solvent removed in vacuo. The resulting crude oil was purified 
by flash column chromatography (eluting gradient EtOAc:40–60 petroleum ether from 0:1 to 
1:15) to give indole 104 as a colourless oil (134 mg, 0.638 mmol, 64%), which was prone to 
decomposition to a dark solid over time. 
Rf = 0.37 (EtOAc:40–60 petroleum ether = 1:10) 
1H NMR (400 MHz, CDCl3): δH = 7.59 (dt, J = 8.0, 0.9 Hz, 1 H, H-4), 7.33 (dt, J = 8.3, 0.9 Hz, 1 
H, H-7), 7.29 (ddd, J = 8.2, 6.9, 1.2 Hz, 1 H, H-6), 7.22 (ddd, J = 8.0, 6.8, 1.2 Hz, 1 H, H-5), 7.09 
(s, 1 H, H-1), 3.79 (s, 3 H, H-9) 
13C NMR (101 MHz, CDCl3): δC = 136.4 (C-8), 127.8 (C-1), 127.4 (C-3), 122.7 (C-6), 120.2 (C-
5), 119.4 (C-4), 109.6 (C-7), 89.5 (C-2), 33.2 (C-9) 
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HRMS (ESI): m/z [M+H]+ calcd for C9H9BrN: 209.9918; found: 209.9908 (Δ = −4.8 ppm) 
Procedure adapted from Yan et al.413  Spectroscopic data are in accordance with the 
literature.479  
 
(±)-Methyl 2-(1-methyl-1H-indol-3-yl)propanoate (59) 
 
A solution of KHMDS in THF (0.91 M, 33.0 mL, 30.0 mmol) was diluted with freshly distilled 
THF (100 mL) and then cooled to −78 °C. A solution of methyl 2-(1H-indol-3-yl)acetate 58 
(1.89 g, 10.0 mmol) in THF (46 mL) was then added slowly. The reaction mixture was warmed 
to 0 °C and stirred for 1 h before re-cooling to −78 °C. Methyl iodide (5.0 mL, 80 mmol) was 
then added slowly to the reaction mixture which was then warmed to 0 °C and stirred for 1 h 
before being placed in a freezer (−30 °C) for 17 h. The reaction was then quenched with H2O 
(135 mL) and then extracted with Et2O (3 × 135 mL). The combined organic phases were 
washed with brine (135 mL), dried with anhydrous MgSO4, and the solvent removed in vacuo. 
The resulting crude oil was purified by flash column chromatography (eluting gradient 
Et2O:40–60 petroleum ether from 0:1 to 1:4) to give indole 59 as a viscous yellow oil (2.08 g, 
9.57 mmol, 96%). 
Rf = 0.17 (Et2O:40–60 petroleum ether = 1:4) 
1H NMR (500 MHz, CDCl3): δH = 7.68 (dt, J = 8.0, 0.9 Hz, 1 H, H-4), 7.31 (dt, J = 8.2, 0.8 Hz, 1 
H, H-7), 7.25 (ddd, J = 8.2, 7.0, 1.1 Hz, 1 H, H-6), 7.14 (ddd, J = 8.0, 7.0, 1.1 Hz, 1 H, H-5), 7.02 
(s, 1 H, H-1), 4.05 (q, 1 H, J = 7.1 Hz, H-10), 3.77 (s, 3 H, H-9), 3.69 (s, 3 H, H-13), 1.62 (d, J = 
7.2 Hz, 3 H, H-11) 
13C NMR (126 MHz, CDCl3): δC = 175.8 (C-12), 137.1 (C-8), 126.9 (C-3), 126.4 (C-1), 121.9 (C-
6), 119.4 (C-4), 119.2 (C-5), 114.1 (C-2), 109.4 (C-7), 52.1 (C-13), 36.9 (C-10), 32.9 (C-9), 18.2 
(C-11) 
HRMS (ESI): m/z [M+H]+ calcd for C13H16NO2: 218.1176; found: 218.1181 (Δ = −2.3 ppm) 






Methyl 2-methyl-2-(1-methyl-1H-indol-3-yl)propanoate (60) 
 
A solution of KHMDS in THF (0.91 M, 13.2 mL, 12.0 mmol) was diluted with freshly distilled 
THF (94 mL) and then cooled to −78 °C. A solution of (±)-methyl 2-(1-methyl-1H-indol-3-
yl)propanoate 59 (1.74 g, 8.00 mmol) in THF (38 mL) was then added slowly. The reaction 
mixture was warmed to 0 °C and stirred for 1 h before re-cooling to −78 °C. Methyl iodide (3.0 
mL, 48 mmol) was then added slowly to the reaction mixture which was then warmed to 0 °C 
and stirred for 45 min. The reaction was then quenched with H2O (80 mL) and then extracted 
with Et2O (3 × 80 mL). The combined organic phases were washed with brine (80 mL), dried 
with anhydrous MgSO4, and the solvent removed in vacuo. The resulting crude product was 
purified by flash column chromatography (eluting gradient Et2O:40–60 petroleum ether from 
0:1 to 1:4) to give indole 60 as a white solid (1.69 g, 7.31 mmol, 91%). 
Rf = 0.21 (Et2O:40–60 petroleum ether = 1:4) 
1H NMR (500 MHz, CDCl3): δH = 7.65 (dt, J = 8.0, 0.9 Hz, 1 H, H-4), 7.31 (dt, J = 8.3, 0.9 Hz, 1 
H, H-7), 7.23 (ddd, J = 8.2, 7.0, 1.1 Hz, 1 H, H-6), 7.10 (ddd, J = 8.0, 7.0, 1.1 Hz, 1 H, H-5), 6.95 
(s, 1 H, H-1), 3.77 (s, 3 H, H-9), 3.65 (s, 3 H, H-13), 1.71 (s, 6 H, H-11) 
13C NMR (126 MHz, CDCl3): δC = 177.8 (C-12), 137.6 (C-8), 126.2 (C-3), 125.4 (C-1), 121.7 (C-
6), 120.4 (C-4), 119.3 (C-2), 119.1 (C-5), 109.5 (C-7), 52.3 (C-13), 42.1 (C-10), 32.8 (C-9), 26.4 
(C-11) 
HRMS (ESI): m/z [M+H]+ calcd for C14H18NO2: 232.1329; found: 232.1332 (Δ = −1.3 ppm) 





Methyl 2-methyl-2-(1-methyl-1H-indol-3-yl)propanoate 60 (1.27 g, 5.50 mmol) was 
dissolved in Et2O (60 mL) and CH2Cl2 (16 mL) and cooled to −78 °C. A solution of DIBAL-H in 
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THF (1.0 M, 19.3 mL, 19.3 mmol) was then added slowly, and the reaction mixture was warmed 
to 0 °C and stirred for 3 h. The reaction was then quenched with H2O (12 mL), allowed to warm 
to rt, and saturated aqueous solution of potassium sodium tartrate (28 mL) was added. The 
phases were separated, and the aqueous phase was extracted with Et2O (2 × 60 mL). The 
combined organic phases were washed with brine (60 mL), dried with anhydrous MgSO4, and 
the solvent removed in vacuo. The resulting crude product was purified by flash column 
chromatography (eluting gradient Et2O:40–60 petroleum ether from 1:20 to 1:1) to give 
alcohol 105 as a white solid (1.07 g, 5.26 mmol, 96%). 
Rf = 0.24 (Et2O:40–60 petroleum ether = 1:1) 
1H NMR (400 MHz, CDCl3): δH = 7.79 (d, J = 8.0 Hz, 1 H, H-4), 7.34 (d, J = 8.2 Hz, 1 H, H-7), 
7.28–7.22 (m, 1 H, H-6), 7.12 (ddd, J = 8.0, 7.0, 1.0 Hz, 1 H, H-5), 6.92 (s, 1 H, H-1), 3.81 (s, 2 
H, H-12), 3.78 (s, 3 H, H-9), 1.47 (s, 6 H, H-11) 
13C NMR (101 MHz, CDCl3): δC = 138.0 (C-8), 127.2 (C-1), 126.1 (C-3), 121.6 (C-6), 121.1 (C-
4), 119.5 (C-2), 118.8 (C-5), 109.7 (C-7), 71.6 (C-12), 37.7 (C-10), 32.8 (C-9), 25.6 (C-11) 
HRMS (ESI): m/z [M+H]+ calcd for C13H18NO: 204.1383; found: 204.1377 (Δ = −2.9 ppm) 





To a mixture of 2-methyl-2-(1-methyl-1H-indol-3-yl)propan-1-ol 105 (1.02 g, 5.00 mmol), 
N-methylmorpholine N-oxide (1.05 g, 9.00 mmol), and 4 Å powdered molecular sieves (1.09 
g) in dry CH2Cl2 (36 mL) were added tetrapropylammonium perruthenate (87.9 mg, 0.250 
mmol). The black reaction mixture was stirred at rt for 20 h, filtered through Celite®, and 
concentrated in vacuo. The crude black oil was purified by flash column chromatography 
(eluting gradient Et2O:40–60 petroleum ether from 0:1 to 1:5) to give aldehyde 69 as a pale-
yellow solid (846 mg, 4.20 mmol, 84%). 
Rf = 0.21 (Et2O:40–60 petroleum ether = 1:4) 
1H NMR (400 MHz, CDCl3): δH = 9.50 (s, 1 H, H-12), 7.57 (d, J = 8.1 Hz, 1 H, H-4), 7.34 (d, J = 
8.2 Hz, 1 H, H-7), 7.26 (t, J = 8.0 Hz, 1 H, H-6), 7.11 (t, J = 7.5 Hz, 1 H, H-5), 6.98 (s, 1 H, H-1), 
3.80 (s, 3 H, H-9), 1.56 (s, 6 H, H-11) 
145 
 
13C NMR (101 MHz, CDCl3): δC = 202.4 (C-12), 137.8 (C-8), 126.8 (C-1), 126.3 (C-3), 122.0 (C-
6), 120.4 (C-4), 119.4 (C-5), 115.2 (C-2), 109.7 (C-7), 46.6 (C-10), 33.0 (C-9), 22.1 (C-11) 
HRMS (ESI): m/z [M+H]+ calcd for C13H16NO: 202.1232; found: 202.1228 (Δ = −2.0 ppm) 









Methylamine solution in MeOH (2 M, 1.10 mL. 2.20 mmol) was added to a solution of 2-
methyl-2-(1-methyl-1H-indol-3-yl)propanal 69 (403 mg, 2.00 mmol) in dry MeOH (5.1 mL). 
3 Å molecular sieves (1.8 g) were then added, and the reaction was stirred at rt for 2 h before 
TFA (184 µL, 2.40 mmol) was added. The reaction mixture was stirred for a further 20 min 
before methyl (S)-2-isocyano-3,3-dimethylbutanoate 101 (373 mg, 2.4 mmol) was added. The 
reaction was stirred at rt for a further 19 h, filtered through Celite®, and the solvent removed 
in vacuo. The crude product was purified by flash column chromatography (eluting gradient 
EtOAc:40–60 petroleum ether from 0:1 to 1:3) to give amide 99a as a white solid (291 mg, 
0.602 mmol, 30%) and 99b as a white solid (382 mg, 0.790 mmol, 40%). A small amount of 
both isomers was re-crystallised from hexane/Et2O for X-ray crystallography. 
 
99a 
Rf = 0.23 (EtOAc:40–60 petroleum ether = 1:3) 
mp = 150–157 °C  
[α]D25 = −21.7° (c = 1.44, CHCl3) 
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1H NMR (400 MHz, CDCl3): δH = 8.27 (d, J = 8.0 Hz, 1 H, H-4), 7.33 (d, J = 7.6 Hz, 1 H, H-7), 
7.31–7.26 (m, 1 H, H-6), 7.22 (ddd, J = 8.0, 6.8, 1.4 Hz, 1 H, H-5), 7.09 (s, 1 H, H-1), 6.33 (s, 1 
H, H-12), 5.91 (d, J = 8.5 Hz, 1 H, N-H), 4.04 (d, J = 8.6 Hz, 1 H, H-17), 3.77 (s, 3 H, H-9), 3.67 
(s, 3 H, H-21), 3.46 (q, 5JH-F = 1.9 Hz, 3 H, H-13), 1.69 (s, 3 H, H-11 or 11’), 1.50 (s, 3 H, H-11’ 
or 11), 0.45 (s, 9 H, H-19) 
13C NMR (101 MHz, CDCl3): δC = 171.9 (C-20), 168.4 (C-16), 159.4 (app d, 2JC-F = 35.6 Hz, C-
14), 138.2 (C-8), 127.1 (C-1), 124.7 (C-3), 122.6 (C-6), 121.1 (C-4), 120.7 (C-2), 120.2 (C-5), 
117.0 (app d, 1JC-F = 288.3 Hz, C-15), 109.8 (C-7), 63.0 (C-12), 60.4 (C-17), 51.7 (C-21), 39.3 (C-
10), 35.0 (q, 4JC-F = 4.2 Hz, C-13), 33.6 (C-18), 32.9 (C-9), 27.5 (C-11’ or 11), 26.0 (C-19), 24.5 
(C-11 or 11’) 
19F NMR (376 MHz, CDCl3): δF = −69.5 
IR (ATR): max / cm-1 = 3358 (w, N-H), 2972 (w, C-H), 1738 (m, C=O), 1673 (s, C=O) 
HRMS (ESI): m/z [M+Na]+ calcd for C24H32F3N323NaO4: 506.2237; found: 506.2238 (Δ = 0.2 ppm) 
 
99b 
Rf = 0.35 (EtOAc:40–60 petroleum ether = 1:3) 
mp = 94–97 °C 
[α]D25 = +60.4° (c = 0.747, CHCl3) 
IR (ATR): max / cm-1 = 3347 (w, N-H), 2967 (w, C-H), 1743 (m, C=O), 1690 (m, C=O), 1673 (s, 
C=O) 
1H NMR (400 MHz, CDCl3): δH = 8.16 (dd, J = 7.0, 1.2 Hz, 1 H, H-4), 7.32 (dd, J = 7.5, 1.7 Hz, 1 
H, H-7), 7.28–7.19 (m, 2 H, H-6 and 5), 6.91 (s, 1 H, H-1), 6.12 (s, 1 H, H-12), 5.63 (d, J = 9.3 
Hz, 1 H, N-H), 4.07 (d, J = 9.0 Hz, 1 H, H-17), 3.72 (s, 3 H, H-9), 3.51 (s, 3 H, H-21), 3.47 (q, 5JH-
F = 1.9 Hz, 3 H, H-13), 1.74 (s, 3 H, H-11 or 11’), 1.49 (s, 3 H, H-11’ or 11), 0.44 (s, 9 H, H-19) 
13C NMR (101 MHz, CDCl3): δC = 170.7 (C-20), 167.6 (C-16), 159.2 (app d, 2JC-F = 36.0 Hz, C-
14), 138.0 (C-8), 126.5 (C-1), 125.1 (C-3), 122.1 (C-6), 120.7 (C-4), 120.1 (C-5), 119.9 (C-2), 
116.8 (q, 1JC-F = 288.2 Hz, C-15), 109.8 (C-7), 62.6 (C-12), 60.1 (C-17), 51.6 (C-21), 39.7 (C-10), 
34.0-33.9 (m, C-13), 33.9 (C-18), 32.6 (C-9), 27.2 (C-11’ or 11), 25.8 (C-19), 24.4 (C-11 or 11’) 
19F NMR (376 MHz, CDCl3): δF = −69.5 







N-Boc-N-methylvaline (3.70 g, 16.0 mmol), N,O-dimethylhydroxylamine hydrochloride (2.03 
g, 20.8 mmol), and PyBOP (8.74 g, 16.8 mmol) were dissolved in dry CH2Cl2 (16 mL). The 
mixture was cooled to 0 °C before DIPEA (8.36 mL, 48.0 mmol) was added and stirred at this 
temperature for 1 min. The reaction was allowed to warm to rt and stirred for a further 2.5 h. 
Et2O (100 mL) was then added and the mixture was washed successively with aqueous HCl (3 
M, 3 × 35 mL), saturated aqueous NaHCO3 (3 × 35 mL), and brine (3 × 35 mL). The organic 
phase was then dried with anhydrous MgSO4, and the solvent was removed in vacuo. The crude 
product was then purified by flash column chromatography (eluting gradient Et2O:40–60 
petroleum ether from 0:1 to 1:1) to give Weinreb amide 110 as a slightly yellow oil (3.86 g, 
14.1 mmol, 88%) 
Rf = 0.50 (EtOAc:40–60 petroleum ether = 1:1) 
[α]D25 = −128.7° (c = 1.07, CHCl3, lit.480 [α]D20 = −163.6°, c = 1.3) 
1H NMR (400 MHz, CDCl3): Major rotamer δH = 5.00 (br d, J = 9.6 Hz, 1 H, H-5), 3.72 (s, 3 H, 
H-10), 3.20* (br s, 3 H, H-9), 2.83 (s, 3 H, H-4), 2.35–2.17* (m, 1 H, H-6), 1.46 (s, 9 H, H-1); 
Minor rotamer δH = 4.70 (br s, 1 H, H-5), 3.68 (s, 3 H, H-10), 3.20* (br s, 3 H, H-9), 2.80 (s, 3 H, 
H-4), 2.35–2.17* (m, 1 H, H-6), 1.49 (s, 9 H, H-1); Unassigned† δH = 0.90 (d, J = 6.8 Hz, 2 H, H-
7 and 7’), 0.88 (d, J = 6.8 Hz, 4 H, H-7 or 7’) 
13C NMR (101 MHz, CDCl3): Major rotamer δC = 172.3 (C-8), 156.3 (C-3), 80.0 (C-2), 61.9 (C-
10), 58.1 (C-5), 32.1 (C-9), 29.8 (C-4), 28.5 (C-1), 27.3 (C-6); Minor rotamer δC = 171.2 (C-8), 
155.7 (C-3), 79.7 (C-2), 61.8 (C-10), 59.9 (C-5), 32.0 (C-9), 29.2 (C-4), 28.6 (C-1), 27.1 (C-6); 
Unassigned† δC = 19.9 (C-7 or 7’), 19.4 (C-7 or 7’), 18.5 (C-7 or 7’) 
*These signals appear as single signals and belong to both rotamers. 
†Unassigned signals cannot be unambiguously assigned to either rotamers. The numbers of 
proton nuclei quoted are with respect to the sum of both rotamers. 
HRMS (ESI): m/z [M+Na]+ calcd for C13H26N223NaO4: 297.1785; found: 297.1784 (Δ = −0.3 ppm) 









Lithium aluminium hydride (190 mg, 5.00 mmol) was added to the solution of Weinreb amide 
110 (1.37 g, 5.00 mmol) in dry THF (5 mL) in one portion at −78 °C. The reaction mixture was 
then warmed to 0 °C and stirred for 15 min. The mixture was then poured into a stirring ice-
cold aqueous solution of KHSO4 (0.25 M, 40 mL), and the phases were separated. The aqueous 
phase was then extracted with Et2O (3 × 30 mL). The combined organic phases were quickly 
washed with aqueous HCl (1 M, 2 × 30 mL), saturated aqueous NaHCO3 (2 × 30 mL), and brine 
(30 mL), dried with anhydrous MgSO4, and concentrated in vacuo (the bath temperature was 
kept below 20 °C) to give the crude aldehyde 111 as a clear volatile liquid which was used in 
the next step without further purification. 
The crude aldehyde obtained was dissolved in dry CH2Cl2 (5 mL) and [(1-
ethoxycarbonyl)ethylidene]triphenylphosphorane (2.72 g, 7.50 mmol) was added. The 
reaction mixture was stirred at rt for 20 h. The reaction was quenched with addition of H2O 
(15 mL), and the phases were separated. The aqueous phase was extracted with Et2O (3 × 30 
mL), and the combined organic phases were washed with brine (30 mL), dried with anhydrous 
MgSO4, and the solvent was removed in vacuo. The crude product was purified by flash column 
chromatography (eluting gradient Et2O:40–60 petroleum ether from 0:1 to 1:4) to give 
unsaturated ester 100 as a colourless oil (798 mg, 2.67 mmol, 53% over two steps). 
Rf = 0.21 (EtOAc:40–60 petroleum ether = 1:4) 
[α]D25 = −83.5° (c = 1.00, CHCl3, lit.359 +61.1°, c = 9.1) 
1H NMR (400 MHz, CDCl3): Rotameric mixtures* δH = 6.66 (br d, J = 9.2 Hz, 1 H, H-8), 4.64–
4.50 (m, 0.5 H, H-5), 4.38–4.26 (m, 0.5 H, H-5), 4.21 (q, J = 7.1 Hz, 2 H, H-12), 2.73 (br s, 3 H, 
H-4), 1.94–1.81 (m, 1 H, H-6), 1.91 (s, 3 H, H-10), 1.47 (s, 9 H, H-1), 1.31 (t, J = 7.1 Hz, 3 H, H-
13), 0.92 (d, J = 6.6 Hz, 3 H, H-7 or 7’), 0.86 (d, J = 6.3 Hz, 3 H, H-7’ or 7) 
13C NMR (126 MHz, CDCl3): Rotameric mixtures* δC = 168.1 (br, C-11), 155.9 (C-3), 155.7 (C-
3), 139.0 (C-8), 138.9 (C-8), 131.9 (C-9), 131.1 (C-9), 79.9 (C-2), 79.5 (C-2), 61.2 (C-12), 60.9 
(C-12), 59.8 (C-5), 58.1 (C-5), 30.5 (C-6), 29.3 (C-4), 29.1 (C-4), 28.6 (C-1), 19.7 (C-7 or 7’), 
19.3 (C-7’ or 7), 19.0 (C-7’ or 7), 14.4 (C-13), 14.1 (C-13), 13.3 (br, C-10) 
*Signals are unassigned to individual rotamers as most protons give the same signals in both 
rotamers. 
HRMS (ESI): m/z [M+Na]+ calcd for C16H29N23NaO4: 322.1989; found: 322.1984 (Δ = −1.6 ppm) 
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To a solution of ethyl (2E,4S)-N-tert-butoxycarbonyl-N-methyl-4-amino-2,5-dimethylhex-
2-enoate 100 (2.29 g, 7.65 mmol) in dioxane (19 mL) was added a solution of HCl in dioxane 
(4 M, 19.1 mL, 76.5 mmol). The reaction mixture was then stirred at rt for 15 h before Et2O 
(100 mL) was added. The white precipitate formed was filtered under reduced pressure and 
washed with a copious amount of Et2O to give the HCl salt of ethyl (2E,4S)-N-methyl-4-
amino-2,5-dimethylhex-2-enoate as a white powder (1.61 g, 6.83 mmol, 90%). The product 
was used in the next step without further purification. 
To a solution of (S)-N-tert-butoxycarbonyl-tert-leucine (3.15 g, 13.6 mmol) and HATU (5.17 
g, 13.6 mmol) in DMF (30 mL) at 0 °C was added DIPEA (2.37 mL, 13.6 mmol). The reaction 
mixture was stirred for 5 min before a solution of the HCl salt of ethyl (2E,4S)-N-methyl-4-
amino-2,5-dimethylhex-2-enoate (1.59 g, 6.7 mmol) and DIPEA (2.37 mL, 13.6 mmol) in DMF 
(15 mL) was added over 2 min. The reaction mixture was stirred for 18 h before EtOAc (500 
mL) was added. The mixture was then successively washed with aqueous HCl (1 M, 3 × 100 
mL), saturated aqueous NaHCO3 (3 × 100 mL), and brine (100 mL). The organic phase was 
then dried with anhydrous MgSO4, and the solvent was removed in vacuo. The crude product 
was purified by flash column chromatography (eluting gradient EtOAc:40–60 petroleum 
ether from 0:1 to 1:5) to give amide 115 as a white solid (2.59 g, 6.28 mmol, 93%). 
Rf = 0.48 (EtOAc:40–60 petroleum ether = 1:3) 
[α]D25 = −126.9° (c = 0.864, CHCl3, lit.359 −76.9°, c = 2.43) 
1H NMR (400 MHz, CDCl3): δH = 6.63 (app dd, J = 9.3, 1.4 Hz, 1 H, H-12), 5.20 (d, J = 10.0 Hz, 1 
H, N-H), 5.09 (t, J = 9.9 Hz, 1 H, H-9), 4.41 (d, J = 10.2 Hz, 1 H, H-4), 4.18 (q, J = 7.1 Hz, 2 H, H-
16), 2.97 (s, 3 H, H-8), 1.93–1.82 (m, 4 H, H-10 and H-14), 1.40 (s, 9 H, H-1), 1.29 (t, J = 7.1 Hz, 
3 H, H-17), 0.94 (s, 9 H, H-6), 0.86 (d, J = 6.6 Hz, 3 H, H-11 or 11’), 0.82 (d, J = 6.6 Hz, 3 H, H-
11’ or 11) 
13C NMR (101 MHz, CDCl3): δC = 172.5 (C-7), 167.9 (C-15), 156.2 (C-3), 138.7 (C-12), 132.7 (C-
13), 79.6 (C-2), 60.9 (C-16), 56.4 (C-4), 56.0 (C-9), 35.0 (C-5), 31.1 (C-8), 30.2 (C-10), 28.4 (C-
1), 26.5 (C-6), 19.6 (C-11 or 11’), 18.7 (C-11’ or 11), 14.3 (C-17), 13.9 (C-14) 
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LCMS (ESI): m/z [M+H]+ calcd for C22H41N2O5: 413.3; found: 413.4 





To a solution of ethyl (S,E)-4-((S)-2-((tert-butoxycarbonyl)amino)-N,3,3-
trimethylbutanamido)-2,5-dimethylhex-2-enoate 115 (744 mg, 1.80 mmol) in dioxane (4.5 
mL) was added a solution of HCl in dioxane (4 M, 4.50 mL, 18.0 mmol). The reaction mixture 
was then stirred at rt for 14 h before volatiles were removed in vacuo to give the crude 
deprotected amine. Ethyl formate (60 mL) and triethylamine (276 µL, 1.98 mmol) were added, 
and the reaction mixture was refluxed for 20 h. The mixture was then filtered through a short 
silica gel plug and eluted with EtOAc. The volatiles were removed in vacuo to give formamide 
116 as a colourless viscous oil which solidified into white needles under a stream of N2 over 
several days (569 mg, 1.67 mmol, 93% over two steps). This compound was used in the next 
step without further purification. 
Rf = 0.50 (EtOAc) 
mp = 71–75 °C 
[α]D25 = −129.3° (c = 0.760, CHCl3) 
1H NMR (400 MHz, CDCl3): δH = 8.21 (d, J = 1.0 Hz, 1 H, H-1), 6.64 (app dd, J = 9.4, 1.3 Hz, 1 H, 
H-10), 6.46 (br d, J = 9.3 Hz, 1 H, N-H), 5.09 (t, J = 10.0 Hz, 1 H, H-7), 4.94 (d, J = 9.7 Hz, 1 H, 
H-2), 4.20 (q, J = 7.1 Hz, 2 H, H-14), 2.99 (s, 3 H, H-6), 1.97–1.83 (m, 4 H, H-8 and H-12),1.31 
(t, J = 7.1 Hz, 3 H, H-15), 0.97 (s, 9 H, H-4), 0.88 (d, J = 6.5 Hz, 3 H, H-9 or 9’), 0.82 (d, J = 6.5 
Hz, 3 H, H-9’ or 9) 
13C NMR (101 MHz, CDCl3): δC = 171.3 (C-5), 167.8 (C-13), 160.8 (C-1), 138.3 (C-10), 132.9 (C-
11), 61.0 (C-14), 56.3 (C-7), 53.3 (C-2), 35.7 (C-3), 31.3 (C-6), 30.1 (C-8), 26.6 (C-4), 19.5 (C-9 
or 9’), 18.9 (C-9’ or 9), 14.3 (C-15), 14.0 (C-12) 
IR (ATR): max / cm-1 = 3264 (w, N-H), 2965 (m, C-H), 1713 (m, C=O), 1674 (m, C=O), 1633 (s, 
C=O) 







To a solution of ethyl (S,E)-4-((S)-2-formamido-N,3,3-trimethylbutanamido)-2,5-
dimethylhex-2-enoate 116 (529 mg, 1.55 mmol) in CH2Cl2 (31 mL) at −50 °C was added 2,6-
lutidine (812 µL, 6.98 mmol) and triphosgene (276 mg, 0.93 mmol) in one portion. The 
reaction mixture was stirred at −50 °C for 21 h before quenching by addition of saturated 
aqueous NaHCO3 (45 mL) and diluting with CH2Cl2 (45 mL). The phases were then separated. 
The organic phase was then washed successively with aqueous HCl (1 M, 30 mL), saturated 
aqueous NaHCO3 (30 mL), and brine (30 mL), dried with anhydrous Na2SO4, filtered, and the 
solvent removed in vacuo. The crude oil was purified by flash column chromatography 
(eluting gradient EtOAc:40–60 petroleum ether from 0:1 to 1:5) to give isocyanide 117 as a 
white solid (423 mg, 1.31 mmol, 84%). 
Rf = 0.38 (EtOAc:40–60 petroleum ether = 1:3) 
mp = 102–104 °C 
[α]D25 = −86.9° (c = 0.452, CHCl3) 
1H NMR (400 MHz, CDCl3): δH =  6.63 (app dd, J = 9.2, 1.4 Hz, 1 H, H-10), 5.10 (t, J = 9.9 Hz, 1 
H, H-7), 4.21 (q, J = 7.2 Hz, 2 H, H-14), 4.19 (s, 1 H, H-2),  2.94 (s, 3 H, H-6), 2.01–1.90 (m, 1 
H, H-8), 1.89 (d, J = 1.4 Hz, 3 H, H-12),1.31 (t, J = 7.1 Hz, 3 H, H-15), 1.12 (s, 9 H, H-4), 0.94 (d, 
J = 6.7 Hz, 3 H, H-9 or 9’), 0.91 (d, J = 6.5 Hz, 3 H, H-9’ or 9) 
13C NMR (101 MHz, CDCl3): δC = 167.7 (C-13), 164.9 (C-5), 158.4 (br, C-1) 137.7 (C-10), 133.4 
(C-11), 61.7 (C-2), 61.1 (C-14), 56.7 (C-7), 35.7 (C-3), 31.1 (C-6), 30.5 (C-8), 26.2 (C-4), 19.6 
(C-9 or 9’), 18.8 (C-9’ or 9), 14.3 (C-15), 13.8 (C-12) 
IR (ATR): max / cm-1 = 2964 (m, C-H), 2153 (m, C≡N), 1715 (s, C=O), 1646 (s, C=O) 





N-trifluoroacetyl hemiasterlin ethyl ester (113a) 
 
and N-trifluoroacetyl epi-hemiasterlin ethyl ester (113b) 
 
Methylamine solution in MeOH (2 M, 55 µL, 0.11 mmol) was added to a solution of 2-methyl-
2-(1-methyl-1H-indol-3-yl)propanal 69 (20.1 mg, 0.100 mmol) in dry MeOH (0.2 mL). 3 Å 
molecular sieves (100 mg) were then added and the reaction was stirred at rt for 2 h before 
TFA (9.78 µL, 0.120 mmol) and sodium trifluoroacetate (16.3 mg, 0.120 mmol) were added. 
The reaction mixture was stirred for a further 30 min before ethyl (S,E)-4-((S)-2-isocyano-
N,3,3-trimethylbutanamido)-2,5-dimethylhex-2-enoate 117 (38.7 mg, 0.120 mmol) was 
added. The reaction was stirred at rt for a further 19 h, filtered through Celite®, and the 
solvent was removed in vacuo. The crude product was purified by flash column 
chromatography (eluting gradient EtOAc:40–60 petroleum ether from 0:1 to 1:3) to give 
protected hemiasterlin 113a as a white solid (26.5 mg, 0.0407 mmol, 41%) and protected epi-
hemiasterlin 113b as a white solid (20.8 mg, 0.0320 mmol, 32%). A small amount of 113a was 
re-crystallised using the slow evaporation method with EtOAc/hexane (1:5) as a solvent for 
X-ray crystallographic analysis. 
 
113a (S,S,S) 
Rf = 0.24 (EtOAc:40–60 petroleum ether = 1:3) 
mp = 181–184 °C  
[α]D25 = −103.8° (c = 0.212, CHCl3) 
1H NMR (400 MHz, CDCl3): δH = 8.28 (d, J = 8.1 Hz, 1 H, H-4), 7.33 (d, J = 8.3 Hz, 1 H, H-7), 
7.28 (ddd, J = 8.1, 6.9, 1.0, 1 H, H-6), 7.21 (ddd, J = 8.0, 6.9, 1.3 Hz, 1 H, H-5), 7.18 (s, 1 H, H-
1), 6.64 (dq, J = 9.2, 1.5 Hz, 1 H, H-25), 6.38 (s, 1 H, H-12), 6.32 (br d, J = 8.7 Hz, 1 H, N-H), 
5.07 (dd, J = 10.5, 9.5 Hz, 1 H, H-22), 4.42 (d, J = 8.8 Hz, 1 H, H-17), 4.20 (q, J = 7.1 Hz, 2 H, H-
29), 3.78 (s, 3 H, H-9), 3.37 (q, 5JH-F = 1.9 Hz, 3 H, H-13), 2.97 (s, 3 H, H-21), 1.97-1.87 (m, 4 H, 
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H-23 and H-27), 1.61 (s, 3 H, H-11 or 11’), 1.47 (s, 3 H, H-11’ or 11), 1.30 (t, J = 7.1 Hz, 3 H, H-
30), 0.91 (d, J = 6.6 Hz, 3 H, H-24 or 24’), 0.87 (d, J = 6.6 Hz, 3 H, H-24’ or 24), 0.44 (s, 9 H, H-
19) 
13C NMR (101 MHz, CDCl3): δC = 171.3 (C-20), 168.6 (C-16), 167.8 (C-28), 159.3 (q, 2JC-F = 35.5 
Hz, C-14), 138.9 (C-25), 138.3 (C-8), 132.7 (C-26), 127.0 (C-1), 124.7 (C-3), 122.6 (C-6), 121.2 
(C-4), 120.9 (C-2), 120.1 (C-5), 117.0 (app d, 1JC-F = 288.1 Hz, C-15), 109.7 (C-7), 63.2 (C-12), 
61.0 (C-29), 56.2 (C-22), 55.5 (C-17), 39.2 (C-10), 35.1 (q, 4JC-F = 4.1 Hz, C-13), 34.0 (C-18), 32.8 
(C-9), 31.3 (C-21), 30.2 (C-23), 27.7 (C-11’ or 11), 26.0 (C-19), 24.3 (C-11 or 11’), 19.6 (C-24 
or 24’), 19.0 (C-24’ or 24), 14.3 (C-30), 14.0 (C-27) 
19F NMR (376 MHz, CDCl3): δF = −69.5 
IR (ATR): max / cm-1 = 3359 (m, N-H), 2967 (m, C-H), 2925 (m, C-H), 1706 (m, C=O), 1686 (m, 
C=O), 1663 (m, C=O), 1634 (m, C=O) 
HRMS (ESI): m/z [M+Na]+ calcd for C34H49F3N423NaO5: 673.3547; found: 673.3564 (Δ = 2.5 ppm) 
 
113b (R,S,S) 
Rf = 0.18 (EtOAc:40–60 petroleum ether = 1:3) 
mp = 150–153 °C 
[α]D25 = −16.2° (c = 0.222, CHCl3) 
1H NMR (400 MHz, CDCl3): δH = 8.07 (d, J = 7.4 Hz, 1 H, H-4), 7.29 (dd, J = 7.5, 1.3 Hz, 1 H, H-
7), 7.24–7.15 (m, 2 H, H-6 and 5), 6.90 (s, 1 H, H-1), 6.54 (dq, J = 9.0, 1.5 Hz, 1 H, H-25), 5.98 
(s, 1 H, H-12), 5.95 (d, J = 9.5 Hz, 1 H, N-H), 4.91 (dd, J = 10.5, 9.2 Hz, 1 H, H-22), 4.49 (d, J = 
9.6 Hz, 1 H, H-17), 4.17 (q, J = 7.1 Hz, 2 H, H-29), 3.71 (s, 3 H, H-9), 3.39 (q, 5JH-F = 1.9 Hz, 3 H, 
H-13), 2.82 (s, 3 H, H-21), 1.79 (d, J = 1.4 Hz, 3 H, H-27), 1.78–1.70 (m, 4 H, H-23 and H-11 or 
11’), 1.49 (s, 3 H, H-11’ or 11), 1.28 (t, J = 7.1 Hz, 3 H, H-30), 0.81 (d, J = 6.6 Hz, 3 H, H-24 or 
24’), 0.55 (d, J = 6.6 Hz, 3 H, H-24’ or 24), 0.40 (s, 9 H, H-19) 
13C NMR (101 MHz, CDCl3): δC = 170.9 (C-20), 167.8 (C-28), 167.4 (C-16), 159.0 (q, 2JC-F = 35.6 
Hz, C-14), 138.6 (C-25), 138.1 (C-8), 133.0 (C-26), 126.6 (C-1), 125.5 (C-3), 122.1 (C-6), 120.8 
(C-4), 120.0 (C-5), 119.9 (C-2), 116.8 (q, 1JC-F = 288.3 Hz, C-15), 109.9 (C-7), 62.9 (C-12), 60.9 
(C-29), 55.6 (C-22), 54.3 (C-17), 39.8 (C-10), 34.5 (C-18), 33.7 (q, 4JC-F = 4.1 Hz, C-13), 32.8 (C-
9), 30.9 (C-21), 30.3 (C-23), 27.3 (C-11’ or 11), 25.7 (C-19), 24.5 (C-11 or 11’), 19.4 (C-24 or 
24’), 18.0 (C-24’ or 24), 14.3 (C-30), 13.8 (C-27) 
19F NMR (376 MHz, CDCl3): δF = −69.7 
IR (ATR): max / cm-1 = 3316 (m, N-H), 2960 (m, C-H), 1687 (s, C=O), 1672 (s, C=O), 1634 (s, 
C=O) 
HRMS (ESI): m/z [M+Na]+ calcd for C34H49F3N423NaO5: 673.3547; found: 673.3562 (Δ = 2.2 ppm) 
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Hemiasterlin trifluoroacetate salt (56·TFA) 
 
LiOH·H2O (16.0 mg, 0.381 mmol) was added to a solution of N-trifluoroacetyl hemiasterlin 
ethyl ester 113a (15.5 mg, 23.8 µmol) in H2O/MeOH (1:1, 2 mL). The reaction was heated to 
60 °C and stirred for 8 days. The mixture was then purified by reverse-phase semi-preparative 
HPLC (30–46%B over 16 min) to give the trifluoroacetate salt of hemiasterlin 56·TFA as a 
white powder (13.1 mg, 20.4 µmol, 86%). 
tR / min = 10.14 (5–95%B over 15 min) 
[α]D25 = −24.1° (c = 0.108, MeOH, lit.359 −76°, c = 0.7, MeOH) 
1H NMR (700 MHz, DMSO-d6): δH = 12.48 (br s, 1 H, COO-H), 8.96–8.78 (m, 2 H, CON-H, NH2+), 
8.11 (br s, 1 H, H-4), 7.46 (d, J = 8.1 Hz, 1 H, H-7), 7.35 (br s, 1 H, NH2+), 7.21 (t, J = 7.5 Hz, 1 H, 
H-6), 7.17 (s, 1 H, H-1), 7.09 (t, J = 7.3 Hz, 1 H, H-5), 6.68 (d, J = 9.4 Hz, 1 H, H-23), 4.94 (t, J = 
10.0 Hz, 1 H, H-20), 4.86 (d, J = 8.2 Hz, 1 H, H-15), 4.43 (br s, 1 H, H-12), 3.76 (s, 3 H, H-9), 
3.03 (s, 3 H, H-19), 2.23 (br s, 3 H, H-13), 2.07–1.96 (m, 1 H, H-21), 1.80 (s, 3 H, H-25), 1.41 (s, 
3 H, H-11 or 11’), 1.38 (s, 3 H, H-11’ or 11), 1.00 (s, 9 H, H-17), 0.81 (d, J = 6.6 Hz, 3 H, H-22 or 
22’), 0.79 (d, J = 6.2 Hz, 3 H, H-22’ or 22) 
13C NMR (176 MHz, DMSO-d6): δC = 170.1 (C-18), 168.6 (C-26), 165.7 (C-14), 157.7 (q, 2JC-F = 
30.9 Hz, CF3COO-), 138.4 (C-23), 137.8 (C-8), 131.8 (C-24), 128.8 (C-1), 125.0 (C-3), 121.3 (C-
6), 120.4 (C-4), 118.5 (C-5), 117.4 (q, 1JC-F = 300.7 Hz, CF3COO-), 116.3 (C-2), 110.2 (C-7), 67.4 
(C-12), 56.3 (C-20), 55.6 (C-15), 37.6 (C-10), 34.8 (C-16), 33.5 (C-13), 32.5 (C-9), 31.1 (C-19), 
28.8 (C-21), 27.0 (C-11’ or 11), 26.4 (C-17), 22.4 (C-11 or 11’), 19.4 (C-22 or 22’), 18.9 (C-22’ 
or 22), 13.6 (C-25) 
19F NMR (376 MHz, DMSO-d6): δF = −73.4 
IR (ATR): max / cm-1 = 2967 (m, C-H), 1673 (s, C=O) 
UV-Vis: λmax / nm = 229, 287 (1 mM in MeCN/H2O (1:4), lit.359 216, 273 in MeOH)  
HRMS (ESI): m/z [M+H]+ calcd for C30H47N4O2: 527.3592; found: 527.3606 (Δ = 2.7 ppm) 




epi-hemiasterlin trifluoroacetate salt (56b·TFA) 
 
LiOH·H2O (256.2 mg, 0.624 mmol) was added to a solution of N-trifluoroacetyl epi-
hemiasterlin ethyl ester 113b (25.4 mg, 39.0 µmol) in H2O/MeOH (1:1, 3 mL). The reaction 
was heated to 60 °C and stirred for 7 days. The mixture was then purified by reverse-phase 
semi-preparative HPLC (30–46%B over 16 min) to give the trifluoroacetate salt of epi-
hemiasterlin 56b·TFA as a white powder (19.5 mg, 30.9 µmol, 78%). 
tR / min = 10.06 (5–95%B over 15 min) 
[α]D25 = −101.8° (c = 0.108, MeOH) 
1H NMR (700 MHz, DMSO-d6): δH = 12.51 (br s, 1 H, COO-H), 9.00 (br s, 1 H, CON-H or NH2+), 
8.89 (br s, 1 H, CON-H or NH2+), 8.09 (d, J = 7.8 Hz, 1 H, H-4), 7.54 (br s, 1 H, CON-H or NH2+), 
7.44 (d, J = 8.2 Hz, 1 H, H-7), 7.20 (t, J = 7.8 Hz, 1 H, H-6), 7.18 (s, 1 H, H-1), 7.08 (t, J = 7.5 Hz, 
1 H, H-5), 6.66 (d, J = 9.5 Hz, 1 H, H-23), 4.90 (t, J = 10.0 Hz, 1 H, H-20), 4.76 (d, J = 9.0 Hz, 1 
H, H-15), 4.53 (d, J = 9.7 Hz, 1 H, H-12), 3.75 (s, 3 H, H-9), 3.02 (s, 3 H, H-19), 2.17 (s, 3 H, H-
13), 2.05–1.95 (m, 1 H, H-21), 1.78 (s, 3 H, H-25), 1.51 (s, 3 H, H-11 or 11’), 1.47 (s, 3 H, H-11’ 
or 11), 0.89 (s, 9 H, H-17), 0.79 (d, J = 6.6 Hz, 3 H, H-22 or 22’), 0.72 (d, J = 6.5 Hz, 3 H, H-22’ 
or 22) 
13C NMR (176 MHz, DMSO-d6): δC = 170.7 (C-18), 168.6 (C-26), 166.5 (C-14), 157.7 (q, 2JC-F = 
30.4 Hz, CF3COO-), 138.4 (C-23), 137.8 (C-8), 131.9 (C-24), 128.6 (C-1), 125.0 (C-3), 121.3 (C-
6), 120.6 (C-4), 118.5 (C-5), 117.5 (app d, 1JC-F = 303.6 Hz, CF3COO-), 116.3 (C-2), 110.1 (C-7), 
67.6 (C-12), 56.2 (C-20), 55.6 (C-15), 37.1 (C-10), 34.2 (C-16), 33.1 (C-13), 32.5 (C-9), 31.1 (C-
19), 28.8 (C-21), 26.6 (C-11’ or 11), 26.3 (C-17), 23.1 (C-11 or 11’), 19.4 (C-22 or 22’), 18.8 (C-
22’ or 22), 13.6 (C-25) 
19F NMR (376 MHz, DMSO-d6): δF = −73.4 
IR (ATR): max / cm-1 = 2970 (m, C-H), 1671 (s, C=O) 
UV-Vis: λmax / nm = 229, 288 (1 mM in MeCN/H2O (1:4))  






2-Methyl-2-phenylpropanoic acid (657 mg, 4.00 mmol) was dissolved in dry Et2O (80 mL) and 
cooled to 0 °C. LiAlH4 (493 mg, 13.0 mmol) was added to the mixture in 3 portions over 10 
min. The reaction was allowed to warm to rt and stirred for 90 min before being cooled to 0 °C. 
The reaction was quenched by the slow addition of aqueous HCl (1 M, 10 mL) and the phases 
separated. The aqueous phase was extracted with Et2O (3 × 25 mL), and the combined organic 
phases were dried with anhydrous MgSO4. The solvent was removed in vacuo to give the crude 
alcohol which was then re-dissolved in dry CH2Cl2 (29 mL). N-methylmorpholine N-oxide 
(844 mg, 7.20 mmol), 4 Å powdered molecular sieves (870 mg), and tetrapropylammonium 
perruthenate (70.3 mg, 0.200 mmol) were added to the solution. The black reaction mixture 
was stirred at rt for 20 h, filtered through Celite®, and concentrated in vacuo (the bath 
temperature was kept below 20 °C). The crude black oil was purified by flash column 
chromatography (eluting gradient Et2O:30–40 petroleum ether from 0:1 to 1:50) to give 
aldehyde 120 as a colourless liquid (460 mg, 3.11 mmol, 78% over two steps). 
Rf = 0.53 (Et2O:40–60 petroleum ether = 1:5) 
1H NMR (400 MHz, CDCl3): δH = 9.52 (s, 1 H, H-1), 7.40 (t, J = 7.5 Hz, 2 H, H-6 or 7), 7.33-7.27 
(m, 3 H, H-5 and 7 or 6), 1.48 (s, 6 H, H-3) 
13C NMR (101 MHz, CDCl3): δC = 202.4 (C-1), 141.3 (C-4), 129.0 (C-5, 6, or 7), 127.4 (C-5, 6, or 
7), 126.8 (C-5, 6, or 7), 50.6 (C-2), 22.6 (C-3) 





Taltobulin trifluoroacetate salt (57·TFA) 
 
and epi-Taltobulin trifluoroacetate salt (57b·TFA) 
 
Methylamine solution in MeOH (2 M, 110 µL, 0.220 mmol) was added to a mixture of 2-
methyl-2-phenylpropanal 120 (29.6 mg, 0.200 mmol) and 3 Å molecular sieves (200 mg)  in 
dry MeOH (0.4 mL), and the reaction was stirred at rt for 2 h. TFA (18.4 µL, 0.240 mmol) and 
sodium trifluoroacetate (81.6 mg, 0.600 mmol) were added. The reaction mixture was stirred 
for a further 25 min before ethyl (S,E)-4-((S)-2-isocyano-N,3,3-trimethylbutanamido)-2,5-
dimethylhex-2-enoate 117 (65.0 mg, 0.202 mmol) was added. The reaction was stirred at rt 
for a further 19 h, filtered through Celite®, and the solvent removed in vacuo. The crude 
product was purified by flash column chromatography (eluting gradient EtOAc:40–60 
petroleum ether from 0:1 to 1:3) to give a partially separable diastereomeric mixture of 
protected taltobulin 121a (80% purity, 28.1 mg, 47.0 µmol, 24%) and protected epi-taltobulin 
121b (80% purity, 38.5 mg, 64.4 µmol, 32%) which were used in the next step without further 
purification. 
The protected taltobulin 121a and 121b were dissolved separately in H2O/MeOH (1:1, 3 mL). 
LiOH·H2O (16 equiv.) was added to each reaction. The reaction mixtures were heated to 60 °C 
and stirred for 8 days. The mixtures were then purified by reverse-phase semi-preparative 
HPLC (5–38%B over 70 min for 57a, 5–36%B over 76 min for 57b) to give the trifluoroacetate 
salt of taltobulin 57·TFA as a white powder (23.0 mg, 39.1 µmol, 20% over two steps) and the 
trifluoroacetate salt of epi-taltobulin 57b·TFA as a white powder (24.0 mg, 40.8 µmol, 20% 
over two steps). 
 
57·TFA (S,S,S) 
tR / min = 9.19 (5–95%B over 15 min) 
[α]D25 = −26.5° (c = 0.102, MeOH, lit.359 [α]D22 = −21.7°, c = 0.23) 
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1H NMR (700 MHz, CD3OD): δH = 7.54 (d, J = 7.5 Hz, 2 H, H-3), 7.45 (t, J = 7.7 Hz, 2 H, H-2), 
7.35 (t, J = 7.3 Hz, 1 H, H-1), 6.78 (app dd, J = 9.7, 1.4 Hz, 1 H, H-18), 5.05 (t, J = 10.1 Hz, 1 H, 
H-15), 4.92 (s, 1 H, H-10), 4.36 (s, 1 H, H-7), 3.14 (s, 3 H, H-14), 2.50 (s, 3 H, H-8), 2.08–2.01 
(m, 1 H, H-16), 1.91 (d, J = 1.4 Hz, 3 H, H-20), 1.47 (s, 3 H, H-6 or 6’), 1.38 (s, 3 H, H-6’ or 6), 
1.07 (s, 9 H, H-12), 0.92–0.88 (m, 6 H, H-17 and 17’) 
13C NMR (176 MHz, CD3OD): δC = 172.3 (C-13), 170.8 (C-21), 167.1 (C-9), 145.0 (C-4), 139.7 
(C-18), 133.6 (C-19), 130.4 (C-2), 128.9 (C-1), 127.4 (C-3), 71.3 (C-7), 58.5 (C-15), 57.8 (C-10), 
42.1 (C-5), 36.0 (C-11), 34.2 (C-8), 31.9 (C-14), 30.8 (C-16), 29.8 (C-6’ or C-6), 26.9 (C-12), 
21.5 (C-6 or 6’), 19.8* (C-17 or 17’), 19.8* (C-17’ or 17), 14.2 (C-20) 
*Denoted signals with equal chemical shifts to 1 decimal place appear as two distinguishable 
signals. 
19F NMR (376 MHz, DMSO-d6): δF = −76.9 
IR (ATR): max / cm-1 = 2966 (m, C-H), 1669 (s, C=O), 1625 (s, C=O) 
UV-Vis: λmax / nm = 206, 212 (1 mM in MeCN/H2O (1:4)) 
HRMS (ESI): m/z [M+H]+ calcd for C27H44N3O6: 474.3326; found: 474.3344 (Δ = 3.8 ppm) 
Spectroscopic data are in accordance with the literature.359 
 
57b (*R,S,S) 
tR / min = 9.32 (5–95%B over 15 min) 
[α]D25 = −89.7° (c = 0.107, MeOH, lit.359 [α]D22 = −96.7°, c = 2.4) 
1H NMR (700 MHz, CD3OD): δH = 7.51 (d, J = 7.5 Hz, 2 H, H-3), 7.44 (t, J = 7.8 Hz, 2 H, H-2), 
7.32 (t, J = 7.3 Hz, 1 H, H-1), 6.75 (app dd, J = 9.7, 1.3 Hz, 1 H, H-18), 5.03 (t, J = 10.2 Hz, 1 H, 
H-15), 4.55 (s, 1 H, H-10), 4.33 (s, 1 H, H-7), 3.12 (s, 3 H, H-14), 2.47 (s, 3 H, H-8), 2.06–1.98 
(m, 1 H, H-16), 1.88 (d, J = 1.3 Hz, 3 H, H-20), 1.54 (s, 3 H, H-6 or 6’), 1.48 (s, 3 H, H-6’ or 6), 
0.91 (s, 9 H, H-12), 0.90–0.86 (m, 6 H, H-17 and 17’) 
13C NMR (176 MHz, CD3OD): δC = 173.1 (C-13), 170.8 (C-21), 167.7 (C-9), 145.0 (C-4), 139.8 
(C-18), 133.6 (C-19), 130.3 (C-2), 128.8 (C-1), 127.4 (C-3), 71.3 (C-7), 58.7 (C-10), 58.5 (C-15), 
41.5 (C-5), 35.0 (C-11), 34.0 (C-8), 31.8 (C-14), 30.8 (C-16), 27.1 (C-6’ or C-6), 27.0 (C-12), 
24.0 (C-6 or 6’), 19.8 (C-17 or 17’), 19.6 (C-17’ or 17), 14.1 (C-20) 
19F NMR (376 MHz, DMSO-d6): δF = −76.9 
IR (ATR): max / cm-1 = 2975 (m, C-H), 1669 (s, C=O) 
UV-Vis: λmax / nm = 206, 214.5 (1 mM in MeCN/H2O (1:4))  
HRMS (ESI): m/z [M+H]+ calcd for C27H44N3O6: 474.3326; found: 474.3343 (Δ = 3.6 ppm) 
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6.3.2. Linker–drug synthesis 
H-Val-Ala-PABA·TFA (134) 
 
Pyrrolidine (83.5 µL, 1.00 mmol) was added to a solution of Alloc-Val-Ala-PABA 122 (189 mg, 
0.500 mmol) and Pd(PPh3)4 (28.9 mg, 0.0250 mmol) in CH2Cl2/DMF (7:1, 20 mL). The reaction 
mixture was stirred at rt for 20 h and the volatiles were removed in vacuo. The crude mixture 
was then purified with reverse-phase semi-preparative HPLC (5–36%B over 8 min) to give the 
trifluoroacetate salt of amine 134 as a white powder (198 mg, 0.486 mmol, 97%) 
tR / min = 4.79 (5–95%B over 15 min) 
[α]D25 = −31.3° (c = 0.668, MeOH) 
1H NMR (400 MHz, CD3OD): δH = 7.53 (d, J = 8.2 Hz, 2 H, H-9), 7.30 (d, J = 8.2 Hz, 2 H, H-10), 
4.56 (s, 2 H, H-12), 4.57–4.49 (m, 1 H, H-5), 3.71 (d, J = 5.7 Hz, 1 H, H-1), 2.23 (octet, J = 6.7 
Hz, 1 H, H-2), 1.47 (d, J = 7.1 Hz, 3 H, H-6), 1.09 (d, J = 6.9 Hz, 3 H, H-3 or 3’), 1.05 (d, J = 6.9 
Hz, H-3’ or 3) 
13C NMR (101 MHz, CD3OD): δC = 172.6 (C-7), 169.3 (C-4), 138.7* (C-8 or 11), 138.7* (C-11 or 
8), 128.6 (C-10), 121.1 (C-9), 64.8 (C-12), 59.6 (C-1), 51.2 (C-5), 31.6 (C-2), 18.9 (C-3 or 3’), 
18.1 (C-6), 17.8 (C-3’ or 3) 
*Denoted signals with equal chemical shifts to 1 decimal place appear as two distinguishable 
signals. 
19F NMR (376 MHz, CD3OD): δF = −77.0 
IR (ATR): max / cm-1 = 3281 (br m, O-H, N-H), 2971 (m, C-H), 1658 (s, C=O), 1606 (m) 




HATU (47.9 mg, 0.126 mmol) was added to a solution of 14-azido-3,6,9,12-
tetraoxatetradecanoic acid (0.5 M in TBME, 264 µL, 0.132 mmol) and DIPEA (25.1 µL, 0.144 
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mmol) in DMF (1 mL) and the mixture was stirred at rt for 1 min. The activated acid solution 
was then added to the mixture of H-Val-Ala-PABA·TFA 134 (48.9 mg, 0.120 mmol) and DIPEA 
(41.8 µL, 0.240 mmol) in DMF (1 mL). The reaction mixture was stirred for 16 h, and then 
EtOAc (40 mL) was added. The mixture was washed successively with saturated aqueous 
NH4Cl (2 × 10 mL), saturated aqueous NaHCO3 (2 × 10 mL), and brine (10 mL), then dried over 
anhydrous Na2SO4. The solvent was removed in vacuo and the crude product purified using 
reverse-phase semi-preparative HPLC (10–70%B over 20 min) to give N3-PEG4-Val-Ala-PABA 
135 as a white solid (50.1 mg, 90.7 µmol, 76%). 
tR / min = 8.17 (5–95%B over 15 min) 
1H NMR (400 MHz, CD3OD): δH = 7.54 (d, J = 8.6 Hz, 2 H, H-19), 7.30 (d, J = 8.7 Hz, 2 H, H-20), 
4.56 (s, 2 H, H-22), 4.48 (q, J = 7.1 Hz, 1 H, H-15), 4.31 (d, J = 6.9 Hz, 1 H, H-11), 4.06 (s, 2 H, 
H-9), 3.76–3.60 (m, 14 H, H-2 to 8), 3.35 (t, J = 4.9 Hz, 2 H, H-1), 2.14 (octet, J = 6.8 Hz, 1 H, 
H-12), 1.44 (d, J = 7.1 Hz, 3 H, H-16), 1.00 (d, J = 7.1 Hz, 3 H, H-13 or 13’), 0.97 (d, J = 6.8 Hz, 
3 H, H-13’ or 13) 
13C NMR (101 MHz, CD3OD): δC = 173.0 (C-14), 172.9 (C-17), 172.7 (C-10), 138.8 (C-18 or 21), 
138.6 (C-21 or 18), 128.6 (C-20), 121.1 (C-19), 72.2, 71.6, 71.6, 71.5, 71.4, 71.1 (C-2 to C-9)*, 
64.8 (C-22), 59.4 (C-11), 51.8 (C-1), 51.1 (C-15), 32.4 (C-12), 19.8 (C-13 or 13’), 18.7 (C-13’ or 
13), 18.0 (C-16) 
*Signals from 72.2 to 71.1 ppm (inclusive) overlap greatly and only six distinguishable signals 
for C-2 to C-9 were observed. 
IR (ATR): max / cm-1 = 3282 (m, N-H, O-H), 2873 (m, C-H), 2098 (m, N=N=N), 1662 (m, C=O), 
1630 (m, C=O) 




DIPEA (176 µL, 1.01 mmol) was added to a solution of N3-PEG4-Val-Ala-PABA 135 (112 mg, 
0.202 mmol) and bis(4-nitrophenyl)carbonate (92.2 mg, 0.303 mmol) in DMF (1 mL) and the 
reaction mixture was stirred at rt for 16 h before EtOAc (50 mL) was added. The mixture was 
washed with saturated aqueous solution of Na2CO3 (6 × 15 mL), dried over anhydrous MgSO4, 
and the solvent was removed in vacuo. The crude product was purified by flash column 
chromatography (eluting gradient MeOH:CH2Cl2 from 0:1 to 1:20) to give N3-PEG4-Val-Ala-
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PABC-OPNP 136 as a colourless oil which solidified under a stream of N2 over several days 
(110 mg, 0.153 mmol, 76%). 
Rf = 0.19 (MeOH/CH2Cl2 = 1:20) 
1H NMR (400 MHz, CDCl3): δH = 8.90 (s, 1 H, H-Nc), 8.28–8.23 (m, 2 H, H-26), 7.63–7.58 (m, 2 
H, H-19), 7.41–7.34 (m, 5 H, H-20, H-25, H-Na), 7.19 (br d, J = 7.2 Hz, 1 H, H-Nb), 5.23 (s, 2 H, 
H-22), 4.64 (qn, J = 7.1 Hz, 1 H, H-15), 4.33 (dd, J = 7.9, 7.0 Hz, 1 H, H-11), 4.11, 4.04 (ABq, JAB 
= 15.8 Hz, 2 H, H-9), 3.76–3.61 (m, 14 H, H-2 to 8), 3.37 (t, J = 5.0 Hz, 2 H, H-1), 2.21 (octet, J 
= 6.7 Hz, 1 H, H-12), 1.45 (d, J = 7.1 Hz, 3 H, H-16), 0.99 (d, J = 6.8 Hz, 3 H, H-13 or 13’), 0.98 
(d, J = 6.8 Hz, 3 H, H-13’ or 13) 
13C NMR (101 MHz, CDCl3): δC = 171.7 (C-14), 171.1 (C-10), 170.4 (C-17), 155.6 (C-27 or 24), 
152.5 (C-23), 145.5 (C-24 or C-27), 138.9 (C-18), 129.9 (C-21), 129.8 (C-20), 125.4 (C-26), 
121.9 (C-25), 120.0 (C-19), 71.3, 70.8, 70.8, 70.7, 70.7, 70.7, 70.4, 70.4, 70.1 (C-2 to C-9, and 
C-22)*, 58.8 (C-11), 50.8 (C-1), 49.9 (C-15), 30.6 (C-12), 19.4 (C-13 or 13’), 18.4 (C-13’ or 13), 
17.2 (C-16) 
*Signals from 71.3 to 70.1 ppm (inclusive) which have the same chemical shifts to 1 decimal 
place are distinguishable. 
IR (ATR): max / cm-1 = 3273 (m, N-H), 2871 (m, C-H), 2097 (m, N=N=N), 1759 (m, C=O), 1665 
(m, C=O), 1633 (s, C=O) 
HRMS (ESI): m/z [M+Na]+ calcd for C32H43N723NaO12: 740.2862; found: 740.2871 (Δ = 1.2 ppm) 
 
Hemiasterlin ethyl ester trifluoroacetate salt (137) 
 
NaBH4 (11.8 mg, 0.310 mmol) was added to a solution of N-trifluoroacetyl hemiasterlin ethyl 
ester 113a (37.0 mg, 56.9 µmol) in EtOH (5 mL) and the reaction mixture was stirred at rt for 
24 h. The reaction was quenched by an addition of H2O (10 mL) and then extracted with CH2Cl2 
(4 × 10 mL). The combined organic phases were dried over anhydrous MgSO4, and the solvent 
was removed in vacuo. The crude product was purified by reverse-phase semi-preparative 
HPLC (5–45%B over 20 min) to give the trifluoroacetate salt of amine 137 as a white powder 
(22.6 mg, 33.8 µmol, 59%). 
tR / min = 11.51 (5–95%B over 15 min) 
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[α]D25 = −33.8° (c = 0.346, MeOH) 
1H NMR (400 MHz, CD3OD): δH = 8.09 (d, J = 8.1 Hz, 1 H, H-4), 7.44 (d, J = 8.2 Hz, 1 H, H-7), 
7.26 (ddd, J = 8.1, 7.1, 0.9 Hz, 1 H, H-6), 7.15 (ddd, J = 8.0, 7.0, 0.9 Hz, 1 H, H-5), 7.14 (s, 1 H, 
H-1), 6.77 (app dd, J = 9.7, 1.5 Hz, 1 H, H-23), 5.07 (t, J = 10.6 Hz, 1 H, H-20), 4.95 (s, 1 H, H-
15), 4.54 (s, 1 H, H-12), 4.21 (q, J = 7.1 Hz, 2 H, H-27), 3.81 (s, 3 H, H-9), 3.15 (s, 3 H, H-19), 
2.45 (s, 3 H, H-13), 2.12–2.00 (m, 1 H, H-21), 1.93 (d, J = 1.4 Hz, 3 H, H-25), 1.58 (s, 3 H, H-11 
or 11’), 1.47 (s, 3 H, H-11’ or 11), 1.30 (t, J = 7.1 Hz, 3 H, H-28), 1.05 (s, 9 H, H-17), 0.91 (d, J = 
6.7 Hz, 3 H, H-22 or 22’), 0.90 (d, J = 6.7 Hz, 3 H, H-22’ or 22) 
13C NMR (101 MHz, CD3OD): δC = 172.4 (C-18), 169.1 (C-26), 167.1 (C-14), 140.0 (C-8), 139.7 
(C-23), 133.5 (C-24), 129.5 (C-1), 126.2 (C-3), 123.1 (C-6), 121.0 (C-4), 120.4 (C-5), 117.5 (C-
2), 111.2 (C-7), 69.8 (C-12), 62.1 (C-27), 58.3 (C-20), 57.9 (C-15), 39.4 (C-10), 35.9 (C-16), 34.3 
(C-13), 33.0 (C-9), 32.0 (C-19), 30.8 (C-21), 27.4 (C-11’ or 11), 26.9 (C-17), 23.2 (C-11 or 11’), 
19.8* (C-22 or 22’), 19.8* (C-22’ or 22), 14.5 (C-28), 14.2 (C-25) 
*Denoted signals with equal chemical shifts to 1 decimal place appear as two distinguishable 
signals. 
19F NMR (376 MHz, CD3OD): δF = −77.1 
IR (ATR): max / cm-1 = 2966 (m, C-H), 1670 (s, C=O) 




To a solution of hemiasterlin ethyl ester trifluoroacetate salt 137 (18.9 mg, 28.3 µmol), N3-
PEG4-Val-Ala-PABC-OPNP 136 (43.1 mg, 60.0 µmol), and HOAt (4.08 mg, 30.0 µmol) in DMF 
(540 µL) was added pyridine (90 µL, 1.1 mmol) and DIPEA (20.9 µL, 120 µmol). The reaction 
was stirred at rt for 7 days before the volatiles were removed under a stream of N2. The crude 
mixture was purified by reverse-phase semi-preparative HPLC (20–95%B over 20 min) to give 
carbamate 139 as a white solid (6.1 mg, 5.4 µmol, 19%, 46%brsm) and the starting material 
hemiasterlin ethyl ester trifluoroacetate salt was recovered (11.1 mg, 16.6 µmol, 59%). 
tR / min = 14.68 (5–95%B over 15 min) 
1H NMR (400 MHz, CDCl3): Unassigned due to complex rotameric mixture. 
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HRMS (ESI): m/z [M+H]+ calcd for C58H89N10O13: 1133.6611; found: 1133.6606 (Δ = −0.4 ppm) 
 
Taltobulin ethyl ester trifluoroacetate salt (138) 
 
NaBH4 (25.5 mg, 0.670 mmol) was added to a solution of N-trifluoroacetyl taltobulin ethyl 
ester 121a (3.35:1 dr, 80.3 mg, 0.134 mmol) in EtOH (10 mL) and the reaction mixture was 
stirred at rt for 24 h. The reaction was quenched by an addition of H2O (15 mL) and then 
extracted with CH2Cl2 (4 × 15 mL). The combined organic phases were dried over anhydrous 
MgSO4, and the solvent was removed in vacuo. The crude product was purified by reverse-
phase semi-preparative HPLC (5–45%B over 75 min) to give amine 138 as a white powder 
(62.8 mg, 0.102 mmol, 99% w.r.t. the desired isomer). 
tR / min = 10.87 (5–95%B over 15 min) 
[α]D25 = −43.5° (c = 0.524, MeOH) 
1H NMR (400 MHz, CD3OD): δH = 7.54 (d, J = 8.0 Hz, 2 H, H-3), 7.45 (t, J = 7.6 Hz, 2 H, H-2), 
7.35 (t, J = 7.2 Hz, 1 H, H-1), 6.76 (d, J = 9.7 Hz, 1 H, H-18), 5.05 (t, J = 10.1 Hz, 1 H, H-15), 4.91 
(s, 1 H, H-10), 4.36 (s, 1 H, H-7), 4.21 (q, J = 7.2 Hz, 2 H, H-22), 3.14 (s, 3 H, H-14), 2.50 (s, 3 
H, H-8), 2.11–1.99 (m, 1 H, H-16), 1.93 (s, 3 H, H-20), 1.47 (s, 3 H, H-6 or 6’), 1.38 (s, 3 H, H-
6’ or 6), 1.30 (t, J = 7.1 Hz, 3 H, H-23), 1.06 (s, 9 H, H-12), 0.90 (d, J = 6.5 Hz, 6 H, H-17 and 17’) 
13C NMR (101 MHz, CD3OD): δC = 172.3 (C-13), 169.1 (C-21), 167.0 (C-9), 145.0 (C-4), 139.7 
(C-18), 133.5 (C-19), 130.4 (C-2), 128.9 (C-1), 127.4 (C-3), 71.2 (C-7), 62.1 (C-22), 58.3 (C-15), 
57.8 (C-10), 42.1 (C-5), 35.9 (C-11), 34.2 (C-8), 31.9 (C-14), 30.8 (C-16), 29.8 (C-6’ or C-6), 
26.9 (C-12), 21.5 (C-6 or 6’), 19.8* (C-17 or 17’), 19.8* (C-17’ or 17), 14.5 (C-23), 14.2 (C-20) 
*Denoted signals with equal chemical shifts to 1 decimal place appear as two distinguishable 
signals. 
19F NMR (376 MHz, CD3OD): δF = −77.2 
IR (ATR): max / cm-1 = 2970 (m, C-H), 1713 (m, C=O), 1669 (s, C=O), 1627 (s, C=O) 
HRMS (ESI): m/z [M+H]+ calcd for C29H48N3O4: 502.3639; found: 502.3648 (Δ = 1.8 ppm) 






To a solution of taltobulin ethyl ester trifluoroacetate salt 138 (24.6 mg, 40.0 µmol), N3-PEG4-
Val-Ala-PABC-OPNP 136 (57.4 mg, 60.0 µmol), and HOAt (5.44 mg, 40.0 µmol) in DMF (720 
µL) was added pyridine (120 µL, 1.48 mmol) and DIPEA (27.9 µL, 160 µmol). The reaction was 
stirred at rt for 7 days before the volatiles were removed under a stream of N2. The crude 
mixture was purified by reverse-phase semi-preparative HPLC (20–95%B over 20 min) to give 
carbamate 140 as a yellow solid (10.1 mg, 9.35 µmol, 23%, 54%brsm) and the starting material 
taltobulin ethyl ester trifluoroacetate salt 138 was recovered (14.0 mg, 22.7 µmol, 57%). 
tR / min = 14.70 (5–95%B over 15 min) 
1H NMR (600 MHz, CDCl3): Unassigned due to complex rotameric mixture. 





The peptide was synthesised by standard manual Fmoc solid-phase peptide synthesis (Fmoc-
SPPS) on LL Rink Amide resin (0.51 mmol/g, 1.00 g). Fmoc-deprotection was performed using 
20% piperidine solution in DMF (1 × 1 min, 2 × 5 min). 
The coupling was performed by the following: Fmoc-protected amino acids (4 equiv.) were 
activated with HATU (4 equiv.) and DIPEA (8 equiv.) in DMF (0.4 M of amino acid) for 10 s. 
The mixture was then added to the resin and agitated by a stream of N2 for 5 min. The tBu 
protecting group was used for the side chain of Glu. 
Completion of peptide couplings was monitored using chloranil test. To a small amount of 
resin swelled in CH2Cl2 was added acetaldehyde (200 µL) then followed by saturated chloranil 
solution in toluene (50 µL). The mixture was shaken for 5 min at rt. Resin beads remaining 
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colourless indicated a complete coupling whereas green colouration indicated an incomplete 
coupling. Any incomplete couplings were subjected to a second round of coupling. 
Peptide cleavage and global deprotection of all amino acid side chains were achieved by the 
treatment of the dried resin with TFA/CH2Cl2/H2O/TIPS (92.5:2.5:2.5:2.5, 20 mL) at 42 °C for 
40 min. The mixture was then filtered through cotton wool, and volatiles were removed under 
a stream of nitrogen. The crude peptides were triturated with Et2O and then washed with Et2O 
(3 × 15 mL) before purification by reverse-phase semi-preparative HPLC (5–25%B over 9 min) 
to give the peptide 141 as a hygroscopic white powder (285 mg, 0.315 mmol, 62% yield). 
tR / min = 5.06 (5–95%B over 15 min) 




4-((4,6-divinylpyrimidin-2-yl)amino)butanoic acid285 142 was synthesised by Hikaru Seki 
from the Spring Group, Department of Chemistry, University of Cambridge. 
DIPEA (11.0 µL, 63.0 µmol) was added to a solution of 4-((4,6-divinylpyrimidin-2-
yl)amino)butanoic acid 142 (12.3 mg, 52.5 µmol) and HATU (19.0 mg, 50.0 µmol) in DMF (0.5 
mL) and the solution was stirred at rt for 5 min. The activated acid solution was then added 
to a solution of peptide 141 (43.2 mg, 47.8 µmol) and DIPEA (69.7 µL, 400 µmol) in DMF (0.5 
mL) and the reaction mixture was stirred at rt for 1 h before purification by automatic reverse-
phase flash column chromatography to give alkynyl DVP 143 as a hygroscopic white powder 
(13.4 mg, 13.3 µmol, 28%). 
tR / min = 6.68 (5–95%B over 15 min) 




DVP-PEG2-Glu3-PEG2-triazole-PEG4-Val-Ala-PABC-hemiasterlin ammonium salt (144) 
 
CuSO4·5H2O (0.29 mg, 1.2 µmol) and THPTA (0.84 mg, 1.9 µmol) were dissolved in a degassed 
mixture of H2O/tBuOH (1:1, 0.5 mL) and stirred at rt for 1 min before Na-L-ascorbate (0.96 
mg, 4.9 µmol) was added. The colourless copper solution was then added to a degassed 
solution of azide 139 (1.10 mg, 0.971 µmol) and alkyne 143 (1.95 mg, 1.94 µmol) in 
H2O/tBuOH (0.5 mL). The reaction mixture was stirred at rt for 3 h before the solvent was 
removed by lyophilisation. The resulting crude triazole ester was re-dissolved in H2O/MeOH 
(1:1, 1 mL). Aqueous LiOH·H2O solution (0.357 M, 13.6 µL, 4.86 µmol) was added to the 
solution, and the reaction was stirred at rt for 6 days, during which extra LiOH·H2O was added 
until the reaction went to completion. The volatiles were then removed in vacuo, and the 
resulting crude product was purified by automatic reverse-phase flash column 
chromatography to give linker–drug 144 as a white powder (0.49 mg, 0.22 µmol, 23% over 
two steps). 
tR / min = 10.66 (5–95%B over 15 min) 
HRMS (ESI): m/z [M+2H]2+ calcd for C100H150N20O30: 1055.5408; found: 1055.5422 (Δ = 1.3 ppm) 
 
DVP-PEG2-Glu3-PEG2-triazole-PEG4-Val-Ala-PABC-taltobulin ammonium salt (145) 
 
CuSO4·5H2O (0.53 mg, 2.1 µmol) and THPTA (1.53 mg, 3.52 µmol) were dissolved in a degassed 
mixture of H2O/tBuOH (1:1, 0.9 mL) and stirred at rt for 1 min before Na-L-ascorbate (1.74 
mg, 8.78 µmol) was added. The colourless copper solution was then added to a degassed 
solution of azide 140 (1.90 mg, 1.76 µmol) and alkyne 143 (3.54 mg, 3.52 µmol) in H2O/tBuOH 
(0.9 mL). The reaction mixture was stirred at rt for 3 h before the solvent was removed by 
lyophilisation. The resulting crude triazole ester was re-dissolved in H2O/MeOH (1:1, 2 mL). 
Aqueous LiOH·H2O solution (0.357 M, 24.6 µL, 8.78 µmol) was added to the solution, and the 
reaction was stirred at rt for 5 days, during which extra LiOH·H2O was added until the reaction 
went to completion. The volatiles were then removed in vacuo, and the resulting crude 
product was purified by automatic reverse-phase flash column chromatography to give 
linker–drug 145 as a white powder (1.70 mg, 0.800 µmol, 45% over two steps). 
tR / min = 10.63 (5–95%B over 15 min) 
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HRMS (ESI): m/z [M+2H]2+ calcd for C97H147N19O30: 1029.0275; found: 1029.0275 (Δ = 0.0 ppm) 
 
6.3.3. Reaction condition screening 
6.3.3.1. Fragment amide coupling 
(S)-3,3-Dimethyl-2-((S)-3-methyl-3-(1-methyl-1H-indol-3-yl)-2-(2,2,2-trifluoro-N-
methylacetamido)butanamido)butanoic acid (109a) 
 
To a solution of ester 99a (96.7 mg, 0.200 mmol) in MeOH/THF (1:1, 8 mL) was added an 
aqueous solution of LiOH (0.25 M, 4.00 mL, 1.00 mmol) which resulted in a cloudy reaction 
mixture. The reaction mixture was stirred at rt for 4 days before H2O (12 mL) was added and 
then washed with Et2O (2 × 10 mL). The aqueous phase was then acidified with 5% aqueous 
H3PO4 to pH 2-3 and was then extracted with EtOAc (3 × 10 mL). The combined organic phases 
were dried over anhydrous Na2SO4, and the solvent was removed in vacuo to give the crude 
acid 109a as a white solid (84.4 mg, 0.180 mmol, 90%), which was used in the next step 
without further purification. 
mp = 200 °C (dec) 
[α]D25 = −15.6° (c = 0.343, CHCl3) 
1H NMR (400 MHz, CDCl3): δH = 8.26 (d, J = 8.0 Hz, 1 H, H-4), 7.35–7.20 (m, 3 H, H-5 to H-7), 
7.03 (s, 1 H, H-1), 6.35 (s, 1 H, H-12), 5.89 (d, J = 8.1 Hz, 1 H, N-H), 4.02 (d, J = 8.6 Hz, 1 H, H-
17), 3.74 (s, 3 H, H-9), 3.49 (s, 3 H, H-13), 1.71 (s, 3 H, H-11 or 11’), 1.51 (s, 3 H, H-11’ or 11), 
0.50 (s, 9 H, H-19) 
13C NMR (101 MHz, CDCl3): δC = 175.5 (C-20), 168.9 (C-16), 159.5 (app d, 2JC-F = 35.5 Hz, C-
14), 138.2 (C-8), 127.0 (C-1), 124.7 (C-3), 122.7 (C-6), 121.0 (C-4), 120.6 (C-2), 120.3 (C-5), 
117.0 (app d, 1JC-F = 287.5 Hz, C-15), 109.9 (C-7), 63.0 (C-12), 60.6 (C-17), 39.5 (C-10), 35.0 (q, 
4JC-F = 3.8 Hz, C-13), 33.3 (C-18), 32.8 (C-9), 27.5 (C-11’ or 11), 26.0 (C-19), 24.5 (C-11 or 11’) 
19F NMR (376 MHz, CDCl3): δF = −69.5 
IR (ATR): max / cm-1 = 2965 (m, C-H), 1663 (s, C=O) 





methylacetamido)butanamido)butanoic acid (109b) 
 
To a solution of ester 99b (96.7 mg, 0.200 mmol) in MeOH/THF (1:1, 8 mL) was added an 
aqueous solution of LiOH (0.25 M, 4.00 mL, 1.00 mmol) which resulted in a cloudy reaction 
mixture. The reaction mixture was stirred at rt for 4 days before H2O (12 mL) was added and 
then washed with Et2O (2 × 10 mL). The aqueous phase was then acidified with 5% aqueous 
H3PO4 to pH 2-3 and was then extracted with EtOAc (3 × 10 mL). The combined organic phases 
were dried over anhydrous Na2SO4 and the solvent was removed in vacuo to give the crude 
acid 109b as a white solid (78.4 mg, 0.167 mmol, 83%), which was used in the next step 
without further purification. 
mp = 104–108 °C 
[α]D25 = +55.0° (c = 0.420, CHCl3) 
1H NMR (400 MHz, CDCl3): δH = 8.13 (d, J = 7.5 Hz, 1 H, H-4), 7.29–7.12 (m, 3 H, H-5 to H-7), 
6.92 (s, 1 H, H-1), 6.15 (s, 1 H, H-12), 5.94 (d, J = 8.7 Hz, 1 H, N-H), 4.06 (d, J = 8.7 Hz, 1 H, H-
17), 3.71 (s, 3 H, H-9), 3.45 (s, 3 H, H-13), 1.74 (s, 3 H, H-11 or 11’), 1.50 (s, 3 H, H-11’ or 11), 
0.50 (s, 9 H, H-19) 
13C NMR (101 MHz, CDCl3): δC = 174.8 (C-20), 167.8 (C-16), 159.4 (app d, 2JC-F = 35.8 Hz, C-
14), 138.2 (C-8), 126.5 (C-1), 125.2 (C-3), 122.3 (C-6), 120.7 (C-4), 120.2 (C-2), 120.0 (C-5), 
116.9 (app d, 1JC-F = 288.2 Hz, C-15), 110.0 (C-7), 63.1 (C-12), 60.1 (C-17), 39.8 (C-10), 34.2 (q, 
4JC-F = 4.3 Hz, C-13), 34.1 (C-18), 32.8 (C-9), 27.4 (C-11’ or 11), 26.0 (C-19), 24.6 (C-11 or 11’) 
19F NMR (376 MHz, CDCl3): δF = −69.6 
IR (ATR): max / cm-1 = 2968 (m, C-H), 1738 (m, C=O), 1665 (s, C=O) 





indol-3-yl)propyl)-2,2,2-trifluoro-1N-methylacetamide (114, as an inseparable 
diastereomeric mixture of 1.7:1 dr) 
 
A white solid. 
Rf = 0.28 (EtOAc:40–60 petroleum ether = 1:5) 
1H NMR (400 MHz, CDCl3): Major diastereomer δH = 7.97 (d, J = 8.0 Hz, 1 H, H-4), 6.29 (d, J = 
1.1 Hz, 1 H, H-12), 3.80 (d, J = 1.4 Hz, 1 H, H-17), 1.83 (s, 3 H, H-11 or 11’), 1.60 (s, 3 H, H-11’ 
or 11), 0.78 (s, 9 H, H-19); Minor diastereomer δH = 7.93 (d, J = 8.1 Hz, 1 H, H-4), 6.22 (d, J = 
1.4 Hz, 1 H, H-12), 1.80 (s, 3 H, H-11 or 11’), 1.62 (s, 3 H, H-11’ or 11), 0.87 (s, 9 H, H-19); 
Overlapping / indistinguishable signals* δH = 7.30–7.26 (m, 1 H, H-7), 7.25–7.18 (m, 1 H, H-
6), 7.17–7.11 (m, 1 H, H-5), 6.93–6.90 (m, 1 H, H-1), 3.75–3.72 (m, 3.4 H, H-9 and H-17 of 
minor diastereomer), 3.21–3.17 (m, 3 H, H-13) 
*The numbers of proton nuclei quoted are with respect to the sum of both diastereomers. 
13C NMR (101 MHz, CDCl3): Major diastereomer δC = 175.9 (C-20), 160.6 (C-16), 158.7 (app d, 
2JC-F = 36.1 Hz, C-14), 137.6 (C-8), 127.1 (C-1), 125.6 (C-3), 121.7‡ (C-6), 120.9 (C-4), 119.5 (C-
5), 119.4‡ (C-2), 116.6† (app d, 1JC-F = 287.6 Hz, C-15), 109.6‡ (C-7), 73.4 (C-17), 59.6 (C-17), 
39.7 (C-10), 35.5 (C-18), 33.8 (q, 4JC-F = 4.4 Hz, C-13), 32.8 (C-9), 27.4 (C-11’ or 11), 25.8 (C-
19), 25.4 (C-11 or 11’); Minor diastereomer δC = 176.1 (C-20), 161.2 (C-16), 158.5 (app d, 2JC-F 
= 36.1 Hz, C-14), 137.7 (C-8), 127.0 (C-1), 125.9 (C-3), 121.7‡ (C-6), 121.0 (C-4), 119.4‡ (C-5), 
119.0‡ (C-2), 116.6† (app d, 1JC-F = 287.6 Hz, C-15), 109.6‡ (C-7), 73.1 (C-17), 60.4 (C-17), 39.8 
(C-10), 35.4 (C-18), 33.9 (q, 4JC-F = 3.9 Hz, C-13), 32.7 (C-9), 27.4‡ (C-11’ or 11), 26.2 (C-11 or 
11’), 26.1 (C-19) 
‡Denoted signals with equal chemical shifts to 1 decimal place appear as two distinguishable 
signals. 
†Appear as a single signal. 
19F NMR (376 MHz, CDCl3): Major diastereomer δF = −70.8; Minor diastereomer δF = −70.7 
IR (ATR): max / cm-1 = 2977 (m, C-H), 1822 (s, C=O), 1676 (s, C=N) 




6.3.3.2. Attempts at improving diastereoselectivity of the Ugi reaction 
Methylamine solution in MeOH or THF (2 M, 27.5 µL, 0.0550 mmol) was added to a mixture 
of 2-methyl-2-(1-methyl-1H-indol-3-yl)propanal 69 (10.1 mg, 0.0500 mmol) and 3 Å 
molecular sieves (200 mg) in dry solvent (1 mL). The reaction was stirred at rt for 2 h before 
TFA (4.59 µL, 0.0600 mmol), additives, and a chiral phosphoric acid (2.5 µmol) were added. 
The reaction mixture was stirred for a further 30 min before isocyanide 17 (17.7 mg, 0.0550 
mmol) was added. The reaction was stirred at rt for a further 19 h, filtered through Celite®, 
eluted with a copious amount of MeOH, and the solvent removed in vacuo. The crude product 
was analysed by 19F-NMR using 4,4’-difluorobenzophenone as an internal standard. 
 
 
6.3.3.3. Carbamate formation screening 
(S)-3,3-Dimethyl-2-((S)-3-methyl-3-(1-methyl-1H-indol-3-yl)-2-
(methylamino)butanamido)butanoic acid trifluoroacetate salt (127a) 
 
To a solution of trifluoroacetamide 109a (70.4 mg, 0.150 mmol) in H2O/MeOH (1:1, 10 mL) 
was LiOH·H2O (101 mg, 2.40 mmol). The reaction mixture was stirred at 60 °C for 10 days 
before MeOH was removed in vacuo. The remaining aqueous solution was acidified to pH 3 
with TFA and then extracted with EtOAc (4 × 5 mL). The combined organic phases were dried 
over anhydrous Na2SO4 and the solvent was removed in vacuo to give the crude product which 
was purified by reverse-phase semi-preparative HPLC (10–50%B over 16 min) to give amine 
127a as a white powder (60.3 mg, 0.124 mmol, 82%). 
tR / min = 8.45 (5–95%B over 15 min) 
[α]D25 = 38.6° (c = 0.220, MeOH) 
1H NMR (400 MHz, CD3OD): δH = 8.06 (d, J = 8.1 Hz, 1 H, H-4), 7.43 (d, J = 8.2 Hz, 1 H, H-7), 
7.25 (t, J = 7.6 Hz, 1 H, H-6), 7.18–7.11 (m, 2 H, H-1 and H-5), 4.50 (s, 1 H, H-12), 4.41 (s, 1 H, 
H-15), 3.81 (s, 3 H, H-9), 2.46 (s, 3 H, H-13), 1.65 (s, 3 H, H-11 or 11’), 1.52 (s, 3 H, H-11’ or 
11), 1.08 (s, 9 H, H-17) 
13C NMR (101 MHz, CD3OD): δC = 173.2 (C-18), 167.2 (C-14), 139.9 (C-8), 129.4 (C-1), 126.3 
(C-3), 123.1 (C-6), 121.0 (C-4), 120.4 (C-5), 117.6 (C-2), 111.2 (C-7), 70.2 (C-12), 62.8 (C-15), 




19F NMR (376 MHz, CD3OD): δF = −77.0 
IR (ATR): max / cm-1 = 2965 (m, C-H), 1663 (s, C=O) 
HRMS (ESI): m/z [M+H]+ calcd for C21H32N3O3: 374.2438; found: 374.2439 (Δ = 0.3 ppm) 
 
Methyl (S)-3,3-dimethyl-2-((S)-3-methyl-3-(1-methyl-1H-indol-3-yl)-2-
(methylamino)butanamido)butanoate trifluoroacetate salt (129a) 
 
To a solution of acid 127a (37.0 mg, 0.0759 mmol) in dry MeOH (1 mL) was added thionyl 
chloride (16.5 µL, 0.228 mmol) at 0 °C. The reaction mixture was then allowed to warm to rt 
and stirred for 19 h before extra thionyl chloride (16.5 µL, 0.228 mmol) was added. The 
reaction mixture was stirred for a further 5 days before the volatiles were removed in vacuo. 
The crude product was purified by reverse-phase semi-preparative HPLC (5–95%B over 20 
min) to give amine 129a as a white powder (21.0 mg, 0.0418 mmol, 55%, 64% brsm) and the 
starting material (5.20 mg, 0.0107 mmol, 14%) was recovered. 
tR / min = 9.52 (5–95%B over 15 min) 
[α]D25 = +28.0° (c = 0.236, MeOH) 
1H NMR (400 MHz, CD3OD): δH = 8.04 (d, J = 8.1 Hz, 1 H, H-4), 7.43 (d, J = 8.3 Hz, 1 H, H-7), 
7.25 (ddd, J = 8.2, 7.2, 1.0 Hz, 1 H, H-6), 7.15 (s, 1 H, H-1), 7.14 (ddd, J = 8.1, 7.1, 1.0 Hz, 1 H, 
H-5), 4.49 (s, 1 H, H-12), 4.41 (s, 1 H, H-15), 3.81 (s, 3 H, H-9), 3.73 (s, 3 H, H-19), 2.47 (s, 3 H, 
H-13), 1.65 (s, 3 H, H-11 or 11’), 1.52 (s, 3 H, H-11’ or 11), 1.04 (s, 9 H, H-17) 
13C NMR (101 MHz, CD3OD): δC = 172.2 (C-18), 167.4 (C-14), 139.9 (C-8), 129.5 (C-1), 126.3 
(C-3), 123.1 (C-6), 121.0 (C-4), 120.4 (C-5), 117.6 (C-2), 111.2 (C-7), 70.2 (C-12), 63.0 (C-15), 
52.3 (C-19), 39.4 (C-10), 35.0 (C-16), 34.3 (C-13), 33.0 (C-9), 27.1 (C-17), 26.8 (C-11’ or 11), 
23.7 (C-11 or 11’) 





(methylamino)butanamido)butanoate trifluoroacetate salt (129b) 
 
NaBH4 (47.5 mg, 1.25 mmol) was added to a solution of trifluoroacetamide 99b (121 mg, 0.250 
mmol) in MeOH (20 mL) at 0 °C. The reaction mixture was allowed to warm to rt and stirred 
for 18 h. The reaction was quenched by an addition of H2O (20 mL) and then extracted with 
CH2Cl2 (3 × 30 mL). The combined organic phases were dried over anhydrous MgSO4, and the 
solvent was removed in vacuo. The crude product was re-dissolved in MeCN/H2O and acidified 
by TFA and then lyophilised to give amine 129b as a white powder (125 mg, 0.250 mmol, 
quant.). 
tR / min = 9.91 (5–95%B over 15 min) 
[α]D25 = −50.8° (c = 0.500, MeOH) 
1H NMR (400 MHz, CD3OD): δH = 7.99 (d, J = 8.1 Hz, 1 H, H-4), 7.42 (d, J = 8.2 Hz, 1 H, H-7), 
7.25 (ddd, J = 8.2, 7.1, 1.0 Hz, 1 H, H-6), 7.16 (ddd, J = 8.1, 7.0, 1.1 Hz, 1 H, H-5), 7.15 (s, 1 H, 
H-1), 4.52 (s, 1 H, H-12), 4.16 (s, 1 H, H-15), 3.79 (s, 3 H, H-9), 3.71 (s, 3 H, H-19), 2.49 (s, 3 H, 
H-13), 1.64 (s, 3 H, H-11 or 11’), 1.57 (s, 3 H, H-11’ or 11), 0.91 (s, 9 H, H-17) 
13C NMR (101 MHz, CD3OD): δC = 172.8 (C-18), 168.2 (C-14), 139.9 (C-8), 129.2 (C-1), 126.4 
(C-3), 123.1 (C-6), 121.1 (C-4), 120.5 (C-5), 117.7 (C-2), 111.2 (C-7), 70.2 (C-12), 63.7 (C-15), 
52.3 (C-19), 39.0 (C-10), 34.14 (C-13), 34.06 (C-16), 32.9 (C-9), 27.1 (C-17), 26.5 (C-11’ or 11), 
24.3 (C-11 or 11’) 
19F NMR (376 MHz, CD3OD): δF = −77.0 
IR (ATR): max / cm-1 = 2968 (m, C-H), 1738 (m, C=O), 1665 (s, C=O) 






DIPEA (122 µL, 0.700 mmol) was added to the solution of Alloc-Val-Ala-PABA 122 (52.8 mg, 
0.140 mmol) and bis(4-nitrophenyl)carbonate (63.9 mg, 0.210 mmol) in DMF (0.5 mL) and the 
reaction mixture was stirred at rt for 18 h. The volatiles were then removed under a stream of 
N2, and the residue was re-partitioned in CH2Cl2 (10 mL) and saturated aqueous NaHCO3 (10 
mL). The phases were separated, and the aqueous layer was extracted with CH2Cl2 (3 × 15 mL). 
The combined organic phases were washed with saturated aqueous NaHCO3 (3 × 15 mL) and 
saturated aqueous K2CO3 (3 × 15 mL), dried over anhydrous MgSO4, and the solvent was 
removed in vacuo to give Alloc-Val-Ala-PABC-OPNP 123 as a pale yellow solid (75.5 mg, 0.139 
mmol, 99%), which was used in the next step without further purification. 
Rf = 0.08 (MeOH:CH2Cl2 = 1:20) 
1H NMR (600 MHz, CDCl3): δH = 8.68 (br s, 1 H, H-Nc), 8.29-8.25 (m, 2 H, H-13), 7.61 (br d, J = 
8.3 Hz , 2 H, H-9, H-10, or H-12), 7.41–7.35 (m, 4 H, H-9, H-10, or H-12), 6.71 (br d, J = 8.3 Hz, 
1 H, H-Na or H-Nb), 5.96–5.87 (m, 1 H, H-1t, 1c or 2), 5.35–5.29 (m, 2 H), 5.27–5.21 (m, 3 H), 
4.67 (qn, J = 7.2 Hz, 1 H, H-7), 4.64–4.56 (m, 2 H, H-3), 4.05 (t, J = 6.5 Hz, 1 H, H-4), 2.19 (octet, 
J = 6.8 Hz, 1 H, H-5), 1.48 (d, J = 7.0 Hz, 3 H, H-8), 0.99 (d, J = 6.8 Hz, 3 H, H-6 or 6’), 0.95 (d, J 
= 6.8 Hz, 3 H, H-6’ or 6) 
LCMS (ESI): m/z [M+H]+ calcd for C26H31N4O9: 543.2; found: 543.4 






To a solution of methyl (S)-3,3-dimethyl-2-((R)-3-methyl-3-(1-methyl-1H-indol-3-yl)-2-
(methylamino)butanamido)butanoate trifluoroacetate salt 129b (25.1 mg, 50.0 µmol), Alloc-
Val-Ala-PABC-OPNP 123 (54.3 mg, 0.100 mmol), and HOAt (6.80 mg, 50.0 µmol) in DMF (900 
µL) was added pyridine (150 µL) and DIPEA (34.8 µL, 0.200 mmol). The reaction was stirred 
at rt for 4 days before the volatiles were removed under a stream of N2. The residue was re-
partitioned in EtOAc (5 mL) and H2O (5 mL), and the phases were separated. The aqueous 
phase was extracted with EtOAc (3 × 5 mL). The combined organic phases were dried over 
anhydrous MgSO4, and the solvent was removed in vacuo. The crude product was purified by 
reverse-phase semi-preparative HPLC (5–95%B over 20 min) to give carbamate 128b as a 
white solid (10.0 mg, 12.6 µmol, 25%, 47%brsm) and the starting material 129b was recovered 
(11.6 mg, 23.1 µmol, 46%). 
tR / min = 10.58 (35–95%B over 15 min) 
[α]D25 = −14.5° (c = 0.200, CHCl3) 
1H NMR (400 MHz, DMSO-d6): Room temperature NMR was unassigned due to complex 
rotameric mixtures. 
1H NMR (500 MHz, DMSO-d6, 130 °C): δH = 9.47 (s, 1 H, H-Nc), 7.83 (br d, J = 7.9 Hz, 1 H, H-
16 or H-N), 7.69 (br d, J = 7.2 Hz, 1 H, H-N or H-16), 7.58–7.54 (m, 2 H, H-9 or H-10), 7.35 (d, 
J = 8.3 Hz, 1 H, H-19), 7.30 (d, J = 8.6 Hz, 2 H, H-10 or H-9), 7.13 (ddd, J = 8.2, 7.1, 0.9 Hz, 1 H, 
H-18), 7.08 (s, 1 H, H-15), 6.97 (t, J = 7.5 Hz, 1 H, H-17), 6.56 (br d, J = 8.1 Hz, 1 H, H-N), 6.14 
(br d, J = 8.1 Hz, 1 H, H-N), 5.92 (ddt, J = 17.3, 10.7, 5.3 Hz, 1 H, H-2), 5.55 (s, 1 H, H-13), 5.30 
(dq, J = 17.3, 1.7 Hz, 1 H, H-1’), 5.17 (dq, J = 10.6, 1.5 Hz, 1 H, H-1), 5.11, 5.05 (ABq, JAB = 12.4 
Hz, 2 H, H-11), 4.56–4.47 (m, 3 H, H-3 and H-7), 4.01 (d, J = 8.8 Hz, 1 H, H-21), 3.94 (dd, J = 
8.7, 6.4 Hz, 1 H, H-4), 3.70 (s, 3 H, H-20), 3.49 (s, 3 H, H-23), 3.03 (s, 3 H, H-12), 2.07 (octet, J 
= 6.7 Hz, 1 H, H-5), 1.65 (s, 3 H, H-14 or 14’), 1.45 (s, 3 H, H-14’ or 14), 1.36 (d, J = 7.0 Hz, 3 H, 
H-8), 0.99 (d, J = 6.8 Hz, 3 H, H-6 or 6’), 0.91 (d, J = 6.9 Hz, 3 H, H-6’ or 6), 0.60 (s, 9 H, H-22) 
13C NMR (101 MHz, CDCl3): Unassigned due to complex rotameric mixtures. 




6.3.4. ADC synthesis 
The ADCs were synthesised following literature procedure:269 
 
To a solution of trastuzumab (50 µL, 17 µM, 2.5 mg/mL) in TBS buffer (25 mM Tris·HCl pH 8, 
25 mM NaCl, 0.5 mM EDTA) was added TCEP solution (5 mM, 10 equiv.). The reaction mixture 
was vortexed and incubated at 37 °C for 1 h. The linker-drug stock solution in DMSO (20 mM, 
60 equiv.) was added (final DMSO percentage at 10% v/v), and the reaction mixture was 
vortexed and incubated at 37 °C for 4 h. The excess reagents were removed using a Zeba™ 
Spin desalting column (40,000 MWCO, 0.5 mL, ThermoFisher) pre-equilibrated with PBS. The 
reaction product was completely buffer exchanged into PBS by repeated diafiltration using 
an Amicon-Ultra centrifugal filter (10,000 MWCO, Merck Millipore). LCMS and SDS-PAGE 
analysis demonstrated >95% conversion to the desired conjugate.  
 
6.3.4.1. SDS-PAGE analysis 
Non-reducing Tris-Glycine SDS-PAGE with 12% acrylamide with 4% stacking gel was 
performed as standard. Broad range molecular weight marker (10–200 kDa, New England 
BioLabs) was run in all gels. Samples (10 µL of 0.4 mg/mL) were prepared with reducing 
loading dye (10 µL, containing β-mercaptoethanol) and heated to 95 °C for 5 min. Gels were 
run at constant voltage (160 V) for 60 min in 1x Laemmli running buffer (LRB). All gels were 
stained with Coomassie dye and imaged on a Syngene gel imaging system. 
 
6.3.4.2. Size exclusion chromatography (SEC) analysis 
SEC was performed on an ÄKTA Pure chromatography system using a Superdex 200 10/300 
gel filtration column equilibrated with PBS. The protein was eluted using PBS and the UV 
trace measured at 280 nm. SEC analysis was performed by Teodors Pantelejevs, Hyvönen 
Group, Department of Biochemistry, University of Cambridge. 
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6.3.5. Biological assays 
The biological assays were performed by Dr Stephen Walsh from the Spring Group, 
Department of Chemistry, University of Cambridge. 
 
6.3.5.1. Cells Lines  
HER2-positive SKBR3 and BT474 cells were obtained from the American Type Culture 
Collection (ATCC), and HER2-negative MCF7 cells were obtained from the European 
Collection of Authenticated Cell Cultures (ECACC). SKBR3 cells were maintained in high 
glucose McCoy’s 5A medium, supplemented with 10% heat-inactivated foetal-bovine serum 
(FBS), 50 U/mL penicillin and 50 µg/mL streptomycin. MCF7 cells were maintained in 
Dulbecco’s Modified Eagle Medium (DMEM) supplemented with 10% heat-inactivated FBS, 2 
mM L-glutamine, 50 U/mL penicillin and 50 µg/mL streptomycin. BT474 cells were 
maintained in RPMI-1640 medium supplemented with 10% heat-inactivated FBS, 2 mM L-
glutamine, 50 U/mL penicillin and 50 µg/mL streptomycin. All cell lines were incubated at 
37 °C with 5% CO2. 
 
6.3.5.2. Cellular viability assays 
Cells were seeded in 96-well plates for 24 h at 37 °C with 5% CO2. SKBR3 cells were seeded at 
20,000 cells/well, BT474 cells were seeded at 20,000 cells/well and MCF7 cells were seeded at 
7,500 cells/well. Serial dilutions of ADC 1, ADC 2, 56, 57, and trastuzumab were added to the 
cells in complete growth medium and incubated at 37 °C with 5% CO2 for 96 h. Cell viability 
was measured using CellTiter-Glo viability assay (Promega) according to the manufacturer’s 
instructions. Cell viability was plotted as a percentage of untreated cells. Each measurement 
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Appendix A — Crystallographic data 
Methyl (S)-3,3-dimethyl-2-((S)-3-methyl-3-(1-methyl-1H-indol-3-yl)-2-(2,2,2-
trifluoro-N-methylacetamido)butanamido)butanoate (99a) 
   
CCDC number 2012415 
Crystal data 
Chemical formula C24H32F3N3O4 
Mr 483.52 
Crystal system, space group Monoclinic, P21 
Temperature (K) 180 
a, b, c (Å) 18.9031 (7), 12.3366 (4), 21.0506 (7) 
β (°) 90.002 (2) 
V (Å3) 4909.0 (3) 
Z 8 
F(000) 2048 
Dx (Mg m-3) 1.308 
Radiation type Cu Kα 
No. of reflections for cell measurement 9656 
θ range (°) for cell measurement 4.2–66.6 
μ (mm-1) 0.88 
Crystal shape Lath 
Crystal size (mm3) 0.18 × 0.10 × 0.06 
 
Data collection 
Diffractometer Bruker D8-QUEST PHOTON-100 
Scan method ω and φ–scans 
Absorption correction Multi-scan  
SADABS (Bruker, 2014) 
Tmin, Tmax 0.661, 0.753 
No. of measured, independent and 
observed [I > 2σ(I)] reflections 




θ values (°) θmax = 67.2, θmin = 2.3 
(sin θ/λ)max (Å-1) 0.598 
 
Refinement 
R[F2 > 2σ(F2)], wR(F2), S 0.055, 0.126, 1.05 
No. of reflections 16567 
No. of parameters 1258 
No. of restraints 541 
H-atom treatment H-atom parameters constrained 
Δρmax, Δρmin (e Å-3) 0.26, -0.29 
Absolute structure Flack x determined using 4819 quotients [(I+)-(I-
)]/[(I+)+(I-)] (Parsons, Flack and Wagner, Acta Cryst. 
B69 (2013) 249-259). 











Chemical formula C24H32F3N3O4 
Mr 483.52 
Crystal system, space group Orthorhombic, P212121 
Temperature (K) 180 
a, b, c (Å) 10.2753 (4), 13.3147 (4), 17.9428 (5) 
V (Å3) 2454.80 (14) 
Z 4 
F(000) 1024 
Dx (Mg m-3) 1.308 
Radiation type Cu Kα 
No. of reflections for cell measurement 4770 
θ range (°) for cell measurement 4.1–66.6 
µ (mm-1) 0.88 
Crystal shape Lath 
Crystal size (mm3) 0.16 × 0.10 × 0.04 
 
Data collection 
Diffractometer Bruker D8-QUEST PHOTON-100 
Scan method ω and φ–scans 
Absorption correction Multi-scan  
SADABS (Bruker, 2014) 
Tmin, Tmax 0.653, 0.753 
No. of measured, independent and 
observed [I > 2σ(I)] reflections 
12912, 4214, 3378   
Rint 0.055 
θ values (°) θmax = 66.7, θmin = 4.1 





R[F2 > 2σ(F2)], wR(F2), S 0.045, 0.109, 1.03 
No. of reflections 4214 
No. of parameters 319 
H-atom treatment H atoms treated by a mixture of independent and 
constrained refinement 
Δρmax, Δρmin (e Å-3) 0.17, -0.17 
Absolute structure Flack x determined using 1196 quotients [(I+)-(I-
)]/[(I+)+(I-)] (Parsons, Flack and Wagner, Acta Cryst. 
B69 (2013) 249-259). 








Chemical formula C34H49F3N4O5 
Mr 650.77 
Crystal system, space group Monoclinic, P21 
Temperature (K) 180 
a, b, c (Å) 16.2983 (9), 6.1314 (4), 17.8581 (10) 
β (°) 96.979 (3) 
V (Å3) 1771.36 (18) 
Z 2 
F(000) 696 
Dx (Mg m-3) 1.220 
Radiation type Cu Kα 
No. of reflections for cell measurement 4141 
θ range (°) for cell measurement 2.7–62.0 
µ (mm-1) 0.77 
Crystal shape Needle 
Crystal size (mm3) 0.45 × 0.03 × 0.03 
 
Data collection 
Diffractometer Bruker D8-QUEST PHOTON-100 
Scan method ω and φ–scans 
Absorption correction Multi-scan  
SADABS (Bruker, 2014) 
Tmin, Tmax 0.608, 0.753 
No. of measured, independent and 
observed [I > 2σ(I)] reflections 
24424, 6173, 3784   
Rint 0.146 
θ values (°) θmax = 66.7, θmin = 2.5 
(sin θ/λ)max (Å-1) 0.596 
 
Refinement 
R[F2 > 2s(F2)], wR(F2), S 0.073, 0.186, 1.01 
208 
 
No. of reflections 6173 
No. of parameters 428 
No. of restraints 1 
H-atom treatment H-atom parameters constrained 
Δρmax, Δρmin (e Å-3) 0.20, -0.21 
Absolute structure Classical Flack method preferred over Parsons because 
s.u. lower. 





Appendix B — NMR spectra 




















































































































B.2. Chapter 5 




























































































































































































































































































indol-3-yl)propyl)-2,2,2-trifluoro-1N-methylacetamide (114, as an inseparable 


















































1H-NMR (rt, DMSO) 
 
























































Appendix C — Selected analytical HPLC and LCMS 
traces 
For HPLC analysis, unless stated otherwise, all compounds were analysed using 5-95%B over 
15 min gradient and monitored at 220 nm. In some HPLC chromatographs, there exists a peak 
at tR ≈ 2 min, corresponding to DMSO. 
C.1. Chapter 4 
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C.2. Chapter 5 






































































































Appendix D — Selected HPLC traces from stability and 
reactivity traces 
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